Table of Contents

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________

FORM 10-K
_____________________

(Mark One)

     
(XBOX)   Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Fiscal Year Ended December 31, 2001

or

     
(BOX)   Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Period From             to            

Commission File Number: 000-32499
________________________

SELECT MEDICAL CORPORATION
(Exact name of Registrant as specified in its charter)

     
Delaware   23-2872718
(State or other jurisdiction of incorporation or organization)   (I.R.S. employer identification number)

4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, Pennsylvania 17055

(Address of principal executive offices and zip code)

(717) 972-1100
(Registrant’s telephone number, including area code)

_____________________

Securities registered pursuant to Section 12(b) of the Act: None

_____________________

Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $.01 per share

_____________________

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES X        NO                YES X             NO       

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.           X

The aggregate market value of the registrant’s voting common stock held by non-affiliates, based on the closing sale price of $12.66 per share as reported on The Nasdaq National Market on February 28, 2002 was $252,259,261.

As of February 28, 2002, the number of outstanding shares of the Registrant’s Common Stock was 46,140,304.

DOCUMENTS INCORPORATED BY REFERENCE

         Portions of Registrant’s Proxy Statement to be filed with the Securities and Exchange Commission for the Registrant’s 2002 Annual Meeting are incorporated by reference into Part III.

 


TABLE OF CONTENTS

PART I
ITEM 1. BUSINESS
ITEM 2. PROPERTIES
ITEM 3. LEGAL PROCEEDINGS
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 9. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
ITEM 11. EXECUTIVE COMPENSATION
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
Report of Independent Accountants
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income (Loss)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
Amended and Restated Bylaws
Amendment #1 to Amended and Restated Bylaws.
Amendment No. 2 to Amended and Restated Bylaws
Amendment No. 4 to Employment Agreement
Amendment No. 3 to Employment Agreement
Fourth Addendum to Lease Agreement
Select Medical Corporation
Amendment to Change of Control, Scott A. Romberger
Change of Control Agreement dated as of March 1,
Amendment dated as of February 23, 2001
Fourth Amendment dated October 5, 2001
Change of Control Agreement dated as of November21
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
Subsidiaries of Select Medical Corporation.
Consent of PricewaterhouseCoopers LLP.


Table of Contents

SELECT MEDICAL CORPORATION
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2001

INDEX

         
   
PART I        
         
      ITEM 1.   BUSINESS   1
         
      ITEM 2.   PROPERTIES   20
         
      ITEM 3.   LEGAL PROCEEDINGS   20
         
      ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS   21
         
PART II        
         
      ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS   21
         
      ITEM 6.   SELECTED CONSOLIDATED FINANCIAL DATA   22
         
      ITEM 7.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   25
         
      ITEM 7A   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
  38
         
      ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA   39
         
      ITEM 9.   CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
  39
         
PART III        
         
      ITEM 10.   DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT   39
         
      ITEM 11.   EXECUTIVE COMPENSATION   39
         
      ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
  39
         
      ITEM 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS   39
         
PART IV        
         
      ITEM 14.   EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON
FORM 8-K
  40

 


Table of Contents

PART I

Forward-Looking Statements

         This discussion contains forward-looking statements relating to the financial condition, results of operations, plans, objectives, future performance and business of Select Medical Corporation. These statements include, without limitation, statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “estimates” or similar expressions. These forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements due to factors including the following:

    general economic, demographic and business conditions, both nationally and in regions where we operate;
 
    the effect of existing or future governmental regulation and federal and state legislative and enforcement initiatives on our business including the Balanced Budget Act of 1997;
 
    a change in government reimbursement for our services that would affect our revenue;
 
    the failure of our long-term acute care hospitals to maintain their status as such, which could negatively impact our profitability;
 
    private third party payors of our services may undertake cost containment initiatives that would decrease our revenue;
 
    shortages in qualified nurses could increase our operating costs significantly;
 
    future acquisitions may use significant resources and expose us to unforeseen risks; and
 
    the effect of liability and other claims asserted against us.

For a discussion of these and other factors affecting our business, see the section captioned “Risk Factors” under “Item 1. Business.”

ITEM 1. BUSINESS

Overview

         We are the largest operator of specialty acute care hospitals for long term stay patients in the United States based on the number of facilities. We are also the second largest operator of outpatient rehabilitation clinics in the United States based on the number of clinics. As of December 31, 2001, we operated 64 specialty acute care hospitals in 22 states and 717 outpatient rehabilitation clinics in 31 states, the District of Columbia and seven Canadian provinces. We began operations in 1997 under the leadership of our current management team, including our co-founders, Rocco A. Ortenzio and Robert A. Ortenzio, both of whom have significant experience in the healthcare industry. Under this leadership, we have grown our business through strategic acquisitions and internal development initiatives. For the year ended December 31, 2001, we had net operating revenues of $959.0 million and EBITDA (defined as net income (loss) before interest, income taxes, depreciation and amortization and special charges, other income, minority interest, and extraordinary items) of $112.0 million. In 2001, we earned 54% of our net operating revenues from our specialty acute care hospitals and 46% from our outpatient rehabilitation business. In April 2001, we completed a $98.3 million initial public offering of our common stock, and in June 2001 we completed a $175 million offering of 9 1/2% senior subordinated notes.

Specialty Acute Care Hospitals

         As of December 31, 2001, we operated 64 specialty acute care hospitals, 56 of which were certified by the federal Medicare program as long term acute care hospitals. The remaining eight hospitals are in the process of becoming certified as long term acute care hospitals.

1


Table of Contents

These hospitals generally have 30 to 40 beds, and as of December 31, 2001, we operated a total of 2,307 available licensed beds. Our specialty acute care hospitals employ approximately 7,000 people, with the majority being registered or licensed nurses and respiratory therapists. In these specialty hospitals we treat patients with serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, cardiac disorders, non-healing wounds, renal disorders and cancer.

         Patients are admitted to our specialty acute care hospitals from general acute care hospitals in our markets. These general acute care hospitals are frequently not the optimum setting in which to treat these patients, because they require longer stays and a higher level of clinical attention than the typical acute care patient. Furthermore, general acute care hospitals’ reimbursement rates usually do not adequately compensate them for the treatment of this type of patient. The differences in clinical expertise and reimbursement rates provide general acute care hospitals and their physicians with incentives to discharge longer stay, medically complex patients to our facilities. As a result of these dynamics, we continually seek to increase our admissions by expanding and improving our relationships with the physicians and general acute care hospitals in our markets that refer patients to our facilities.

         Below is a table that shows the distribution by medical condition of patients in our hospitals for the year ended December 31, 2001.

           
      Distribution
Medical Condition   of Patients
 
Respiratory failure
    30 %
Neuromuscular disorder
    26  
Cardiac disorder
    12  
Wound care
    10  
Renal disorder
    5  
Cancer
    3  
Other
    14  
 
   
 
 
Total
    100 %
 
   
 

         When a patient is referred to one of our hospitals by a physician, case manager, health maintenance organization or insurance company, a nurse liaison makes an assessment to determine the degree of care required and expected length of stay. This initial patient assessment is critical to our ability to provide the appropriate level of patient care. Based on the determinations reached in this clinical assessment, an admission decision is made by the attending physician.

         Upon admission, an interdisciplinary team reviews a new patient’s condition. The interdisciplinary team comprises a number of clinicians, including the attending physician, a specialty nurse, a dietician, a pharmacist and a case manager. Upon completion of an initial evaluation by each member of the treatment team, an individualized treatment plan is established and implemented. The case manager coordinates all aspects of the patient’s hospital stay and serves as a liaison with the insurance carrier’s case management staff when appropriate. The case manager communicates progress, resource utilization, and treatment goals between the patient, the treatment team and the payor.

         Each of our specialty hospitals has an onsite management team consisting of a chief executive officer, a director of clinical services and a director of provider relations. These teams manage local strategy and day-to-day operations, including oversight of per patient costs and average length of stay. They also assume primary responsibility for developing relationships with the general acute care providers and clinicians in our markets that refer patients to our specialty hospitals. We provide our hospitals with centralized accounting, payroll, legal, reimbursement, human resources, compliance, management information systems, billing and collecting services. The centralization of these services improves efficiency and permits hospital staff to spend more time on patient care.

2


Table of Contents

“Hospital within a Hospital” Model

         Of the 64 specialty hospitals we operated as of December 31, 2001, two are freestanding facilities and 62 are located in leased space within a host general acute care hospital. These leased spaces are separately licensed hospitals and are commonly referred to as a “hospital within a hospital.” As of December 31, 2001, we operated the largest number of specialty acute care hospitals operating with this “hospital within a hospital” model in the United States. We believe this model provides several advantages to patients, host hospitals, physicians and us.

    The host hospital’s patients benefit from being admitted to a setting specialized to meet their unique medical needs without having the disruption of being transferred to another location.
 
    In addition to being provided with a place to transfer high-cost, long-stay patients, host hospitals benefit by receiving payments from us for rent and ancillary services.
 
    Physicians affiliated with the host hospital are provided with the convenience of being able to monitor the progress of their patients without traveling to another location.
 
    We benefit from the ability to operate specialty hospitals without the capital investment often associated with buying or building a freestanding facility. We also gain operating cost efficiencies by contracting with these host hospitals for selected services at discounted rates.

         In addition, our specialty hospitals serve the broader community where they operate, treating patients from other general acute care hospitals in the local market. During the year ended December 31, 2001, 51% of the patients in our “hospital within a hospital” facilities were referred to us from general acute care hospitals other than the host hospitals.

Specialty Acute Care Hospital Strategy

Provide High Quality and Cost Effective Care

         We believe that our patients benefit from our experience in addressing the complex medical needs of long term stay patients. A typical patient admitted to our specialty hospitals has multiple medical conditions and requires a high level of attention by our clinical staff. To effectively address the complex nature of our patients’ medical conditions, we have developed specialized treatment programs focused solely on their needs. We have also implemented specific staffing models that are designed to ensure that patients have access to the necessary level of clinical attention. These staffing models also allow us to allocate our resources efficiently, which reduces costs.

         Our treatment and staffing programs benefit patients because they give our clinicians access to the regimens that we have found to be most effective in treating various conditions such as respiratory failure, non-healing wounds and neuromuscular disorders. In addition, we combine or modify these programs to provide a treatment plan tailored to meet a patient’s unique needs.

         We continually monitor the quality of our patient care by several measures, including patient, payor and physician satisfaction, as well as clinical outcomes. Quality measures are collected monthly and reported quarterly and annually. In order to benchmark ourselves against other healthcare organizations, we have contracted with outside vendors to collect our clinical and patient satisfaction information and compare it to other healthcare organizations. The information collected is reported back to each hospital, to the corporate office, and directly to the Joint Commission on Accreditation of Healthcare Organizations. As of December 31, 2001, all but seven of our most recently opened hospitals had been accredited by the Joint Commission on Accreditation of Healthcare Organizations. See “—Government Regulations—Licensure—Accreditation.”

3


Table of Contents

Reduce Costs

         We continually seek to improve operating efficiency and reduce costs at our hospitals by standardizing operations and centralizing key administrative functions. These initiatives include:

    optimizing staffing based on our occupancy and the clinical needs of our patients;
 
    centralizing administrative functions such as accounting, payroll, legal, reimbursement, compliance and human resources;
 
    standardizing management information systems to aid in financial reporting as well as billing and collecting; and
 
    participating in group purchasing arrangements to receive discounted prices for pharmaceuticals and medical supplies.

Increase Higher Margin Commercial Volume

         We typically receive higher reimbursement rates from commercial insurers than we do from the federal Medicare program. As a result, we work to expand relationships with insurers to increase commercial patient volume. Each of our hospitals has employees who focus on commercial contracting initiatives within their regions. Contracting professionals in our central office work with these hospital employees to ensure that our corporate contracting standards are met. Our goal in commercial contracting is to give discounted rates to those commercial payors that we expect to add significant patient volume to our hospitals.

         We believe that commercial payors seek to contract with our hospitals because we offer patients quality, cost effective care. Although the level of care we provide is complex and staff intensive, we typically have lower operating expenses than a freestanding general acute care facility’s intensive care unit because of our “hospital within a hospital” operating model. General acute care hospitals incur substantial overhead costs in order to provide a wide array of patient services. We provide a much narrower range of patient services, and our hospitals within a hospital lease underutilized space within a general acute care hospital. These factors permit our hospitals to operate with lower overhead costs per patient than general acute care hospitals can. As a result of these lower costs, we offer more attractive rates to commercial payors. Additionally, we provide their enrollees with customized treatment programs not offered in traditional acute care facilities.

Develop New Specialty Acute Care Hospitals

         Our goal is to open eight to ten new specialty acute care hospitals each year using our “hospital within a hospital” model. We seek to lease space from general acute care hospitals with leadership positions in the markets in which they operate. We have successfully contracted with various types of general hospitals, including for-profit, not-for-profit and university affiliated.

         We have a dedicated development team with significant market experience. When we target a host hospital, the development team conducts an extensive review of all of its discharges to determine the number of referrals we would have likely received from it on a historical basis. Next, we review the host hospital’s contracts with commercial insurers to determine the market’s general reimbursement trends and payor mix. Ultimately, when we sign a lease with a new host hospital, the project is transitioned to our start-up team, which is experienced in preparing a specialty hospital for opening. The start-up team oversees facility improvements, equipment purchases, licensure procedures, and the recruitment of a full-time management team. After the facility is opened, responsibility for its management is transitioned to this new management team and our corporate operations group.

4


Table of Contents

         During 1999, 2000 and 2001, we had completed the development and opening of the following 26 specialty acute care hospitals:

                     
Hospital Name   City   State   Opening Date   Licensed Beds

 
 
 
 
SSH-Wilmington   Wilmington   DE   January 1999     35  
SSH-Milwaukee   Milwaukee   WI   March 1999     34  
SSH-Youngstown   Youngstown   OH   April 1999     31  
SSH-Mesa   Mesa   AZ   September 1999     37  
SSH-Battle Creek   Battle Creek   MI   October 1999     32  
SSH-Omaha   Omaha   NE   October 1999     40  
SSH-Gulfport   Gulfport   MS   January 2000     38  
SSH-Denver   Denver   CO   February 2000     32  
SSH-Tri-Cities   Bristol   TN   March 2000     25  
SSH-St. Louis   St. Louis   MO   April 2000     33  
SSH-Wichita   Wichita   KS   June 2000     35  
SSH-San Antonio   San Antonio   TX   July 2000     34  
SSH-Greensburg   Greensburg   PA   August 2000     31  
SSH-Erie   Erie   PA   October 2000     35  
SSH-North Dallas   Dallas   TX   November 2000     11  
SSH-Fort Smith   Fort Smith   AR   December 2000     34  
SSH-Birmingham   Birmingham   AL   February 2001     38  
SSH-Jefferson Parish   New Orleans   LA   February 2001     34  
SSH-Pontiac*   Pontiac   MI   June 2001     30  
SSH-Camp Hill*   Camp Hill   PA   June 2001     31  
SSH-Wyandotte*   Wyandotte   MI   September 2001     35  
SSH-Charleston*   Charleston   WV   December 2001     32  
SSH-Northwest Detroit*   Detroit   MI   December 2001     36  
SSH-Scottsdale*   Scottsdale   AZ   December 2001     29  
SSH-Bloomington*   Bloomington   IN   December 2001     30  
SSH-Phoenix-Downtown*   Phoenix   AZ   December 2001     33  
                 
 
      Total                 845  
                 
 


*   As of December 31, 2001, certification as a long term acute care hospital pending, subject to successful completion of a start-up period and/or surveys by the applicable licensure or certifying agencies. See “—Governmental Regulations—Licensure—Certification.”

Grow Through Acquisitions

         In addition to our development initiatives, we intend to grow our network of specialty hospitals through strategic acquisitions. When we acquire a hospital or a group of hospitals, a team of our professionals is responsible for formulating and executing an integration plan. We have generally been able to increase margins at acquired facilities by centralizing administrative functions and implementing our standardized staffing models and resource management programs. Since our inception in 1997 we have acquired and integrated 37 hospitals which all share our centralized billing and purchasing programs and operate standardized management information systems.

Outpatient Rehabilitation

         We are the second largest operator of outpatient rehabilitation clinics in the United States, based on the number of our clinics. As of December 31, 2001, we operated 622 clinics throughout 31 states and the District of Columbia and 95 clinics in seven provinces throughout Canada. Our outpatient rehabilitation division employs approximately 8,500 people. Typically, each of our clinics is located in a freestanding facility in a highly visible medical complex or retail location. In addition to providing therapy in our outpatient clinics, we provide rehabilitation management services and staffing on a contract basis to hospitals, schools, nursing facilities and home health agencies.

5


Table of Contents

         In our clinics and through our contractual relationships, we provide physical, occupational and speech rehabilitation programs and services. Our patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. These impairments are often associated with accidents, sports injuries, strokes, heart attacks and other medical conditions. Our rehabilitation programs and services are designed to help these patients minimize physical and cognitive impairments and maximize functional ability. We also design services to prevent short-term disabilities from becoming chronic conditions. Our rehabilitation services are provided by our professionals including licensed physical therapists, occupational therapists, certified athletic trainers, psychiatrists, speech-language pathologists, respiratory therapists, exercise physiologists and physical rehabilitation counselors.

         Outpatient rehabilitation patients are generally referred or directed to our clinics by a physician, employer or health insurer who believes that a patient, employee or member can benefit from the level of therapy we provide in an outpatient setting. We believe that our services are attractive to healthcare payors who are seeking to provide the most cost-effective level of care to their members. In our outpatient rehabilitation division, approximately 91% of our net operating revenues come from rehabilitation management services and commercial payors, including healthcare insurers, managed care organizations and workers’ compensation programs. The balance of our reimbursement is derived from Medicare and other government sponsored programs.

         We have grown our outpatient rehabilitation business through acquisitions and new development. Our most significant outpatient acquisition was the purchase of the Physical Rehabilitation and Occupational Health Division of NovaCare, Inc. in November of 1999 through which we added approximately 500 outpatient rehabilitation clinics.

Outpatient Strategy

Increase Market Share

         Our goal is to be a leading provider of outpatient rehabilitation services in our local markets. Having a strong market share in our local markets allows us to benefit from heightened brand awareness, economies of scale and increased leverage when negotiating payor contracts. To increase our market share, we seek to expand the services and programs we provide and generate loyalty with patients and referral sources by providing high quality care and strong customer service.

    Expand Rehabilitation Programs and Services. We assess the healthcare needs of our markets and implement programs and services targeted to meet the demands of the local community. In designing these programs we benefit from the knowledge we gain through our national network of clinics. This knowledge is used to design programs that optimize treatment methods and measure changes in health status, clinical outcomes and patient satisfaction. Our programs and services include, among others, back care and rehabilitation; work injury management and prevention; sports rehabilitation and athletic training; and health, safety and prevention programs. Other services that vary by location include aquatic therapy, speech therapy, neurological rehabilitation and post-treatment care.
 
    Provide High Quality Care and Service. We believe that by focusing on quality care and offering a high level of customer service we develop brand loyalty in our markets. This loyalty allows us to retain patients and strengthen our relationships with the physicians, employers, and health insurers in our markets who refer or direct additional patients to us. We are focused on providing a high level of service to our patients throughout their entire course of treatment. To measure satisfaction with our service we have developed surveys for both patients and physicians. Our clinics utilize the feedback from these surveys to continuously refine and improve service levels.

6


Table of Contents

Optimize the Profitability of Our Payor Contracts

         Before we enter into a new contract with a commercial payor, we evaluate it with the aid of our contract management system. We assess potential profitability by evaluating past and projected patient volume, clinic capacity, and expense trends. Each contract we enter into is continually re-evaluated to determine how it is affecting our profitability. We create a retention strategy for each of the top performing contracts and a re-negotiation strategy for contracts that do not meet our defined criteria.

Grow Through New Development and Disciplined Acquisitions

         We intend to open new clinics in our current markets where we believe that we can benefit from existing referral relationships and brand awareness to produce incremental growth. From time to time, we also intend to also evaluate acquisition opportunities that may enhance the scale of our business and expand our geographic reach. Potential acquisitions are closely evaluated and we seek to buy only those assets that are complementary to our business and that are expected to give us a strong return on our invested capital.

Maintain Strong Employee Relations

         We believe that the relationships between our employees and the referral sources in their communities are critical to our success. Our referral sources, such as physicians and healthcare case managers, send their patients to our clinics based on three factors: the quality of our care, the service we provide and their familiarity with our therapists. We seek to retain and motivate our therapists by implementing a performance-based bonus program, a defined career path with the ability to be promoted from within, timely communication on company developments, and internal training programs. We also focus on empowering our employees by giving them a high degree of autonomy in determining local market strategy. This management approach reflects the unique nature of each market in which we operate and the importance of encouraging our employees to assume responsibility for their clinic’s performance.

Sources of Net Operating Revenues

         The following table presents the approximate percentages by source of net operating revenue received for healthcare services we provided for the periods indicated.

                           
      Year ended December 31,
     
Net Operating Revenues by Payor Source   2001   2000   1999

 
 
 
Commercial insurance (a)
    51.4 %     51.2 %     34.6 %
Medicare
    37.3       35.1       48.1  
Private and other (b)
    10.2       12.4       15.7  
Medicaid
    1.1       1.3       1.6  
 
   
     
     
 
 
Total
    100.0 %     100.0 %     100.0 %
 
   
     
     
 


(a)   Includes commercial healthcare insurance carriers, health maintenance organizations, preferred provider organizations, workers’ compensation and managed care programs.
(b)   Includes self payors, Canadian revenues, contract management services and non-patient related payments.

Non-Government Sources

         A majority of our net operating revenues come from private payor sources. These sources include insurance companies, workers’ compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies, and employers, as well as by patients

7


Table of Contents

directly. Patients are generally not responsible for any difference between customary charges for our services and amounts paid by Medicare and Medicaid programs, insurance companies, workers’ compensation companies, health maintenance organizations, preferred provider organizations, and other managed care companies, but are responsible for services not covered by these programs or plans, as well as for deductibles and co-insurance obligations of their coverage. The amount of these deductibles and co-insurance obligations has increased in recent years. Collection of amounts due from individuals is typically more difficult than collection of amounts due from government or business payors. To further reduce their healthcare costs, an increasing number of insurance companies, health maintenance organizations, preferred provider organizations, and other managed care companies are negotiating discounted fee structures or fixed amounts for hospital services performed, rather than paying healthcare providers the amounts billed. If an increased number of insurance companies, health maintenance organizations, preferred provider organizations, and other managed care companies succeed in negotiating discounted fee structures or fixed amounts, our results of operations may be negatively affected.

Government Sources

         Medicare is a federal program that provides medical insurance benefits to persons age 65 and over, some disabled persons, and persons with end-stage renal disease. Medicaid is a federal-state funded program, administered by the states, which provides medical benefits to individuals who are unable to afford healthcare. All of our hospitals are certified as providers of Medicare, and our outpatient rehabilitation clinics regularly receive Medicare payments for their services. Additionally, our specialty hospitals participate in six state Medicaid programs. Amounts received under the Medicare and Medicaid programs are generally less than the customary charges for the services provided. In recent years, changes made to the Medicare and Medicaid programs have further reduced payment to healthcare providers. Since an important portion of our revenues comes from patients under the Medicare program, our ability to operate our business successfully in the future will depend in large measure on our ability to adapt to changes in the Medicare program. See “—Government Regulations—Overview of U.S. and State Government Reimbursements.”

Government Regulations

General

         The healthcare industry is required to comply with many laws and regulations at the federal, state and local government levels. These laws and regulations require that hospitals and outpatient rehabilitation clinics meet various requirements, including those relating to the adequacy of medical care, equipment, personnel, operating policies and procedures, maintenance of adequate records, compliance with building codes and environmental protection. These laws and regulations are extremely complex and, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. If we fail to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in the Medicare, Medicaid and other federal and state healthcare programs.

Licensure

          Facility Licensure . Our healthcare facilities are subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. In order to assure continued compliance with these various regulations, governmental and other authorities periodically inspect our facilities.

         Some states still require us to get approval under certificate of need regulations when we create, acquire or expand our facilities or services. If we fail to show public need and obtain approval in these states for our facilities, we may be subject to civil or even criminal penalties, lose our facility license or

8


Table of Contents

become ineligible for reimbursement if we proceed with our creation or acquisition of the new facility or service.

          Professional Licensure and Corporate Practice. Healthcare professionals at our hospitals and outpatient rehabilitation clinics are required to be individually licensed or certified under applicable state law. We take steps to ensure that our employees and agents possess all necessary licenses and certifications.

         In some states, business corporations such as ours are restricted from practicing therapy through the direct employment of therapists. In those states, in order to comply with the restrictions imposed, we either contract to obtain therapy services from an entity permitted to employ therapists, or we manage the physical therapy practice owned by licensed therapists through which the therapy services are provided.

          Certification. In order to participate in the Medicare program and receive Medicare reimbursement, each facility must comply with the applicable regulations of the United States Department of Health and Human Services relating to, among other things, the type of facility, its equipment, its personnel and its standards of medical care, as well as compliance with all applicable state and local laws and regulations. All of our hospitals participate in the Medicare program. In addition, we provide the majority of our outpatient rehabilitation services through clinics certified by Medicare as rehabilitation agencies or “rehab agencies.”

          Accreditation. Our hospitals receive accreditation from the Joint Commission on Accreditation of Healthcare Organizations, a nationwide commission which establishes standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of hospitals. As of December 31, 2001, all but seven of our most recently opened hospitals had been accredited by the Joint Commission on Accreditation of Healthcare Organizations. Typically, we wait until our hospitals have been in operation for at least six months before applying for accreditation.

Overview of U.S. and State Government Reimbursements

          Medicare. The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services and the Centers for Medicare & Medicaid Services. For the year ended December 31, 2001, we received approximately 37.3% of our revenue from Medicare.

          Long Term Acute Care Hospital Medicare Reimbursement. Our long-term acute care hospitals receive cost reimbursement, subject to a maximum cap. In contrast, Medicare inpatient costs for short-term acute care hospitals are reimbursed based upon a fixed payment amount per discharge using diagnosis related groups, commonly referred to as DRGs. The DRG payment under a prospective payment system is based upon the national average cost of treating a Medicare patient’s condition. Although the average length of stay varies for each DRG, the average stay for all Medicare patients subject to prospective payment system is approximately six days. Thus, a prospective payment system creates an economic incentive for general short-term acute care hospitals to discharge medically complex Medicare patients as soon as clinically possible. We believe that the incentive for short-term acute care hospitals to discharge medically complex patients as soon as clinically possible creates a substantial referral source for our long term acute care hospitals.

         Prior to qualifying as an exempt long-term acute care hospital, a new long-term acute care hospital initially receives payment under the acute care DRG-based reimbursement system. The long-term acute care hospital must continue to be paid DRGs for a minimum of six months while meeting

9


Table of Contents

certain Medicare long-term acute care hospital requirements, the most significant requirement being an average length of stay of more than 25 days. A “hospital within a hospital” facility must also establish itself as a hospital separate from its host by, among other things, obtaining separate licensure and certification, and limiting the services it purchases directly from its host to 15% of its total operating costs, or limiting the number of patient admissions from its host to 25% of total admissions.

         Once the hospital qualifies for exempt status, long-term acute care hospitals currently are paid on the basis of Medicare reasonable costs per case subject to limits. Under cost-based reimbursement, costs accepted for reimbursement depend on a number of factors, including necessity, reasonableness, related-party principles and relatedness to patient care. Qualifying costs under Medicare’s cost-reimbursement system typically include all operating costs and also capital costs that include interest expense, depreciation, amortization, and rental expense. Non-qualifying costs include marketing costs.

         The cost reimbursement received by a long-term acute care hospital is subject to per-discharge payment limits. During a long-term acute care hospital’s initial operations, Medicare payment is capped at the average national target rate established by the Tax Equity and Fiscal Responsibility Act of 1982, commonly known as TEFRA. After the second year of operations, payment is subject to a target amount based on the lesser of the hospital’s cost-per-discharge or the national ceiling in the applicable base year. Legislation enacted in December 2000, the “Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000,” increases the target amount by 25 percent and the national ceiling by 2 percent for cost reporting periods beginning after October 1, 2000.

         Congress has required the Secretary of the Department Health and Human Services to submit to Congress by October 1, 1999 a proposal to establish a prospective payment system for long-term acute care hospitals. This requirement was later extended until October 1, 2001, but no proposal has yet been submitted. Current law provides that a prospective payment system is to be effective for cost reporting periods beginning on or after October 1, 2002. When developing the prospective payment system, the December 2000 legislation requires the Secretary to examine the feasibility and impact of basing payment on the existing (or refined) short term acute hospital DRGs and the most recently available hospital discharge data. The Secretary is required to implement a prospective payment system using the existing short term acute hospital DRGs that have been modified where feasible, unless a different prospective payment system is implemented by October 1, 2002.

          Outpatient Rehabilitation Services Medicare Reimbursement. We provide the majority of our outpatient rehabilitation services in our rehabilitation clinics. Through our contract services agreements, we also provide outpatient rehabilitation services in the following settings:

    schools;
 
    physician-directed clinics;
 
    hospitals; and
 
    skilled nursing facilities.

Essentially, all of our outpatient rehabilitation services are provided in rehabilitation agencies and are not provided through rehabilitation hospitals.

         Prior to January 1, 1999, outpatient physical therapy, occupational therapy, and speech-language pathology services, which we refer to as outpatient therapy services, were reimbursed on the basis of the lower of 90% of reasonable costs or actual charges. Beginning January 1, 1999, outpatient rehabilitation services were reimbursed on a fee schedule, subject to annual limits. These outpatient rehabilitation providers receive a fixed fee for each procedure performed, which is adjusted by the geographical area in which the facility is located.

10


Table of Contents

         In November 1999, the Balanced Budget Refinement Act provided some relief to providers by unbundling speech-language pathology services from other outpatient rehabilitation services. The following lists the current annual limits per Medicare beneficiary by services offered:

    $1,500 for outpatient physical therapy services,
 
    $1,500 for speech-language pathology services, and
 
    $1,500 for outpatient occupational health services.

         A moratorium has since been placed on these limits for the years 2000 through 2002 pending a review by the Secretary of the Department of Health and Human Services of the clinical needs of these patients and the appropriate level of limitations.

         The Secretary of the U.S. Department of Health and Human Services is required to report the results of this review to Congress, together with any relevant legislative recommendations, potentially including revised coverage policies as an alternative to the therapy caps. The Secretary is also required to study therapy utilization patterns and report the findings to Congress. The December 2000 legislation also requires the Secretary to study the implications of eliminating the “in the room” supervision requirement for Medicare payment for physical therapy assistants who are supervised by physical therapists and the implications of this requirement on the physical therapy cap.

         Historically, outpatient rehabilitation services have been subject to scrutiny by the Medicare program for, among other things, medical necessity for services, appropriate documentation for services, billing for group therapy, and Medicare billing practices by skilled nursing facilities. In addition, payment for rehabilitation services furnished to patients of skilled nursing facilities has been affected by the establishment of a Medicare prospective payment system and consolidated billing requirement for skilled nursing facilities. The resulting pressure on skilled nursing facilities to reduce their costs by negotiating lower payments to therapy providers, such as our contract therapy services, and the inability of the therapy providers to bill the Medicare program directly for their services have tended to reduce the amounts that rehabilitation providers can receive for services furnished to many skilled nursing facility residents.

          Long Term Acute Care Hospital Medicaid Reimbursement. The Medicaid program is designed to provide medical assistance to individuals unable to afford care. The program is governed by the Social Security Act of 1965 and administered and funded jointly by each individual state government and the Centers for Medicare & Medicaid Services. Most state Medicaid payments are made under a prospective payment system or under programs that negotiate payment levels with individual hospitals. In addition, Medicaid programs are subject to statutory and regulatory changes, administrative rulings, interpretations of policy by the state agencies and certain government funding limitations, all of which may materially increase or decrease the level of program payments to our hospitals. Medicaid payments accounted for about 1.7% of our long term acute care net operating revenues for the year ended December 31, 2001.

          Workers’ Compensation. Workers’ compensation programs accounted for approximately 18.5% of our revenue from outpatient rehabilitation services for the year ended December 31, 2001. Workers’ compensation is a state-mandated, comprehensive insurance program that requires employers to fund or insure medical expenses, lost wages and other costs resulting from work-related injuries and illnesses. Workers’ compensation benefits and arrangements vary on a state-by-state basis and are often highly complex. In some states, payment for services covered by workers’ compensation programs are subject to cost containment features, such as requirements that all workers’ compensation injuries be treated through a managed care program, or the imposition of payment caps. In addition, these workers’ compensation programs may impose requirements that affect the operations of our outpatient rehabilitation services.

11


Table of Contents

Canadian Reimbursement

         The Canada Health Act governs the Canadian healthcare system, and provides for federal funding to be transferred to provincial health systems. Our Canadian outpatient rehabilitation clinics receive funding primarily through workers’ compensation benefits, which are administered by provincial workers’ compensation boards. The workers’ compensation boards assess employers’ fees based on their industry and past claims history. These fees are then distributed independently by each provincial workers’ compensation board as payments for healthcare services. Therefore, the payments each of our rehabilitation clinics receive for similar services can vary substantially because of the different payment regulations in each province. For the year ended December 31, 2001, we derived about 3.9% of our total net operating revenues from our operations in Canada.

Other Healthcare Regulations

          Fraud and Abuse Enforcement. Various federal laws prohibit the submission of false or fraudulent claims, including claims to obtain payment under Medicare, Medicaid and other government healthcare programs. Penalties for violation of these laws include civil and criminal fines, imprisonment and exclusion from participation in federal and state healthcare programs. In recent years, federal and state government agencies have increased the level of enforcement resources and activities targeted at the healthcare industry. In addition, the federal False Claims Act allows an individual to bring lawsuits on behalf of the government, in what are known as  qui tam or “whistleblower” actions, alleging false or fraudulent Medicare or Medicaid claims or other violations of the statute. The use of these private enforcement actions against healthcare providers has increased dramatically in the recent past, in part because the individual filing the initial complaint is entitled to share in a portion of any settlement or judgment.

         From time to time, various federal and state agencies, such as the Department of Health and Human Services, issue a variety of pronouncements, including fraud alerts, the Office of Inspector General’s Annual Work Plan and other reports, identifying practices that may be subject to heightened scrutiny. These pronouncements can identify issues relating to long-term acute care hospitals or outpatient rehabilitation services or providers. For example, the Office of Inspector General’s 2002 Work Plan describes the government’s intention to study providers’ use of satellite units and the “hospital within a hospital” model for furnishing long term acute care hospital services and the effectiveness of the Centers for Medicare & Medicaid Services’ payment safeguards relating to such services. We monitor these issuances to ensure that our resources are focused on compliance with areas targeted for enforcement.

         We endeavor to conduct our operations in compliance with applicable laws, including healthcare fraud and abuse laws. If we identify any practices as being potentially contrary to applicable law, we will take appropriate action to address the matter, including, where appropriate, disclosure to the proper authorities.

          Remuneration, Fraud and Anti-dumping Measures. The federal “anti-kickback” statute prohibits some business practices and relationships under Medicare, Medicaid and other federal healthcare programs. These practices include the payment, receipt, offer or solicitation of money in connection with the referral of patients covered by a federal or state healthcare program. Violations of the anti-kickback law may be punished by a criminal fine of up to $50,000 or imprisonment for each violation, civil monetary penalties of $50,000 and damages of up to three times the total amount of remuneration, and exclusion from participation in federal or state health care programs.

         Section 1877 of the Social Security Act, commonly known as the “Stark Law,” prohibits referrals for designated health services by physicians under the Medicare and Medicaid programs to other healthcare providers in which the physicians have an ownership or compensation arrangement unless an exception applies. Sanctions for violating the Stark Law include civil monetary penalties of up

12


Table of Contents

to $15,000 per prohibited service provided, assessments equal to twice the dollar value of each such service provided and exclusion from the Medicare and Medicaid programs. The statute also provides a penalty of up to $100,000 for a circumvention scheme. In addition, many states have adopted or may adopt similar anti-kickback or anti-self-referral statutes. Some of these statutes prohibit the payment or receipt of remuneration for the referral of patients, regardless of the source of the payment for the care.

         Medicare-participating hospitals are also subject to the Emergency Medical Treatment and Active Labor Act, an “anti-dumping” statute commonly referred to as EMTALA. If a patient with an emergency condition enters a hospital with an emergency department, this federal law requires the hospital to stabilize a patient suffering from this emergency condition or make an appropriate transfer of the patient to a facility that can handle the condition. There are severe penalties under EMTALA if a hospital refuses to screen or appropriately stabilize or transfer a patient or if the hospital delays appropriate treatment in order to first inquire about the patient’s ability to pay. Although none of our hospitals operate emergency departments, the government has interpreted EMTALA broadly to cover situations in which any type of hospital inpatient is transferred in an unstable condition.

          Provider-based Status. The designation “provider-based” refers to circumstances in which a subordinate facility ( e.g. , a separately-certified Medicare provider, a department of a provider or a satellite facility) is treated as part of a provider for Medicare payment purposes. In these cases, the services of the subordinate facility are included on the “main” provider’s cost report and overhead costs of the main provider can be allocated to the subordinate facility, to the extent that they are shared. We operate seven long term acute care hospitals that are treated as provider-based satellites of certain of our other facilities, and we provide rehabilitation management and staffing services to hospital rehabilitation departments that may be treated as provider-based.

          Health Information Practices. In addition to broadening the scope of the fraud and abuse laws, the Health Insurance Portability and Accountability Act also mandates, among other things, the adoption of standards for the exchange of electronic health information in an effort to encourage overall administrative simplification and enhance the effectiveness and efficiency of the healthcare industry. Among the standards that the Department of Health and Human Services will adopt pursuant to the Health Insurance Portability and Accountability Act are standards for the following:

    electronic transactions and code sets;
 
    unique identifiers for providers, employers, health plans and individuals;
 
    security and electronic signatures;
 
    privacy; and
 
    enforcement.

         Although the Health Insurance Portability and Accountability Act was intended ultimately to reduce administrative expenses and burdens faced within the healthcare industry, we believe the law will initially bring about significant and, in some cases, costly changes. The Department of Health and Human Services has finalized two rules to date mandating the use of new standards with respect to certain healthcare transactions and health information. The first rule requires the use of uniform standards for common healthcare transactions, including healthcare claims information, plan eligibility, referral certification and authorization, claims status, plan enrollment and disenrollment, payment and remittance advice, plan premium payments and coordination of benefits.

         Second, the Department of Health and Human Services has finalized new standards relating to the privacy of individually identifiably health information. These standards not only require our compliance with rules governing the use and disclosure of protected health information, but they also

13


Table of Contents

require us to impose those rules, by contract, on any business associate to whom such information is disclosed. Rules governing the security of health information and setting standards for electronic signatures have been proposed but have not yet been issued in final form.

         The Department of Health and Human Services finalized the new transaction standards on August 17, 2000, with a compliance date of October 16, 2002. In December 2001, Congress enacted a law that delays the effective date until October 16, 2003 for entities that submit a plan for being compliant by that date. We have not yet determined whether we will seek to delay our effective date. The privacy standards under the Health Insurance Portability and Accountability Act were issued on December 28, 2000, and became effective on April 14, 2001. We will be required to comply with them by April 14, 2003. Once the security regulations are issued in final form, we will have approximately two years to be fully compliant. Sanctions for failing to comply with the Health Insurance Portability and Accountability Act include criminal penalties, civil sanctions, and exclusion from the Medicare program.

         We are evaluating the effect of the Health Insurance Portability and Accountability Act and have developed a task force to address the Health Insurance Portability and Accountability Act regulations as they have been adopted to date and as additional standards are adopted in the coming months. At this time, we anticipate that we will be able to fully comply with those Health Insurance Portability and Accountability Act requirements that have been adopted. However, we cannot at this time estimate the cost of such compliance, nor can we estimate the cost of compliance with standards that have not yet been finalized by the Department of Health and Human Services. Although the new and proposed health information standards are likely to have a significant effect on the manner in which we handle health data and communicate with payors, based on our current knowledge, we believe that the cost of our compliance will not have a material adverse effect on our business, financial condition or results of operations.

Employees

         As of December 31, 2001 we employed approximately 15,900 people throughout the United States and Canada. A total of approximately 9,900 of our employees are full-time and the remaining approximately 6,000 are part-time employees. Outpatient, contract therapy and physical rehabilitation and occupational health employees totaled approximately 8,500 and inpatient employees totaled approximately 7,000. The remaining employees were in corporate management and administration.

Competition

         We compete primarily on the basis of pricing and quality of the patient services we provide. Our specialty acute care hospitals face competition principally from general acute care hospitals in the communities in which we operate. General acute care hospitals usually have the capability to provide the same services we provide. Our hospitals also face competition from large national operators of similar facilities, such as Kindred Healthcare, Inc.

         Our outpatient rehabilitation clinics face competition principally from locally owned and managed outpatient rehabilitation clinics in the communities they serve. Many of these clinics have longer operating histories and greater name recognition in these communities than our clinics, and they may have stronger relations with physicians in these communities on whom we rely for patient referrals. In addition, HealthSouth Corporation, which operates more outpatient rehabilitation clinics in the United States than we do, competes with us in a number of our markets.

14


Table of Contents

Compliance Program

Our Compliance Program

         In late 1998, we voluntarily adopted our code of conduct, which is the basis for our company-wide compliance program. Our written code of conduct provides guidelines for principles and regulatory rules that are applicable to our patient care and business activities. These guidelines are implemented by a compliance officer, a director of compliance who assists the compliance officer, a compliance committee and sub-committees, and employee education and training. We also have established a reporting system, auditing and monitoring programs, and a disciplinary system as a means for enforcing the code’s policies.

Operating Our Compliance Program

         We focus on integrating compliance responsibilities with operational functions. We recognize that our compliance with applicable laws and regulations depends upon individual employee actions as well as company operations. Our corporate executives, with the advice of outside experts, designed the programs of the compliance committee. We have adopted an operations team approach to compliance. We use facility leaders in our compliance sub-committees for employee-level implementation of our code of conduct. This approach is intended to enforce our company-wide commitment to operate in accordance with the laws and regulations that govern our business.

Compliance Committee

         Our compliance committee is made up of members of our senior management and in-house counsel. The compliance committee meets on a quarterly basis and reviews the activities, reports and operation of our compliance program. In addition, the compliance sub-committees meet on a regular basis and review compliance for each of our business divisions.

Compliance Issue Reporting

         In order to facilitate our employees’ ability to report known, suspected or potential violations of our code of conduct, we have developed a system of anonymous reporting. This anonymous reporting may be accomplished through our toll-free compliance hotline or our compliance post office box. The compliance officer and the compliance committee are responsible for reviewing and investigating each compliance incident in accordance with the compliance department’s investigation policy.

Compliance Monitoring and Auditing/Comprehensive Training and Education

         Monitoring reports and the results of compliance for each of our business divisions are reported to the compliance committee on a quarterly basis. We train and educate our employees regarding the code of conduct, as well as the legal and regulatory requirements relevant to each employee’s work environment. New and current employees are required to sign a compliance certification form certifying that the employee has read, understood, and has agreed to abide by the code of conduct.

Policies and Procedures Reflecting Compliance Focus Areas

         We review our current policies and procedures for our compliance program, and we intend to continue to review them on an annual basis in order to improve operations and to ensure compliance with requirements of standards, laws and regulations and to reflect the on-going compliance focus areas which have been identified by the compliance committee.

15


Table of Contents

Internal Audit

         In addition to and in support of the efforts of our compliance department, we have established during 2001 an internal audit function led by our full time internal auditor.

Risk Factors

          Our business involves a number of risks, some of which are beyond our control. The risk and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties that we do not currently know or that we currently believe to be immaterial may also adversely affect our business.

If there are changes in the rates or methods of government reimbursements for our services, our net operating revenues and net income could decline.

         Approximately 37.3% of our net operating revenues for the year ended December 31, 2001 came from the highly regulated federal Medicare program. The methods and rates of Medicare reimbursements may change at any time. Our specialty acute care hospitals operate as Medicare-designated long term acute care hospitals. As long term acute care hospitals, they receive reimbursements from Medicare based on the actual costs incurred during the treatment of a patient, subject to a cap. Many other types of healthcare providers, including general acute care hospitals, receive reimbursements from Medicare under prospective payment systems. These systems reimburse providers fixed amounts, subject to adjustments, based on each patient’s expected cost of treatment. Congress has directed the Secretary of the U.S. Department of Health and Human Services to develop a prospective payment system applicable to long term acute care hospitals. The Secretary is currently developing such a prospective payment system. The Secretary has not announced the details of the prospective payment system, but is expected to do so in the near future. The application of a prospective payment system to long term acute care hospitals could reduce the level of reimbursement we receive from the Medicare program for our services and negatively affect our profit margins.

         Our outpatient rehabilitation clinics receive payments from the Medicare program under a fee schedule. These payments were to be subject to annual limits, originally $1,500 per patient, effective January 1, 1999. Congress has imposed a moratorium on these limits through 2002. The Secretary of the U.S. Department of Health and Human Services is required to review this annual limit and make a proposal to Congress to revise the payment system for outpatient rehabilitation. Any changes adopted by Congress, which could include reduced annual limits or a new payment system, could have an adverse effect on our outpatient rehabilitation business.

If our hospitals fail to maintain their exemption from the Medicare prospective payment system or fail to qualify as hospitals separate from their host hospitals, our profitability may decline.

         As of December 31, 2001, 56 of our 64 hospitals were certified as Medicare long term acute care hospitals, and the remaining eight were in the process of becoming certified as Medicare long term acute care hospitals. If our hospitals fail to meet or maintain the standards for certification as long term acute care hospitals, such as average minimum length of patient stay, they will not receive cost-based reimbursement but will instead receive predetermined payments applicable to general acute care hospitals under the prospective payment system. Such predetermined payments would likely result in our hospitals receiving less Medicare reimbursement than they currently receive for their patient services. Moreover, nearly all of our hospitals are subject to additional Medicare criteria because they operate as separate hospitals located in space leased from, and located in, a general acute care hospital, known as a host hospital. This is known as a “hospital within a hospital” model. These additional criteria include limitations on services purchased from the host hospital and other requirements concerning separateness from the host hospital. If several of our hospitals were to lose their cost-based

16


Table of Contents

reimbursement status or failed to comply with the separateness requirements, our profit margins would likely decrease. See “—Government Regulations—Overview of U.S. and State Government Reimbursements—Long Term Acute Care Hospital Medicare Reimbursement.”

Future cost containment initiatives undertaken by private third party payors may limit our future net operating revenues and profitability.

         Initiatives undertaken by major insurers and managed care companies to contain healthcare costs affect the profitability of our specialty acute care hospitals and outpatient rehabilitation clinics. These payors attempt to control healthcare costs by contracting with hospitals and other healthcare providers to obtain services on a discounted basis. We believe that this trend may continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, our profit margins may decline, or we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

We conduct business in a heavily regulated industry, and changes in regulations or violations of regulations may result in increased costs or sanctions that reduce our net operating revenues and profitability.

         The healthcare industry is subject to extensive federal, state and local laws and regulations relating to:

    facility and professional licensure, including certificates of need;
 
    conduct of operations, including financial relationships among healthcare providers, Medicare fraud and abuse, and physician self-referral;
 
    addition of facilities and services; and
 
    payment for services.

         Recently, there have been heightened coordinated civil and criminal enforcement efforts by both federal and state government agencies relating to the healthcare industry, including the specialty acute care hospital and outpatient rehabilitation clinic businesses. The ongoing investigations relate to, among other things, various referral practices, cost reporting, billing practices, physician ownership and joint ventures involving hospitals. In the future, different interpretations or enforcement of these laws and regulations could subject our current practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services and capital expenditure programs, and increase our operating expenses. If we fail to comply with these extensive laws and government regulations, we could become ineligible to receive government program reimbursement, suffer civil or criminal penalties or be required to make significant changes to our operations. In addition, we could be forced to expend considerable resources responding to an investigation or other enforcement action under these laws or regulations. See “—Government Regulations.”

If we fail to cultivate new or maintain established relationships with the physicians in our markets, our net operating revenues may decrease.

         Our success is, in part, dependent upon the admissions and referral practices of the physicians in the communities our hospitals and our outpatient rehabilitation clinics serve, and our ability to maintain good relations with these physicians. Physicians referring patients to our hospitals and clinics are generally not our employees and, in many of the markets that we serve, most physicians have admitting privileges at other hospitals and are free to refer their patients to other providers. If we are unable to successfully cultivate and maintain strong relationships with these physicians, our hospitals’ admissions and clinics’ businesses may decrease, and our net operating revenues may decline.

17


Table of Contents

Shortages in qualified nurses could increase our operating costs significantly.

         Our specialty acute care hospitals are highly dependent on nurses for patient care. The availability of qualified nurses has declined in recent years, and the salaries for nurses have risen accordingly. We cannot assure you we will be able to attract and retain qualified nurses in the future. Additionally, the cost of attracting and retaining nurses may be higher than we anticipate, and as a result, our profitability could decline.

Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.

         As part of our growth strategy, we intend to pursue acquisitions of specialty acute care hospitals and outpatient rehabilitation clinics. Acquisitions may involve significant cash expenditures, debt incurrence, additional operating losses, dilutive issuances of equity securities and expenses that could have a material adverse effect on our financial condition and results of operations. Acquisitions involve numerous risks, including:

    difficulties integrating acquired personnel and harmonizing distinct cultures into our business;
 
    diversion of management’s time from existing operations;
 
    potential loss of key employees or customers of acquired companies; and
 
    assumption of the liabilities and exposure to unforeseen liabilities of acquired companies, including liabilities for failure to comply with healthcare regulations.

         We cannot assure you that we will succeed in obtaining financing for acquisitions at a reasonable cost, or that such financing will not contain restrictive covenants that limit our operating flexibility. We also may be unable to operate acquired hospitals and outpatient rehabilitation clinics profitably or succeed in achieving improvements in their financial performance.

Restrictions imposed by our senior credit facilities and the indenture governing our 9 1/2% senior subordinated notes limit our ability to engage in or enter into business, operating and financing arrangements, which could prevent us from taking advantage of potentially profitable business opportunities.

         The operating and financial restrictions and covenants in our debt instruments, including the senior credit facilities and our 9 1/2% senior subordinated notes, may adversely affect our ability to finance our future operations or capital needs or engage in other business activities that may be in our interest. For example, our senior credit facilities limit our ability to, among other things:

         •     incur additional debt;

         •     pay dividends;

         •     make certain investments;

         •     incur or permit to exist certain liens;

         •     enter into transactions with affiliates;

         •     merge, consolidate or amalgamate with another company;

18


Table of Contents

         •     transfer or otherwise dispose of assets;

         •     redeem subordinated debt;

         •     incur capital expenditures; and

         •     incur contingent obligations.

         The indenture governing our 9 1/2% senior subordinated notes includes similar restrictions. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Capital Resources and Liquidity.”

Competition may limit our ability to acquire hospitals and clinics and adversely affect our growth.

         We have historically faced limited competition in acquiring specialty acute care hospitals and outpatient rehabilitation clinics, but we may face heightened competition in the future. Our competitors may acquire or seek to acquire many of the hospitals and clinics that would be suitable candidates for us. This could limit our ability to grow by acquisitions or make our cost of acquisitions higher and less profitable.

If we fail to compete effectively with other hospitals, clinics and healthcare providers, our net operating revenues and profitability may decline.

         The healthcare business is highly competitive, and we compete with other hospitals, rehabilitation clinics and other healthcare providers for patients. If we are unable to compete effectively in the specialty acute care hospital and outpatient rehabilitation businesses, our net operating revenues and profitability may decline. More than half of our specialty hospitals operate in geographic areas where we compete with at least one other hospital that provides similar services. Our outpatient rehabilitation clinics face competition from a variety of local and national outpatient rehabilitation providers. Other outpatient rehabilitation clinics in markets we serve may have greater name recognition and longer operating histories than our clinics. The managers of these clinics may also have stronger relationships with physicians in their communities, which could give them a competitive advantage for patient referrals.

Significant legal actions could subject us to substantial uninsured liabilities.

         In recent years, physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large claims and significant defense costs. To protect ourselves from the cost of these claims, we maintain professional malpractice liability insurance and general liability insurance coverage in amounts and with deductibles that we believe to be appropriate for our operations. PHICO Insurance Company, which provided us medical malpractice coverage from June 1998 to December 2000, has recently been placed in liquidation. See “Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations—Capital Resources and Liquidity—Commitments and Contingencies.” During the last year, the medical malpractice insurance markets have seen dramatic cost increases. Many insurance underwriters have become more selective in the insurance limits and types of coverage they will provide as a result of the September 11 terrorist activities, rising settlement costs and the significant failures of some nationally known insurance underwriters, such as PHICO Insurance Company. Our insurance coverage does not cover punitive damages and may not cover all claims against us or continue to be available at a reasonable cost. If we are unable to maintain adequate insurance coverage or are required to pay punitive damages, we may be exposed to substantial liabilities. We are also subject to lawsuits under a federal whistleblower statute designed to combat fraud and abuse in the healthcare industry. These lawsuits can involve significant monetary damages and award bounties to private plaintiffs who successfully bring the suits. See “Item 3. Legal Proceedings” and “Business—Government Regulations—Other Healthcare Regulations.

19


Table of Contents

We may experience difficulties integrating the information systems relating to our outpatient rehabilitation business, which could cause business interruption.

         We currently manage our outpatient rehabilitation business using six billing systems. Throughout 2002, we will continue our transition to a common system to manage all of our scheduling, billing, collecting and patient information for our outpatient rehabilitation clinics. If our systems integration fails or works improperly, we could face interruption in the segments of our business undergoing the transition while we correct the problem. The interruption in the affected segment of our business could include our inability to bill patients and payors for the services we provide. A sustained inability to bill and collect payments would have a material adverse effect on our cash flows and results of operations.

ITEM 2. PROPERTIES

         We currently lease most of our facilities, including clinics, offices, long term acute care hospitals and the corporate headquarters. We lease all of our clinics and related offices, which, as of December 31, 2001, included 717 outpatient rehabilitation clinics throughout the United States and Canada. The outpatient rehabilitation clinics generally have a five-year lease term with two three-year renewals.

         We also lease all of our hospital facilities except for one 176,000 square foot facility located in Houston, Texas. As of December 31, 2001, we had 62 hospital within a hospital leases and one freestanding building lease.

         We generally seek a five-year lease for our hospitals, with an additional five-year renewal at our option. We lease our corporate headquarters, which is approximately 63,000 square feet, located in Mechanicsburg, Pennsylvania. We lease several other administrative spaces related to administrative and operational support functions. As of December 31, 2001, this comprised 23 locations throughout the U.S. with approximately 141,000 square feet in total.

ITEM 3. LEGAL PROCEEDINGS

         On August 10, 1998 a complaint in the U.S. District Court for the Eastern District of Pennsylvania was filed that named as defendants NovaCare, Inc. (now known as NAHC, Inc.), other named defendants and 100 defendants who were to be named at a later time. This qui tam action sought triple damages and penalties under the False Claims Act against NAHC. The Department of Justice did not intervene in this action. The allegations involve, among other things, the distinction between individual and group billing in physical rehabilitation clinics that we acquired from NovaCare. On October 16, 2000 the relator plaintiff made a motion to amend the complaint to, among other things, add Select Medical Corporation and some of its subsidiaries acquired in the NovaCare acquisition as defendants in this case. This motion was granted in September of 2001. The amended complaint alleges that from about January 1, 1995 through the present, the defendants submitted false or fraudulent bills for physical therapy to various federal health programs. The United States Attorneys Office has asserted that because the complaint is being amended to add allegations against new defendants, it is entitled to a new period to determine whether to intervene in the new allegations. On January 3, 2002, NAHC and its related subsidiaries (including the subsidiaries acquired in the NovaCare acquisition) entered into a settlement agreement with the relator plaintiff and the government, pursuant to which, in exchange for a payment by NAHC of $375,000, the parties settled all claims arising out of conduct that took place before Select Medical’s acquisition of the NovaCare subsidiaries that are defendants in the case. Claims against the Company and the NovaCare subsidiaries regarding conduct occurring after the NovaCare acquisition were not settled. As of February 28, 2002, the government had not advised the Company whether it intends to intervene in any remaining claims, and Select and the subsidiaries have not been served with the amended complaint. Based on a review of the amended complaint, we do not believe that this lawsuit is meritorious, and we intend to vigorously

20


Table of Contents

defend against this action. However, because of the uncertain nature of the litigation, we cannot predict the outcome of this matter.

         In addition, as part of our business, we are subject to legal actions alleging liability on our part. To cover claims arising out of the operations of our hospitals and outpatient rehabilitation facilities, we generally maintain professional malpractice liability insurance and general liability insurance in amounts and with deductibles that we believe to be sufficient for our operations. We also maintain umbrella liability coverage covering claims which, due to their nature or amount, are not covered by our insurance policies. We cannot assure you that professional liability insurance will cover all claims against us or continue to be available at reasonable costs for us to maintain adequate levels of insurance. These insurance policies also do not cover punitive damages. See “Item 1. Business—Risk Factors—Risks Relating to our Business—Significant legal actions could subject us to substantial uninsured liabilities.”

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         There were no matters submitted to a vote of security holders during the fourth quarter ended December 31, 2001, or through the date of this filing.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

         Our common stock is quoted on The Nasdaq National Market under the symbol “SLMC.” Prior to our initial public offering on April 5, 2001, there was no public market for our common stock. As of February 28, 2002, there were approximately 140 record holders of our common stock.

         The following table sets forth, on a quarterly basis, the highest and lowest sale price for our common stock for the year ended December 31, 2001 as reported by the Nasdaq National Market:

                 
2001   HIGH   LOW

 
 
Quarter:
               
Second (from April 5, 2001)
  $ 20.50     $ 9.50  
Third
  $ 22.00     $ 11.93  
Fourth
  $ 18.50     $ 13.65  

         We have never declared or paid dividends on our common stock, and we do not intend to pay dividends in the foreseeable future. Our current credit facilities and our 9 1/2% senior subordinated notes restrict us from declaring or paying dividends on our common stock. We plan to retain any earnings for use in the operation of our business and to fund future growth. See applicable discussion under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources” and Note 6 to Select Medical Corporation’s consolidated financial statements.

21


Table of Contents

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

         You should read the following selected consolidated historical financial data in conjunction with our consolidated financial statements and the accompanying notes. You should also read “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All of these materials are contained in this report. Our operations commenced February 7, 1997 when we acquired all of the outstanding common stock of our predecessor company, Sports and Orthopedic Rehabilitation Services, P.A. The predecessor company data for the period from January 1, 1997 through February 6, 1997 has been derived from unaudited financial statements, which are not included in this report. The data as of December 31, 1997, 1998, 1999, 2000 and 2001 and for the years ended December 31, 1997, 1998, 1999, 2000 and 2001 have been derived from consolidated financial statements audited by PricewaterhouseCoopers LLP, independent accountants.

22


Table of Contents

                                                     
                                                Predecessor
                                                Company
                                               
                                                January 1,
                                                1997
        Year Ended December 31,   Through
       
  February 6,
        2001   2000   1999   1998   1997   1997
       
 
 
 
 
 
        (in thousands, except per share data)   (unaudited)
Consolidated Statement of Operations Data
                                               
Net operating revenues
  $ 958,956     $ 805,897     $ 455,975     $ 149,043     $ 11,194     $ 456  
Operating expenses (a)
    846,938       714,227       413,731       145,450       13,740       300  
Depreciation and amortization
    32,290       30,401       16,741       4,942       285       8  
Special charge (b)
                5,223       10,157              
 
   
     
     
     
     
     
 
Income (loss) from operations
    79,728       61,269       20,280       (11,506 )     (2,831 )     148  
Other income
                            6,022        
Interest expense (income), net
    29,209       35,187       21,099       4,976       (64 )     9  
 
   
     
     
     
     
     
 
Income (loss) before minority interests, income taxes and extraordinary item
    50,519       26,082       (819 )     (16,482 )     3,255       139  
Minority interests (c)
    3,491       4,144       3,662       1,744              
 
   
     
     
     
     
     
 
Income (loss) before income taxes and extraordinary item
    47,028       21,938       (4,481 )     (18,226 )     3,255       139  
Income tax provision (benefit)
    8,671       9,979       2,811       (182 )     1,308       38  
 
   
     
     
     
     
     
 
Net income (loss) before extraordinary item
    38,357       11,959       (7,292 )     (18,044 )     1,947       101  
Extraordinary item (d)
    8,676       6,247       5,814                    
 
   
     
     
     
     
     
 
Net income (loss)
    29,681       5,712       (13,106 )     (18,044 )     1,947     $ 101  
Less: Preferred dividends
    (2,513 )     (8,780 )     (5,175 )     (2,540 )     (266 )    
 
 
   
     
     
     
     
         
Net income (loss) available to common stockholders
  $ 27,168     $ (3,068 )   $ (18,281 )   $ (20,584 )   $ 1,681          
 
   
     
     
     
     
         
Net income (loss) per common share:
                                               
 
Basic:
                                               
   
Net income (loss) before extraordinary item
  $ 0.90     $ 0.13     $ (0.50 )   $ (1.64 )   $ 0.26          
   
Extraordinary item
    (0.22 )     (0.25 )     (0.24 )                    
 
   
     
     
     
     
         
   
Net income (loss) per common share
  $ 0.68     $ (0.12 )   $ (0.74 )   $ (1.64 )   $ 0.26          
 
   
     
     
     
     
         
 
Diluted:
                                               
   
Net income (loss) before extraordinary item
  $ 0.81     $ 0.12     $ (0.50 )   $ (1.64 )   $ 0.26          
   
Extraordinary item
    (0.19 )     (0.24 )     (0.24 )                    
 
   
     
     
     
     
         
   
Net income (loss) per common share
  $ 0.62     $ (0.12 )   $ (0.74 )   $ (1.64 )   $ 0.26          
 
   
     
     
     
     
         
Weighted average common shares outstanding (e):
                                               
 
Basic
    39,957       25,457       24,557       12,517       6,557          
 
Diluted
    45,464       25,907       24,557       12,517       6,564          
Other Data
                                               
EBITDA (f)
  $ 112,018     $ 91,670     $ 42,244     $ 3,593     $ (2,546 )   $ 156  
EBITDA as a % of net revenue
    11.7 %     11.4 %     9.3 %     2.4 %     (22.7 )%     34.2 %
Cash flow data
Cash flow (used in) provided by operating activities
  $ 95,770     $ 22,513     $ (25,157 )   $ (24,702 )   $ (2,367 )        
 
Cash flow (used in) provided by investing activities
    (61,947 )     14,197       (181,262 )     (209,481 )     (671 )        
 
Cash flow provided by (used in) financing activities
    (26,164 )     (37,616 )     197,480       242,298       7,897          

23


Table of Contents

                                         
    As of December 31,
   
    2001   2000   1999   1998   1997
   
 
 
 
 
    (in thousands)
Consolidated Balance Sheet Data
                                       
Cash and cash equivalents
  $ 10,703     $ 3,151     $ 4,067     $ 13,001     $ 4,859  
Working capital
    126,749       105,567       132,598       39,807       4,248  
Total assets
    650,845       586,800       620,718       336,949       18,191  
Total debt
    288,423       302,788       340,821       156,080       3,059  
Preferred stock
          129,573       120,804       55,843       5,717  
Total stockholders’ equity
    234,284       48,498       49,437       60,494       5,052  

            ______________________
  (a)   Operating expenses include cost of services, general and administrative expenses, and bad debt expenses.
 
  (b)   Reflects asset impairments of $6.3 million and litigation settlement costs of $3.8 million in 1998 and asset impairments of $5.2 million in 1999.
 
  (c)   Reflects interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by us.
 
  (d)   Reflects the write-off of deferred financing costs that resulted from the refinancing of our senior credit facilities in November 1999 and September 2000. Also reflects the write-off of deferred financing costs and discounts, net of tax, resulting from the repayment of debt with the proceeds from our initial public offering in April 2001 and the 9 1/2% senior subordinated notes offering in June 2001.
 
  (e)   For information concerning calculation of weighted average shares outstanding, see note 15 to Select Medical Corporation’s consolidated financial statements.
 
  (f)   We define EBITDA as net income (loss) before interest, income taxes, depreciation and amortization and special charges, other income, minority interest, and extraordinary items. EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from EBITDA are significant components in understanding and assessing financial performance. EBITDA is a measure commonly used by financial analysts and investors to evaluate the financial results of companies in our industry, and we believe it therefore provides useful information to investors. EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is susceptible to varying calculations, EBITDA as presented may not be comparable to similarly titled measures of other companies.

           The following table reconciles EBITDA to net income (loss):

                                         
    Year Ended December 31,
   
    2001   2000   1999   1998   1997
   
 
 
 
 
    (in thousands)
EBITDA
  $ 112,018     $ 91,670     $ 42,244     $ 3,593     $ (2,546 )
Depreciation and amortization
    (32,290 )     (30,401 )     (16,741 )     (4,942 )     (285 )
Special charge
                (5,223 )     (10,157 )      
Other income
                            6,022
Interest income
    507       939       362       406       206  
Interest expense
    (29,716 )     (36,126 )     (21,461 )     (5,382 )     (142 )
Minority interest
    (3,491 )     (4,144 )     (3,662 )     (1,744 )      
Income tax expense
    (8,671 )     (9,979 )     (2,811 )     182       (1,308 )
Extraordinary item
    (8,676 )     (6,247 )     (5,814 )            
 
   
     
     
     
     
Net income (loss)
  $ 29,681     $ 5,712     $ (13,106 )   $ (18,044)     $ 1,947
 
   
     
     
     
     
 

24


Table of Contents

ITEM 7.      MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
                    RESULTS OF OPERATIONS.

           As of December 31, 2001, we were the largest operator of specialty acute care hospitals for long term stay patients in the United States based on the number of facilities. We are also the second largest operator of outpatient rehabilitation clinics in the United States based on the number of clinics. As of December 31, 2001, we operated 64 specialty acute care hospitals in 22 states and 717 outpatient rehabilitation clinics in 31 states, the District of Columbia and seven Canadian provinces. We began operations in 1997 under the leadership of our current management team.

           We operate through two business segments, our specialty acute care hospital segment and our outpatient rehabilitation segment. For the year ended December 31, 2001, we had net operating revenues of $959.0 million. Of this total, we earned 54% of our net operating revenues from our specialty hospitals and 46% from our outpatient rehabilitation businesses.

           Our specialty acute care hospital segment consists of hospitals designed to serve the needs of long term stay acute patients. These patients typically suffer from serious and often complex medical conditions that require a high degree of care. Our outpatient rehabilitation business consists of clinics and contract services that provide physical, occupational and speech rehabilitation services. Our patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.

Significant Acquisition

           On November 19, 1999, we acquired the Physical Rehabilitation and Occupational Health Division of NovaCare, Inc. for approximately $200 million consisting of cash and the assumption of seller notes. The purchase was funded through the sale of Class B Preferred Stock, common stock, issuance of senior subordinated debt, and borrowings under our credit facility. At the time of the acquisition, NovaCare operated approximately 500 physical rehabilitation clinics and 35 occupational health centers. Following the completion of the acquisition, we sold 26 and closed 2 of these occupational health centers. As a result of this acquisition, the results of operations for the year ended December 31, 1999 and December 31, 2000 are not comparable.

25


Table of Contents

Development of New Specialty Acute Care Hospitals and Clinics

           Our goal is to open eight to ten new specialty acute care hospitals each year, utilizing our “hospital within a hospital” model. We internally developed and opened six hospitals in 1999 and ten hospitals in both 2000 and 2001. Each internally developed hospital has typically required approximately $500,000 for leasehold improvements and approximately $250,000 for equipment. During the initial year of operations, each newly developed hospital has typically incurred losses of approximately $500,000 and required an additional investment of $2.0 million to fund working capital. We also intend to open new clinics in our current markets where we can benefit from existing referral relationships and brand awareness to produce incremental growth. From time to time, we also intend to evaluate acquisition opportunities that may enhance the scale of our business and expand our geographic reach.

Critical Accounting Matters

Sources of Revenue

           Our net operating revenues are derived from a number of sources, including commercial, managed care, private and governmental payors. Our net operating revenues include amounts estimated by management to be reimbursable from each of the applicable payors and the federal Medicare program. Amounts we receive for treatment of patients are generally less than the standard billing rates. We account for the differences between the estimated reimbursement rates and the standard billing rates as contractual adjustments, which we deduct from gross revenues to arrive at net operating revenues.

           Our specialty hospitals are paid by Medicare under a cost-based reimbursement methodology. These payments are subject to final cost report settlements based on administrative review and audit by third parties. An annual cost report is filed for each provider to report the cost of providing services and to settle the difference between the interim payments we receive and final costs. We record adjustments to the original estimates in the periods that such adjustments become known. Historically these adjustments have not been significant. Because our routine payments from Medicare are different than the final reimbursement due to us under the cost based reimbursement system, we record a receivable or payable for the difference. As of December 31, 2000 we had a receivable from Medicare of $2.8 million. At December 31, 2001 we had a net amount due to Medicare of $3.4 million. We recorded this amount as due to third party payors on our balance sheet. Substantially all Medicare cost reports are settled through 1998.

           Net operating revenues generated directly from the Medicare program represented approximately 37.3%, 35.1% and 48.1% of net operating revenues for the years ended December 31, 2001, 2000 and 1999, respectively. The decline in the percentage of our net operating revenue coming from Medicare during the year ended December 31, 2000 was principally related to the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division in the last quarter of 1999, which receives a comparatively lower percentage of its revenues from Medicare.

           Legislative and regulatory action has resulted in continuing uncertainty about the Medicare reimbursement programs. The federal government might, in the future, reduce the funds available under that program or require more stringent utilization and quality reviews of hospital facilities. For example, because Congress has directed the Secretary of the Department of Health and Human Services to develop a prospective payment system for long term acute care hospitals, the way in which our specialty hospitals are reimbursed will change. The Secretary has not developed such a system to date, but is likely to do so in the near future. This change, when implemented, could reduce the reimbursements we receive from the Medicare program. Additionally, there may be a continued rise in managed care programs or future restructuring of the financing and delivery of healthcare in the United States. These events could have an adverse effect on our future financial results.

26


Table of Contents

           Other revenue primarily represents amounts the Medicare program reimburses us for a portion of our corporate expenses that are related to our specialty hospital operations.

Bad Debts

           We estimate our bad debts based upon the age of our accounts receivable and our historical collection percentages. These estimates are sensitive to changes in the economy that affect our customers.

Results of Operations

           The following table outlines, for the periods indicated, selected operating data as a percentage of net operating revenues.

                         
    Year Ended December 31,
   
    2001   2000   1999
   
 
 
Net operating revenues
    100.0 %     100.0 %     100.0 %
Cost of services (a)
    81.0       81.5       84.1  
General and administrative
    3.7       3.5       4.7  
Bad debt expense
    3.6       3.6       1.9  
 
   
     
     
 
EBITDA (b)
    11.7       11.4       9.3  
Depreciation and amortization
    3.4       3.8       3.7  
Special charges
                1.2  
 
   
     
     
 
Income from operations
    8.3       7.6       4.4  
Interest expense, net
    3.0       4.4       4.6  
 
   
     
     
 
Income (loss) before minority interests, income taxes and extraordinary item
    5.3       3.2       (0.2 )
Minority interests
    0.4       0.5       0.8  
 
   
     
     
 
Income (loss) before income taxes and extraordinary item
    4.9       2.7       (1.0 )
Income tax
    0.9       1.2       0.6  
 
   
     
     
 
Net income (loss) before extraordinary item
    4.0       1.5       (1.6 )
Extraordinary item
    0.9       0.8       1.3  
 
   
     
     
 
Net income (loss)
    3.1 %     0.7 %     (2.9 )%
 
   
     
     
 

27


Table of Contents

           The following table summarizes selected financial data by business segment, for the periods indicated.

                                           
      Year Ended December 31,
     
                              Increase   Increase
                              (Decrease)   (Decrease)
                             
 
      2001   2000   1999   2000-2001   1999-2000
     
 
 
 
 
    (dollars in thousands)        
Net operating revenues:
                                       
 
Specialty hospitals
  $ 503,021     $ 378,910     $ 307,464       32.8 %     23.2 %
 
Outpatient rehabilitation
    440,791       416,775       141,740       5.8       194.0  
 
Other
    15,144       10,212       6,771       48.3       50.8  
 
 
   
     
     
     
     
 
 
Total company
  $ 958,956     $ 805,897     $ 455,975       19.0 %     76.7 %
 
 
   
     
     
     
     
 
EBITDA: (b)
Specialty hospitals
  $ 57,556     $ 44,550     $ 35,929       29.2 %     24. 0 %
 
Outpatient rehabilitation
    76,127       65,420       22,697       16.4       188.2  
 
Other
    (21,665 )     (18,300 )     (16,382 )     (18.4 )     (11.7 )
 
 
   
     
     
     
     
 
 
Total company
  $ 112,018     $ 91,670     $ 42,244       22.2 %     117.0 %
 
 
   
     
     
     
     
 
Income (loss) from operations:
                                       
 
Specialty hospitals
  $ 46,472     $ 35,421     $ 28,016       31.2 %     26.4 %
 
Outpatient rehabilitation
    60,790       50,422       16,222       20.6       210.8  
 
Other
    (27,534 )     (24,574 )     (23,958 )     (12.0 )     (2.6 )
 
 
   
     
     
     
     
 
 
Total company
  $ 79,728     $ 61,269     $ 20,280       30.1 %     202.1 %
 
 
   
     
     
     
     
 
EBITDA margins: (b)
Specialty hospitals
    11.4 %     11.8 %     11.7 %     (3.4 )%     0.9 %
 
Outpatient rehabilitation
    17.3       15.7       16.0       10.2       (1.9 )
 
Other
      NM      NM       NM   NM   NM
 
 
   
     
     
     
     
 
 
Total company
    11.7 %     11.4 %     9.3 %     2.6 %     22.6 %
 
 
   
     
     
     
     
 
Total assets:
                                       
 
Specialty hospitals
  $ 303,910     $ 246,495     $ 250,034                  
 
Outpatient rehabilitation
    318,224       329,874       350,419                  
 
Other
    28,711       10,431       20,265                  
 
   
     
     
                 
 
Total company
  $ 650,845     $ 586,800     $ 620,718                  
 
   
     
     
                 
Capital expenditures:
                                       
 
Specialty hospitals
  $ 13,452     $ 13,677     $ 7,243                  
 
Outpatient rehabilitation
    8,800       6,399       3,085                  
 
Other
    1,759       2,354       568                  
 
   
     
     
                 
 
Total company
  $ 24,011     $ 22,430     $ 10,896                  
 
   
     
     
                 


    NM–Not Meaningful.
(a)   Cost of services include salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.
(b)   We define EBITDA as net income (loss) before interest, income taxes, depreciation and amortization and special charges, other income, minority interest and extraordinary items. EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from EBITDA are significant components in understanding and assessing financial performance. EBITDA is a measure commonly used by financial analysts and investors to evaluate the financial results of companies in our industry, and we believe it therefore provides useful information to investors. EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is susceptible to varying calculations, EBITDA as presented may not be comparable to similarly titled measures of other companies.

28


Table of Contents

           The following table reconciles EBITDA to net income (loss):

                         
            Year Ended December 31,        
    2001   2000   1999
   
 
 
            (in thousands)        
EBITDA
  $ 112,018     $ 91,670     $ 42,244  
Depreciation and amortization
    (32,290 )     (30,401 )     (16,741 )
Special charge
                (5,223 )
Interest income
    507       939       362  
Interest expense
    (29,716 )     (36,126 )     (21,461 )
Minority interest
    (3,491 )     (4,144 )     (3,662 )
Income tax expense
    (8,671 )     (9,979 )     (2,811 )
Extraordinary item
    (8,676 )     (6,247 )     (5,814 )
 
   
     
     
 
Net income (loss)
  $ 29,681     $ 5,712     $ (13,106 )
 
   
     
     
 

Special Charge

           We recorded a special charge of $5.2 million related to the impairment of goodwill, leasehold improvements and equipment that resulted from closures and relocations of certain hospitals and clinics in December 1999. See Note 11 to our consolidated financial statements.

Year Ended December 31, 2001 Compared to Year Ended December 31, 2000

Net Operating Revenues

           Our net operating revenues increased by 19.0% to $959.0 million for the year ended December 31, 2001 compared to $805.9 million for the year ended December 31, 2000.

            Specialty Acute Care Hospitals . Our specialty hospital net operating revenues increased 32.8% to $503.0 million for the year ended December 31, 2001 compared to $378.9 million for the year ended December 31, 2000. Net operating revenues for the specialty hospitals opened before January 1, 2000 and operated throughout both periods increased 20.2% to $430.4 million for the year ended December 31, 2001 from $358.0 million for the year ended December 31, 2000. This resulted from an improved occupancy rate and a higher non-Medicare payor mix. The remaining increase of $51.7 million resulted from the internal development of new specialty hospitals that commenced operations in 2000 and 2001.

            Outpatient Rehabilitation . Our outpatient rehabilitation net operating revenues increased 5.8% to $440.8 million for the year ended December 31, 2001 compared to $416.8 million the year ended December 31, 2000. The increase was related to an increase in the number of visits and the net revenue per visit experienced at our outpatient rehabilitation location.

            Other . Our other revenues increased to $15.1 million for the year ended December 31, 2001 compared to $10.2 million for the year ended December 31, 2000. The increase in other revenue reflects higher corporate general and administrative costs in 2001, which resulted in higher Medicare reimbursements for those costs.

Operating Expenses

           Our operating expenses increased by 18.6% to $846.9 million for the year ended December 31, 2001 compared to $714.2 million for the year ended December 31, 2000. The increase in operating expenses was principally related to the internal development of new specialty hospitals that commenced operations in 2000 and 2001. As a percent of our net operating revenues, our operating expenses

29


Table of Contents

declined to 88.3% for the year ended December 31, 2001 from 88.6% for the year ended December 31, 2000. Our operating expenses include our cost of services, general and administrative expense and bad debt expense. Cost of services as a percent of operating revenues declined to 81.0% for the year ended December 31, 2001 from 81.5% for the year ended December 31, 2000. These costs primarily reflect our labor expenses. The relative reduction in cost of services as a percentage of net operating revenue resulted from a reduction in non-labor costs experienced in both of our operating segments. General and administrative expense as a percentage of net operating revenues increased to 3.7% for the year ended December 31, 2001 compared to 3.5% for the year ended December 31, 2000. This increase is principally due to litigation costs associated with disputes that we assumed through our NovaCare acquisition and the costs associated with a secondary stock offering that was terminated in November 2001. Our bad debt expense as a percentage of net operating revenues remained stable at 3.6% for both periods.

EBITDA

           Our total EBITDA increased 22.2% to $112.0 million for the year ended December 31, 2001 compared to $91.7 million for the year ended December 31, 2000. Our EBITDA margins increased to 11.7% for the year ended December 31, 2001 compared to 11.4% for the year ended December 31, 2000. For cash flow information, see “—Capital Resources and Liquidity.”

            Specialty Acute Care Hospitals . EBITDA increased by 29.2% to $57.6 million for the year ended December 31, 2001 compared to $44.6 million for the year ended December 31, 2000. The hospitals opened before January 1, 2000 and operated throughout both periods accounted for $11.9 million of the increase. This increase in the same hospital EBITDA resulted from an increase in non-Medicare patient days and its associated revenue per patient day. The balance of the increase of $1.1 million resulted from our newly developed hospitals. Our EBITDA margins declined slightly to 11.4% for the year ended December 31, 2001 from 11.8% for the year ended December 31, 2000. The decline resulted from the effects of aggregate EBITDA losses generated by our newly opened hospitals. Our same hospital EBITDA margin increased to 13.5% for 2001 from 12.9% in 2000.

            Outpatient Rehabilitation . EBITDA increased by 16.4% to $76.1 million for the year ended December 31, 2001 compared to $65.4 million for the year ended December 31, 2000. Our EBITDA margins increased to 17.3% for the year ended December 31, 2001 from 15.7% for the year ended December 31, 2000. This increase in EBITDA margins was the result of lower costs of services, as discussed above under “Operating Expenses,” and a reduction in our relative bad debt percentage.

            Other . The EBITDA loss increased to $21.7 million for the year ended December 31, 2001 compared to a loss of $18.3 million for the year ended December 31, 2000. This increase resulted from the increase in general and administrative costs needed to support the growth of the organization and the litigation and secondary stock offering costs discussed above under “Operating Expenses.”

Income from Operations

           Income from operations increased 30.1% to $79.7 million for the year ended December 31, 2001 compared to $61.3 million for the year ended December 31, 2000. The increase in income from operations resulted from the EBITDA increases described above, offset by an increase in depreciation and amortization. Depreciation and amortization increased by 6.2% to $32.3 million for the year ended December 31, 2001 from $30.4 million for the year ended December 31, 2000. The increase resulted primarily from increases in depreciation on fixed asset additions that are principally related to new hospital development.

30


Table of Contents

Interest Expense

           Interest expense decreased by $6.4 million to $29.7 million for the year ended December 31, 2001 from $36.1 million for the year ended December 31, 2000. The decline in interest expense is due to the lower debt levels outstanding in 2001 compared to 2000 and a lower effective interest rate in 2001. The lower average debt levels in 2001 resulted from the significant repayment of debt that occurred in the third and fourth quarters of 2000 as a result of the NovaCare settlement which is discussed below under “Capital Resources and Liquidity,” and the divestiture of the NovaCare Occupational Health businesses. Additionally, during 2001 we used a portion of our operating cash flow to repay debt.

Minority Interests

           Minority interests in consolidated earnings decreased 15.8% to $3.5 million for the year ended December 31, 2001 compared to $4.1 million for the year ended December 31, 2000. This decrease resulted from a smaller percentage of ownership held by minority interests. See “—Capital Resources and Liquidity” for a discussion of our repurchase of minority interests.

Income Taxes

           We recorded income tax expense of $8.7 million for the year ended December 31, 2001. The expense represented an effective tax rate of 18.4%. Our lower effective tax rate resulted from the reversal of our tax valuation allowance. The reversal represented a reduction in the effective tax rate of 20.6 percentage points. Had the reversal not occurred, our effective tax rate would have approximated the combined statutory federal and state tax rate of 39.0%. We recorded income tax expense of $10.0 million for the year ended December 31, 2000. This expense represented an effective tax rate of 45.5%. This exceeded the statutory rates primarily due to non-deductible goodwill. In 2001, we were able to utilize net operating loss carryovers to offset the effect of our non-deductible goodwill.

           As a result of our limited operating history and the cumulative losses incurred in prior years, we historically provided a valuation allowance for substantially all of our deferred tax assets. Because of the cumulative profitable operations over the last three years, we have concluded that it is more likely than not that these deferred tax items will be realized. The reversal of these valuation allowances in the fourth quarter of 2001 resulted in a reduction in the tax provision of $9.7 million and a reduction in goodwill of $18.5 million. The reduction in goodwill relates to those deferred tax assets originating through acquisitions. The reduction in the tax provision generated a positive earnings per share effect of $0.19 in the fourth quarter and $0.21 for the year.

Extraordinary Item

           As a result of our initial public offering of stock in April 2001 and the issuance of $175 million of 9 1/2 % Senior Subordinated Notes in June 2001, we repaid $75 million of our U.S. term loan and all $90 million of our 10% Senior Subordinated Notes. The extraordinary item consists of $1.3 million of unamortized deferred financing costs related to the repayment of our U.S. term loan and $12.9 million of deferred financing costs and unamortized discount related to the repayment of our 10% Senior Subordinated Notes. These costs were offset by a tax benefit of $5.5 million.

Year Ended December 31, 2000 Compared to Year Ended December 31, 1999

Net Operating Revenues

           Our net operating revenues increased 76.7% to $805.9 million for the year ended December 31, 2000 compared to $456.0 million for the year ended December 31, 1999. The percentage of our net operating revenues coming from Medicare declined to 35.1% during the year ended December 31, 2000

31


Table of Contents

from 48.1% for 1999. This decline was principally related to the acquisition of NovaCare, which receives a comparatively lower percentage of its revenue from Medicare.

            Specialty Acute Care Hospitals. Our specialty hospital revenues increased 23.2% to $378.9 million for the year ended December 31, 2000 compared to $307.5 million for the year ended December 31, 1999. Net operating revenues for the specialty hospitals operated throughout both periods increased 11.0% to $325.3 million for 2000 from $293.1 million for 1999. This increase resulted from an improved occupancy rate and a higher non-Medicare payor mix. The remaining increase of $39.2 million resulted from the internal development of new specialty hospitals that commenced operations in 1999 and 2000.

            Outpatient Rehabilitation. Our outpatient rehabilitation revenues increased 194.0% to $416.8 million for the year ended December 31, 2000 compared to $141.7 million for the year ended December 31, 1999. This increase was principally related to the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division in November 1999, which accounted for $261.8 million of the increase. The remaining increase resulted primarily from increased volume in existing businesses.

            Other. Our other revenues increased 50.8% to $10.2 million for the year ended December 31, 2000 compared to $6.8 million for the year ended December 31, 1999. The increase in other revenue reflects higher corporate general and administrative costs in 2000, which resulted in higher Medicare reimbursements for those costs.

Operating Expenses

           Our operating expenses increased by $300.5 million to $714.2 million for the year ended December 31, 2000 compared to $413.7 million for the year ended December 31, 1999. The increase in operating expenses was principally related to the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division, which accounted for $220.0 million of the increase. Our specialty hospital segment experienced an increase in operating expenses of $62.8 million. This increase principally related to growth in operating expenses associated with the hospitals opened in 1999 and 2000. As a percent of our net operating revenues, our operating expenses declined to 88.6% in 2000 from 90.7% in 1999. Our operating expenses include our cost of services, general and administrative expense and bad debt expense. Cost of services as a percent of net operating revenues declined to 81.5% during 2000 from 84.1% during 1999. These costs primarily reflect our labor expenses. During the same time period, general and administrative expense as a percent of net operating revenues declined to 3.5% from 4.7%. The relative reductions in cost of services and general and administrative expense were primarily the result of our acquisition of NovaCare and the lower cost associated with providing outpatient rehabilitation services relative to our specialty hospital services. Bad debt expense as a percent of net operating revenues increased to 3.6% during 2000 compared to 1.9% during 1999. This increase resulted primarily from our acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division, which incurs higher bad debt as a percentage of net operating revenues because of the large volume of relatively difficult to collect, smaller dollar accounts receivables generated in an outpatient environment.

EBITDA

           Our total EBITDA increased 117.0% to $91.7 million for the year ended December 31, 2000 compared to $42.2 million for the year ended December 31, 1999. Our EBITDA margins increased to 11.4% for 2000 compared to 9.3% for 1999. For cash flow information, see “—Capital Resources and Liquidity.”

            Specialty Acute Care Hospitals. EBITDA increased 24.0% to $44.6 million for the year ended December 31, 2000 compared to $35.9 million for the year ended December 31, 1999. Our EBITDA margins remained consistent at 11.8% and 11.7% in 2000 and 1999, respectively. The hospitals we

32


Table of Contents

operated throughout both periods accounted for $5.3 million of the increase. This increase in same hospital EBITDA resulted from an increase in non-Medicare payor mix. Our same hospital EBITDA margin increased from 12.6% to 13.0%. The balance of the increase of $3.4 million resulted from our newly developed hospitals.

            Outpatient Rehabilitation. EBITDA increased by 188.2% to $65.4 million for the year ended December 31, 2000 compared to $22.7 million for the year ended December 31, 1999. The major contributor to this increase was the NovaCare Physical Rehabilitation and Occupational Health Division acquisition that accounted for $41.9 million of the increase. The remaining increase of $0.8 million resulted from growth in our existing business. Our EBITDA margins declined to 15.7% during 2000 from 16.0% during 1999. This decline resulted from the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division, which historically had lower margins than our existing outpatient rehabilitation business. These lower margins were the result of higher bad debt expense and costs of services as a percentage of net operating revenues.

            Other . EBITDA loss increased by 11.7% to a loss of $18.3 million for the year ended December 31, 2000 compared to a loss of $16.4 million for the year ended December 31, 1999. This increase resulted from the increase in general and administrative expenses associated with the growth of the organization, principally the addition of the NovaCare division and our new hospital development.

Income from Operations

           Income from operations increased 202.1% to $61.3 million for the year ended December 31, 2000 compared to $20.3 million for the year ended December 31, 1999. The increase in income from operations resulted from EBITDA increases described above and from a reduction in the amount recorded as a special charge, offset by an increase in depreciation and amortization. Depreciation and amortization increased by 81.6% to $30.4 million for 2000 compared to $16.7 million for 1999. Approximately $10.3 million of the increase in the depreciation and amortization was related to the amortization of goodwill and identifiable intangibles resulting from the NovaCare acquisition and the depreciation of the acquired NovaCare fixed assets. The remaining increase resulted from depreciation of new fixed assets.

Interest Expense

           Interest expense increased to $36.1 million for the year ended December 31, 2000 from $21.5 million for the year ended December 31, 1999. The increase in interest expense resulted from higher average debt levels outstanding in 2000 compared to 1999, including the debt assumed as a result of the NovaCare acquisition, and an increase in the average interest rate associated with borrowings.

Minority Interests

           Minority interests increased by $0.4 million to $4.1 million for the year ended December 31, 2000 compared to $3.7 million for the year ended December 31, 1999. This increase resulted from improved operating performance in our operating subsidiaries that are structured with a minority interest component.

Income Taxes

           We recorded income tax expense of $10.0 million for the year ended December 31, 2000. The expense represented an effective tax rate of 45.5% and exceeded statutory federal and state tax rates as a result of non-deductible goodwill. We recorded income tax expense of $2.8 million for the year ended December 31, 1999. This expense represented an effective tax rate of 62.7%. We had a higher effective tax rate in this period as a result of non-deductible goodwill and state income taxes in the jurisdictions where we reported taxable income.

33


Table of Contents

Extraordinary Item

           On September 22, 2000, we entered into a new $230 million senior credit facility with a syndicate of banks that replaced our $225 million credit facility dated November 19, 1999. The extraordinary item consists of the unamortized deferred financing costs of $6.2 million related to the November 19, 1999 credit facility.

Capital Resources and Liquidity

Years Ended December 31, 2001, 2000, and 1999

           Operating activities generated $95.8 million and $22.5 million in cash during the years ended December 31, 2001 and December 31, 2000, respectively, compared to cash usage of $25.2 million in the year ended December 31, 1999. The increase in cash flow is attributable to improved operating income, continued management of payables and lower accounts receivable days outstanding. Our accounts receivable days outstanding were 77 days at December 31, 2001 compared to 85 days at December 31, 2000. The use of cash in 1999 was primarily attributable to net losses and an increase in accounts receivable that resulted from our growth.

           Investing activities used $61.9 million of cash flow for the year ended December 31, 2001. This usage resulted from purchases of property and equipment of $24.0 million related principally to new hospital development. Additionally, we incurred earnout and acquisition related payments of $5.7 million and $33.1 million, respectively. The earnout payments relate to obligations we assumed as part of the NovaCare acquisition. Acquisition related payments consist of approximately $22.2 paid for new business acquisitions and the remainder relate to our purchases of minority interests. The terms of our agreements with these minority owners allowed some of them to sell their minority interests to us upon the completion of our initial public offering. In total, we paid these minority owners $15.9 million for their ownership interests. Of this amount, $10.9 million was paid in cash and $5.0 million was paid in our stock.

           Investing activities provided $14.2 million of cash flow during 2000 compared to cash usages of $181.3 million in the year ended December 31, 1999. For the year ended December 31, 2000, we received proceeds of $29.9 million from two escrow funds established as part of the NovaCare acquisition and proceeds of $13.0 million from the sale of the occupational health centers. These occupational health centers were an operating division of NovaCare. The claim against the escrow fund resulted from an increase in uncollectible accounts receivable, which were paid with the proceeds from the escrow fund. Cash inflows were offset principally by the purchases of $22.4 million of equipment and acquisition and earnout payments of $9.3 million. The increase in property and equipment purchases reflects the growth in new hospital development during 2000. The principal usage of cash in 1999 was to fund acquisitions. Our investment in property and equipment during 1999 was not material because our operations required minimal capital expenditures on an ongoing basis, and most of our locations were leased. Our investment in equipment is mostly related to development of new hospitals.

           Financing activities used $26.2 million of cash for the year ended December 31, 2001. This was due principally to the repayment of seller and other debt. In 2001, we had two significant financing transactions that refinanced existing capital. On April 10, 2001 we completed an initial public offering of 9 million shares of our common stock. Our net proceeds after deducting expenses and underwriting discounts and commissions were approximately $77.3 million. On April 20, 2001 the underwriters exercised their option to purchase an additional 1.35 million shares of common stock to cover overallotments. The net proceeds from the exercise of this option were $11.9 million after deduction of the underwriters discount. The proceeds of the stock offering were used to repay $24.0 million of our senior debt under the term loan portion of our bank credit facility, to redeem $52.8 million of our Class A Preferred Stock and the remainder was used for general corporate purposes including the purchases of

34


Table of Contents

minority interests. On June 11, 2001, we issued and sold $175.0 million of 9 1/2% Senior Subordinated Notes due 2009. The net proceeds from the sale were approximately $169.5 million, after deducting discounts, commissions and expenses of the offering. We used $90.0 million of the net proceeds to retire our 10% Senior Subordinated Notes which were issued in December 1998, February 1999 and November 1999. We used an additional $79.0 million of the net proceeds to repay part of our senior indebtedness under both the term loan and revolving portions of our senior credit facility. The remainder of the net proceeds was used to pay accrued interest.

           Financing activities used $37.6 million of cash for the year ended December 31, 2000. This was due principally to the repayment of debt. In 1999 we had cash inflows of $197.5 million. We raised capital through the issuance of common and preferred stock, senior subordinated debt and borrowings under our senior credit facility. We incurred debt in connection with the acquisition of the NovaCare Physical Rehabilitation and Occupational Health Division.

Capital Resources

           Net working capital was $126.7 million at December 31, 2001 compared to $105.6 million at December 31, 2000. This increase is principally related to the increase in the deferred tax asset of $28.9 million resulting from the reversal of our valuation allowance.

           On September 22, 2000 we entered into a new credit agreement that refinanced our existing bank debt. In January 2001, in anticipation of our initial public offering, we entered into an amendment to our credit agreement that became effective in April 2001. The amendment allowed for the use of the net proceeds of the offering to repay $24.0 million of our senior debt under the U.S. term loan portion of our bank credit facility and to redeem $52.8 million of our Class A Preferred Stock. In May 2001, in anticipation of the senior subordinated note offering, we entered into another amendment to our credit agreement that became effective in June 2001. The amendment allowed for the use of net proceeds to repay $51.0 million of our senior debt under the U.S. term loan portion and $28.0 million of our senior debt under the U.S. revolving portion of our bank credit facility and to repay $90.0 million of existing subordinated debt. The amendment to the credit facility also increased our revolving credit facility by $77.4 million. Our credit facility now consists of a term facility of approximately $91.8 million, and a revolving credit facility of approximately $152.4 million. The term debt began quarterly amortization in September, 2001, with a final maturity date of September 2005. As of December 31, 2001 we had availability to borrow an additional $143.1 million under our revolving facility. The revolving facility terminates in September 2005.

           Borrowings under the credit agreement bear interest at a fluctuating rate of interest based upon financial covenant ratio tests. As of December 31, 2001, our weighted average interest rate under our credit agreement was approximately 7.6%. A portion of the amount borrowed under our U.S. term loan portion of our credit agreement is hedged through an interest rate swap transaction, which fixes the rate paid through the term of the agreement. See Item 7A “Quantitative and Qualitative Disclosures on Market Risk” for a discussion of our floating interest rates on borrowings under our credit facility.

           We are required to pay a quarterly commitment fee at a rate that ranges from .375% to .500%, based upon financial covenant ratio tests. This fee applies to unused commitments under the revolving credit facility.

           The terms of the credit agreement include various restrictive covenants. These covenants include:

    restrictions against incurring additional indebtedness,
 
    disposing of assets,

35


Table of Contents

    incurring capital expenditures,
 
    making investments,
 
    restrictions against paying certain dividends,
 
    engaging in transactions with affiliates,
 
    incurring contingent obligations, and
 
    allowing or causing fundamental changes.

           The covenants also require us to maintain various financial ratios regarding total indebtedness, interest, fixed charges and net worth. The borrowings are collateralized by substantially all of the tangible and intangible assets of us and our subsidiaries, including all of the capital stock of our domestic subsidiaries and 65% of the capital stock of our direct foreign subsidiaries. In addition, the loans have been guaranteed by our domestic subsidiaries.

           On June 11, 2001, we issued and sold $175.0 million aggregate principal amount of 9 1/2% senior subordinated notes due June 15, 2009. The notes were issued under an indenture dated as of June 11, 2001 between us and State Street Bank and Trust Company, N.A., as Trustee. Interest on the notes is payable semiannually in arrears on June 15 and December 15 of each year, commencing December 15, 2001. The notes are unsecured senior subordinated obligations of Select Medical, are subordinated in right of payment to all existing and future senior indebtedness of Select Medical, and are senior in right of payment to all future subordinated indebtedness of Select Medical. The notes are guaranteed on a senior subordinated basis by all of our wholly-owned domestic subsidiaries, subject to certain exceptions. On or after June 15, 2005, the notes may be redeemed at our option, in whole or in part, at redemption prices that decline annually to 100% on and after June 15, 2008, plus accrued and unpaid interest.

           Upon a change of control of Select Medical, each holder of notes may require us to repurchase all or any portion of the holder’s notes at a purchase price equal to 101% of the principal amount plus accrued and unpaid interest to the date of purchase. The indenture contains certain covenants that, among other things, limit the incurrence of additional debt by Select Medical and certain of its subsidiaries; the payment of dividends on capital stock of Select Medical and the purchase, redemption or retirement of capital stock or subordinated indebtedness; investments; certain transactions with affiliates; sales of assets, including capital stock of subsidiaries; and certain consolidations, mergers and transfers of assets. The indenture also prohibits certain restrictions on distributions from certain subsidiaries. All of these limitations and prohibitions, however, are subject to a number of qualifications.

           We believe that existing cash balances, internally generated cash flows and borrowings under our revolving credit facility will be sufficient to finance operations for at least the next twelve months. In the year ended December 31, 2001, we opened ten specialty hospitals. A new specialty hospital has historically required approximately $3.3 million per hospital over the initial year of operations to fund leasehold improvements, equipment, start-up losses and working capital. From time to time, we may complete acquisitions of specialty hospitals and outpatient rehabilitation businesses. As of December 31, 2001 we had approximately $143.1 million of unused capacity under our revolving credit facility, some of which can be used for acquisitions. Based on the size of the acquisition, approval of the acquisition by our lenders may be required. If funds required for future acquisitions exceed existing sources of capital, we will need to increase our credit facilities or obtain additional capital by other means.

36


Table of Contents

Commitments and Contingencies

           In February 2002, PHICO Insurance Company (“PHICO”), at the request of the Pennsylvania Insurance Department, was placed in liquidation by an Order of the Commonwealth Court of Pennsylvania (“Liquidation Order”). From June 1998 through December 2000, we had placed our primary malpractice insurance coverage through PHICO. In January 2001, these policies were replaced with policies issued by other insurers. Currently we have approximately 20 unsettled claims in eleven states from the policy years covered by PHICO issued policies. The Liquidation Order refers these claims to various state guaranty associations. These state guaranty association statutes generally provide for coverage between $100,000-$300,000 per insured claim, depending upon the state. Some states also have catastrophic loss funds to cover settlements in excess of the available state guaranty funds. Most state insurance guaranty statutes provide for net worth and residency limitations that, if applicable, may limit or prevent us from recovering from these state guaranty association funds. At this time, we believe that we will meet the requirements for coverage under the applicable state guaranty association statutes, and that the resolution of these claims will not have a material adverse effect on our financial position, cash flow and results of operations. However, because the rules related to state guaranty association funds are subject to interpretation, and because these claims are still in the process of resolution, our conclusions may change as this process progresses.

           The following table summarizes our contractual obligations at December 31, 2001, and the effect such obligations are expected to have on our liquidity and cash flow in future periods.

                                         
                    Payments Due by Year                
Contractual Obligations   Total   2002   2003-2005   2006-2007   After 2007

 
 
 
 
 
(in thousands)
9 1/2% Subordinated Notes
  $ 175,000                       $ 175,000  
Credit Facility
    96,782     $ 17,714     $ 79,068              
Seller Notes
    14,849       8,659       6,102     $ 88        
Capital Lease Obligations
    1,473       303       1,170              
Other Debt Obligations
    319       98       221              
 
   
     
     
     
     
 
Total Debt
    288,423       26,774       86,561       88       175,000  
Letters of Credit Outstanding
    4,361       250       4,111              
Officer Life Insurance Policy
    11,250       1,250       3,750       2,500       3,750  
Naming, Promotional and Sponsorship Agreement
    39,419       1,400       4,298       2,996       30,725  
Operating Leases
    155,492       53,247       81,207       15,116       5,922  
Related Party Operating Leases
    16,619       1,197       3,467       2,304       9,651  
 
   
     
     
     
     
 
Total Contractual Cash Obligations
  $ 515,564     $ 84,118     $ 183,394     $ 23,004     $ 225,048  
 
   
     
     
     
     
 

Related Party

           We are party to various rental and other agreements with companies affiliated through common ownership. These transactions and commitments are described more fully in Note 17 to our consolidated financial statements.

37


Table of Contents

Inflation

           The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. In addition, suppliers pass along rising costs to us in the form of higher prices. We have implemented cost control measures, including our case and resource management program, to curtail increases in operating costs and expenses. We have, to date, offset increases in operating costs by increasing reimbursement for services and expanding services. However, we cannot predict our ability to cover or offset future cost increases.

Recent Accounting Pronouncements

           In October 2001, the Financial Accounting Standards Board approved SFAS No. 144 “Accounting for the Impairment of Disposal of Long-Lived Assets” which is effective for financial statements issued for fiscal years beginning after December 15, 2001. SFAS 144 supersedes the accounting provisions of APB 30 that address the disposal of a segment of a business and requires that such long-lived assets be reported at fair value less cost to sell. It requires that long lived assets to be abandoned, exchanged for similar productive assets or distributed to owners in a spin-off be considered held for use until they are abandoned, exchanged or distributed. It also eliminates the exception to consolidation for a subsidiary while control is expected to be temporary. We adopted SFAS 144 on January 1, 2002 with no material effect on net income.

           In June 2001, the Financial Accounting Standards Board issued SFAS No. 141 “Business Combinations” and No. 142 “Goodwill and Other Intangible Assets” which are effective for us on July 1, 2001 and January 1, 2002, respectively. SFAS 141 requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001. Under SFAS 142, amortization of goodwill, including goodwill recorded in past business combinations, will discontinue upon adoption of this standard. In addition, goodwill recorded as a result of business combinations completed during the six-month period ending December 31, 2001 was not amortized. All goodwill and intangible assets will be tested for impairment in accordance with the provisions of the Statement. An initial impairment test must be performed in 2002. At this time, we believe that any impairment charge in 2002 resulting from the adoption of SFAS 142 will not be significant. If the new standard had been in effect in 2001, pre-tax amortization expense in 2001 would have been reduced by approximately $8.7 million or approximately $0.12 per diluted share.

ITEM 7A.      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

           We are exposed to interest rate changes, primarily as a result of floating interest rates on borrowings under our credit facility. A change in interest rates by one percentage point on variable rate debt would have resulted in interest expense fluctuating approximately $0.8 million for the year ended December 31, 2001. As required by our credit agreement, on March 30, 2001 we entered into an interest rate swap agreement that fixes the interest rate cost to us on a portion of the U.S. term loans outstanding under our credit facility for a period of four years. The swap became effective on April 27, 2001. In January 2002 we amended the swap to mature in March 2003. As of December 31, 2001, approximately $69 million of variable credit facility debt has been converted to fixed rate debt. The fixed rate portion of all of our outstanding U.S. term loans was 91% as of December 31, 2001.

           Approximately 17% of our term-loan borrowings under our credit agreement are denominated in Canadian dollars. Although we are not required by our credit agreement to maintain a hedge on our foreign currency risk, we have entered into a five year agreement that allows us to limit the cost of Canadian dollars to a range of U.S.$0.6631 to U.S.$0.6711 per Canadian dollar to limit our risk on the potential fluctuation in the exchange rate of the Canadian dollar to the U.S. dollar.

38


Table of Contents

ITEM 8.      FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

           See Consolidated Financial Statements and Notes thereto commencing at Page F-1.

ITEM 9.      CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

           Not applicable

PART III

ITEM 10.      DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

           The information required under this item with respect to the Directors of the Registrant will appear under the caption “Election of Directors (Item 1 on Proxy Card)” in the definitive Proxy Statement relating to the Registrant’s 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and is hereby specifically incorporated herein by reference thereto.

           The information required under this item with respect to the Executive Officers of the Registrant will appear under the caption “Executive Officers” in the definitive Proxy Statement relating to the Registrant’s 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto.

ITEM 11.      EXECUTIVE COMPENSATION

           The information required under this item will appear under the caption “Executive Compensation” in the definitive Proxy Statement relating to the Registrant’s 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto, except for the “Report of the Compensation Committee of the Board of Directors on Executive Compensation” contained therein, which is not so incorporated by reference.

ITEM 12.      SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

           The information required under this item will appear under the caption “Security Ownership of Certain Beneficial Owners and Management” in the definitive Proxy Statement relating to the Registrant’s 2002 Annual Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference thereto.

ITEM 13.      CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

           The information required under this item will appear under the caption “Certain Relationships and Related Transactions” in the definitive Proxy Statement relating to the Registrants 2002 Annual

39


Table of Contents

Meeting of Stockholders, to be filed by the Registrant with the Commission pursuant to Section 14(a) of the Exchange Act, and is hereby specifically incorporated herein by reference hereto.

PART IV

EXHIBITS, FINANCIAL STATEMENTS SCHEDULE, AND
REPORTS ON FORM 8-K

ITEM 14.      EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

           (a)  The consolidated financial statements filed as part of this Annual Report on Form 10-K are described in the Index to Financial Statements.

           (b)  Form 8-K, dated October 1, 2001, pursuant to Item 5, in connection with the adoption by our Board of Directors of a Shareholder Rights Plan.

           (c)  The following exhibits are hereby filed as part of this Annual Report on Form 10-K:

     
Exhibit    
Number   Document

 
2.1   Stock Purchase Agreement dated as of October 1, 1999 by and among Select Medical Corporation, NC Resources, Inc. and NovaCare, Inc., incorporated by reference to Exhibit 2.3 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
2.2   First Amendment dated as of November 19, 1999 to Stock Purchase Agreement dated as of October 1, 1999 by and among Select Medical Corporation, NC Resources, Inc. and NovaCare, Inc., incorporated by reference to Exhibit 2.4 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
3.1   Form of Restated Certificate of Incorporation, incorporated by reference to Exhibit 3.1 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
3.2   Amended and Restated Bylaws.
3.3   Amendment No. 1 to Amended and Restated Bylaws.
3.4   Amendment No. 2 to Amended and Restated Bylaws.
4.1   Indenture governing 9 1/2% Senior Subordinated Notes due 2009 among Select Medical Corporation, the Subsidiary Guarantors named therein and State Street Bank and Trust Company, N.A., dated June 11, 2001, incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
4.2   Form of 9 1/2% Senior Subordinated Notes due 2009 (included in Exhibit 4.1).

40


Table of Contents

     
Exhibit    
Number   Document

 
4.3   Exchange and Registration Rights Agreement, dated June 11, 2001 by and among Select Medical Corporation, the Subsidiary Guarantors named therein, J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse First Boston Corporation, CIBC World Markets Corp. and First Union Securities, Inc, incorporated by reference to Exhibit 4.3 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.1   Registration Agreement dated as of February 5, 1997 by and among Select Medical Corporation; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.1 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.2   Amendment No. 1 dated as of December 15, 1998 to Registration Agreement dated as of February 5, 1997 by and among Select Medical Corporation; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.2 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.3   Amendment No. 2 dated as of November 19, 1999 to Registration Agreement dated as of February 5, 1997 by and among Select Medical; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.3 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.4   Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.4 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.5   Employment Agreement dated as of December 16, 1998 between Select Medical Corporation and David W. Cross, incorporated by reference to Exhibit 10.8 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.6   Other Senior Management Agreement dated as of June 2, 1997 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.9 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.7   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.10 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.8   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.11 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

41


Table of Contents

     
Exhibit    
Number   Document

 
10.9   Employment Agreement dated as of December 21, 1999 between RehabClinics, Inc. and Edward R. Miersch, incorporated by reference to Exhibit 10.12 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.10   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Edward R. Miersch, incorporated by reference to Exhibit 10.13 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.11   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.14 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.12   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.15 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.13   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.16 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.14   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.17 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.15   Split Dollar Agreement dated as of October 6, 2000 between Select Medical Corporation, Michael E. Salerno and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.18 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.16   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.19 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.17   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.20 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.18   Other Senior Management Agreement dated as of March 28, 1997 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.21 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

42


Table of Contents

     
Exhibit    
Number   Document

 
10.19   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.22 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.20   Employment Agreement dated as of May 22, 2000 between Select Medical Corporation and LeRoy S. Zimmerman, incorporated by reference to Exhibit 10.23 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.21   Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.24 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.22   First Addendum dated June 1999 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.25 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.23   Second Addendum dated as of February 1, 2000 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.26 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.24   Office Lease Agreement dated as of June 17, 1999 between Select Medical Corporation and Old Gettysburg Associates III, incorporated by reference to Exhibit 10.27 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.25   Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.28 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.26   First Amendment dated as of December 8, 1997 to Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.29 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.27   Second Amendment dated as of January 28, 2000 to Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.30 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.28   Amended and Restated 1997 Stock Option Plan, amended and restated February 22, 2001, incorporated by reference to Exhibit 10.31 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

43


Table of Contents

     
Exhibit    
Number   Document

 
10.29   First Amendment dated as of October 15, 2000 to Employment Agreement dated as of December 16, 1998 between Select Medical Corporation and David W. Cross, incorporated by reference to Exhibit 10.33 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.30   Amended and Restated Senior Management Agreement dated as of May 7, 1997 between Select Medical Corporation, John Ortenzio, Martin Ortenzio, Select Investments II, Select Partners, L.P. and Rocco Ortenzio, incorporated by reference to Exhibit 10.34 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.31   Amendment No. 1 dated as of January 1, 2000 to Amended and Restated Senior Management Agreement dated May 7, 1997 between Select Medical Corporation and Rocco Ortenzio, incorporated by reference to Exhibit 10.35 of the Company’s Registration Statement on Form S-1 (Reg. No. 333- 48856).
10.32   Naming, Promotional and Sponsorship Agreement dated as of October 1, 1997 between NovaCare, Inc. and the Philadelphia Eagles Limited Partnership, assumed by Select Medical Corporation in a Consent and Assumption Agreement dated November 19, 1999 by and among NovaCare, Inc., Select Medical Corporation and the Philadelphia Eagles Limited Partnership, incorporated by reference to Exhibit 10.36 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.33   Cost Sharing Agreement, dated December 11, 2000, among Select Transport, Inc., Select Medical Corporation and Select Air II Corporation, incorporated by reference to Exhibit 10.39 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.34   Amended and Restated Deferred Compensation Agreement dated January 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.40 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.35   Settlement Agreement dated as of July 6, 2000 by and among Select Medical Corporation, NC Resources, Inc, NAHC Inc., and NovaCare Holdings, Inc, incorporated by reference to Exhibit 10.44 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.36   First Amendment dated December 28, 2000 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.45 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.37   Second Amendment dated January 18, 2001 to the Amended Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.46 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

44


Table of Contents

     
Exhibit    
Number   Document

 
10.38   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.47 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.39   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.48 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.40   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.49 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.41   Amendment No. 1 dated as of February 23, 2001 to Employment Agreement dated as of May 22, 2000 between Select Medical Corporation and LeRoy S. Zimmerman, incorporated by reference to Exhibit 10.50 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.42   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Edward R. Miersch, incorporated by reference to Exhibit 10.51 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.43   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.44   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.45   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.54 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
10.46   Third Amendment dated May 31, 2001 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC Inc., incorporated by reference to Exhibit 10.49 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.47   Amendment No. 3 dated as of April 24, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.50 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).

45


Table of Contents

     
Exhibit    
Number   Document

 
10.48   First Amendment to Cost Sharing Agreement dated as of April 1, 2001 by and among Select Medical Corporation, Select Transport, Inc. and Select Air II Corporation, incorporated by reference to Exhibit 10.51 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.49   Third Addendum dated as of May 17, 2001 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.50   Office Lease Agreement dated as of May 15, 2001 by and between Select Medical Corporation and Old Gettysburg Associates II, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.51   Purchase Agreement, dated June 11, 2001 by and among Select Medical Corporation, the Subsidiary Guarantors named therein, J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse First Boston Corporation, CIBC World Markets Corp. and First Union Securities, Inc, incorporated by reference to Exhibit 10.54 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
10.52   Amendment No. 4 to Employment Agreement dated as of September 17, 2001 between Select Medical Corporation and Rocco A. Ortenzio.
10.53   Amendment No. 3 to Employment Agreement dated as of September 17, 2001 between Select Medical Corporation and Robert A. Ortenzio.
10.54   Fourth Addendum to Lease Agreement dated as of September 1, 2001 by and between Old Gettysburg Associates and Select Medical Corporation.
10.55   Rights Agreement dated as of September 17, 2001, between Select Medical Corporation and Mellon Investor Services LLC, as Rights Agent, incorporated by reference to Exhibit 1.1 of the Company’s Registration Statement on Form 8-A filed October 1, 2001 (SEC File No. 000-32499).
10.56   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Scott A. Romberger.
10.57   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Scott A. Romberger.
10.58   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and James J. Talalai.
10.59   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and James J. Talalai.

46


Table of Contents

     
Exhibit    
Number   Document

 
10.60   Fourth Amendment dated October 5, 2001 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, the Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC Inc.
10.61   Change of Control Agreement dated as of November 21, 2001 between Select Medical Corporation and David W. Cross.
12.1   Computation of Ratio of Earnings to Fixed Charges.
21.1   Subsidiaries of Select Medical Corporation.
23.1   Consent of PricewaterhouseCoopers LLP.

47


Table of Contents

Select Medical Corporation

Consolidated Financial Statements

With Report of Independent Accountants

 

Contents

         
 
       
Report of Independent Accountants
    F-1  
Consolidated Balance Sheets
    F-2  
Consolidated Statements of Operations
    F-3  
Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income (Loss)
    F-4  
Consolidated Statements of Cash Flows
    F-5  
Notes to Consolidated Financial Statements
    F-6  

 


Table of Contents

Report of Independent Accountants

 

To the Board of Directors and Stockholders
of Select Medical Corporation

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, changes in stockholders’ equity and comprehensive income (loss) and cash flows present fairly, in all material respects, the consolidated financial position of Select Medical Corporation and its subsidiaries (the Company) as of December 31, 2001 and 2000 and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America. These consolidated financial statements are the responsibility of the Company’s management; our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

/s/ PricewaterhouseCoopers LLP
Harrisburg, Pennsylvania
February 15, 2002

F-1


Table of Contents

Select Medical Corporation
Consolidated Balance Sheets
(in thousands, except share and per share amounts)

                         
            December 31,
           
            2001   2000
           
 
Assets
               
Current Assets:
               
 
Cash and cash equivalents
  $ 10,703     $ 3,151  
 
Accounts receivable, net of allowance for doubtful accounts of $79,889 and $75,517 in 2001 and 2000, respectively
    218,393       196,505  
 
Prepaid income taxes
          1,093  
 
Current deferred tax asset
    28,945        
 
Other current assets
    18,444       17,407  
 
   
     
 
Total Current Assets
    276,485       218,156  
Property and equipment, net
    92,005       84,976  
Intangible assets
    247,257       251,399  
Non-current deferred tax asset
    6,674        
Other assets
    28,424       32,269  
 
   
     
 
Total Assets
  $ 650,845     $ 586,800  
 
   
     
 
Liabilities and Stockholders’ Equity
             
Current Liabilities:
               
 
Bank overdrafts
  $ 6,083     $ 14,218  
 
Current portion of long-term debt and notes payable
    26,774       18,746  
 
Accounts payable
    33,520       28,795  
 
Accrued payroll
    27,160       21,466  
 
Accrued vacation
    12,820       7,701  
 
Accrued restructuring
    1,819       4,701  
 
Accrued other
    23,568       15,451  
 
Income taxes payable
    1,735        
 
Due to third party payors
    16,257       1,511  
 
   
     
 
Total Current Liabilities
    149,736       112,589  
Long-term debt, net of current portion
    261,649       284,042  
 
   
     
 
Total Liabilities
    411,385       396,631  
Commitments and Contingencies (Note 18)
               
Minority interest in consolidated subsidiary companies
    5,176       12,098  
Preferred stock — Class A, non-voting, $1,000 per share redemption value Authorized shares — 55,000, Issued and outstanding shares — 52,838 in 2000
          65,481  
Convertible Preferred stock — Class B, non-voting, $3.75 per share redemption value Authorized shares — 16,000,000, Issued and outstanding shares — 16,000,000 shares in 2000
          64,092  
Stockholders’ Equity:
               
 
Common stock — $.01 per value: Authorized shares — 200,000,000 and 78,000,000 in 2001 and 2000, respectively, Issued shares — 46,488,000 and 25,697,000 in 2001 and 2000, respectively
    465       257  
 
Capital in excess of par
    231,349       73,069  
 
Retained earnings (accumulated deficit)
    5,924       (23,757 )
 
Treasury stock, at cost — 461,000 and 221,000 shares in 2001 and 2000, respectively
    (1,560 )     (1,039 )
 
Accumulated other comprehensive loss
    (1,894 )     (32 )
 
   
     
 
Total Stockholders’ Equity
    234,284       48,498  
 
   
     
 
Total Liabilities and Stockholders’ Equity
  $ 650,845     $ 586,800  
 
   
     
 

The accompanying notes are an integral part of these consolidated financial statements.

F-2


Table of Contents

Select Medical Corporation
Consolidated Statements of Operations
(in thousands, except per share amounts)

                               
          For the Year Ended December 31,
         
          2001   2000   1999
         
 
 
Net operating revenues
  $ 958,956     $ 805,897     $ 455,975  
 
   
     
     
 
Costs and expenses:
                       
 
Cost of services
    776,295       656,461       383,453  
 
General and administrative
    35,630       28,431       21,420  
 
Bad debt expense
    35,013       29,335       8,858  
 
Depreciation and amortization
    32,290       30,401       16,741  
 
Special charge
                5,223  
 
   
     
     
 
Total costs and expenses
    879,228       744,628       435,695  
 
   
     
     
 
Income from operations
    79,728       61,269       20,280  
Other income and expense:
                       
Interest income
    (507 )     (939 )     (362 )
Interest expense
    29,716       36,126       21,461  
 
   
     
     
 
Income (loss) before minority interests and income taxes
    50,519       26,082       (819 )
Minority interest in consolidated subsidiary companies
    3,491       4,144       3,662  
 
   
     
     
 
Income (loss) before income taxes
    47,028       21,938       (4,481 )
Income tax expense
    8,671       9,979       2,811  
 
   
     
     
 
Net income (loss) before extraordinary item
    38,357       11,959       (7,292 )
Extraordinary item, net of tax
    8,676       6,247       5,814  
 
   
     
     
 
Net income (loss)
  $ 29,681     $ 5,712     $ (13,106 )
Less: Preferred dividends
    2,513       8,780       5,175  
 
   
     
     
 
Net income (loss) available to common stockholders
  $ 27,168     $ (3,068 )   $ (18,281 )
 
   
     
     
 
Net income (loss) per common share:
                       
   
Basic:
                       
     
Income (loss) before extraordinary item
  $ 0.90     $ 0.13     $ (0.50 )
     
Extraordinary item
    (0.22 )     (0.25 )     (0.24 )
 
   
     
     
 
     
Income (loss) per common share
  $ 0.68     $ (0.12 )   $ (0.74 )
 
   
     
     
 
   
Diluted:
                       
     
Income (loss) before extraordinary item
  $ 0.81     $ 0.12     $ (0.50 )
     
Extraordinary item
    (0.19 )     (0.24 )     (0.24 )
 
   
     
     
 
     
Income (loss) per common share
  $ 0.62     $ (0.12 )   $ (0.74 )
 
   
     
     
 
Weighted average shares outstanding:
                       
   
Basic
    39,957       25,457       24,557  
   
Diluted
    45,464       25,907       24,557  

The accompanying notes are an integral part of these consolidated financial statements.

F-3


Table of Contents

Select Medical Corporation
Consolidated Statements of Changes in Stockholders’ Equity and Comprehensive Income (Loss)
(in thousands)

                                                           
              Common           Retained           Accumulated        
              Stock   Capital in   Earnings/           Other        
      Common   Par   Excess of   (Accumulated   Treasury   Comprehensive   Comprehensive
      Stock   Value   Par   Deficit)   Stock   Loss   Income (Loss)
     
 
 
 
 
 
 
Balance at December 31, 1998
    24,393     $ 244     $ 76,688     $ (16,363 )   $ (48 )   $ (27 )        
 
Net loss
                            (13,106 )                   $ (13,106 )
 
Other comprehensive income
                                            5       5  
 
                                                   
 
 
Total comprehensive loss
                                                  $ (13,101 )
 
                                                   
 
 
Issuance of common stock
    1,132       11       6,239                                  
 
Accretion of preferred stock issuance costs
                    (639 )                                
 
Issuance of warrants
                    2,389                                  
 
Purchase of treasury stock
                                    (781 )                
 
Preferred stock dividends
                    (5,175 )                                
 
   
     
     
     
     
     
         
Balance at December 31, 1999
    25,525       255       79,502       (29,469 )     (829 )     (22 )        
 
Net income
                            5,712                     $ 5,712  
 
Other comprehensive loss
                                            (10 )     (10 )
 
                                                   
 
 
Total comprehensive income
                                                  $ 5,702  
 
                                                   
 
 
Issuance of common stock
    172       2       1,116                                  
 
Purchase of treasury stock
                                    (210 )                
 
Issuance of warrants
                    1,104                                  
 
Valuation of non-employee options
                    127                                  
 
Preferred stock dividends
                    (8,780 )                                
 
   
     
     
     
     
     
         
Balance at December 31, 2000
    25,697     257     73,069     (23,757 )   (1,039 )     (32 )        
 
Net income
                            29,681                     $ 29,681  
 
Other comprehensive loss
                                            (1,862 )     (1,862 )
 
                                                   
 
 
Total comprehensive income
                                                  $ 27,819  
 
                                                   
 
 
Issuance of common stock in connection with initial public offering, net of issuance costs of $2,262
    10,350       104       89,077                                  
 
Conversion of Class B Preferred Stock
    9,216       92       59,908                                  
 
Stock issued to acquire minority interest
    523       5       4,968                                  
 
Purchase of treasury stock
                                    (521 )                
 
Issuance of common stock
    702       7       4,327                                  
 
Tax benefit of stock option exercises
                    2,513                                  
 
Preferred stock dividends
                    (2,513 )                                
 
   
     
     
     
     
     
         
Balance at December 31, 2001
    46,488     $ 465     $ 231,349     $ 5,924     $ (1,560 )   $ (1,894 )        
 
   
     
     
     
     
     
         

The accompanying notes are an integral part of these consolidated financial statements.

F-4


Table of Contents

Select Medical Corporation
Consolidated Statements of Cash Flows
(in thousands)

                             
        For the Year Ended December 31,
       
        2001   2000   1999
       
 
 
Operating activities
                       
Net income (loss)
  $ 29,681     $ 5,712     $ (13,106 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
                       
 
Depreciation and amortization
    32,290       30,401       16,741  
 
Provision for bad debts
    35,013       29,335       8,858  
 
Special charge
                5,223  
 
Extraordinary item, net of tax
    8,676       6,247       5,814  
 
Deferred income taxes
    (9,670 )            
 
Loss (gain) on sale of assets
          111       (215 )
 
Minority interests
    3,491       4,144       3,662  
 
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
                       
   
Accounts receivable
    (49,432 )     (36,964 )     (47,290 )
   
Other current assets
    (456 )     (2,692 )     (1,728 )
   
Other assets
    1,053       (5,019 )     (10,868 )
   
Accounts payable
    4,715       1,380       29  
   
Due to third-party payors
    14,746       (17,673 )     8,715  
   
Accrued expenses
    14,023       (17 )     (2,688 )
   
Income taxes
    11,640       7,548       1,696  
 
   
     
     
 
Net cash provided by (used in) operating activities
    95,770       22,513       (25,157 )
 
   
     
     
 
Investing activities
                       
Purchases of property and equipment, net
    (24,011 )     (22,430 )     (10,896 )
Escrow receivable
          29,948        
Proceeds from disposal of assets held for sale
          13,000        
Proceeds from disposal of assets
    808       2,947       988  
Earnout payments
    (5,660 )     (3,430 )      
Acquisition of businesses, net of cash acquired
    (33,084 )     (5,838 )     (171,354 )
 
   
     
     
 
Net cash provided by (used in) investing activities
    (61,947 )     14,197       (181,262 )
 
   
     
     
 
Financing activities
                       
Issuance of 9.5% Senior Subordinated Notes
    175,000              
Proceeds from issuance of debt
                68,194  
Net proceeds (repayments) on credit facility debt
    (98,320 )     (12,000 )     86,655  
Repayment of 10% Senior Subordinated Notes
    (90,000 )            
Principal payments on seller and other debt
    (19,030 )     (27,577 )     (10,064 )
Net proceeds from issuance of Class B convertable preferred stock
                59,361  
Proceeds from initial public offering, net of fees
    89,181              
Proceeds from issuance of common stock
    4,334       1,118       1,041  
Acquisition of treasury stock
          (210 )     (781 )
Redemption of Class A Preferred Stock
    (52,838 )     (11 )     (214 )
Payment of Class A and Class B Preferred Stock dividends
    (19,248 )            
Proceeds from (payments of) bank overdrafts
    (8,135 )     7,253       4,893  
Payment of deferred financing costs
    (4,681 )     (4,563 )     (10,883 )
Distributions to minority interests
    (2,427 )     (1,626 )     (722 )
 
   
     
     
 
Net cash provided by (used in) financing activities
    (26,164 )     (37,616 )     197,480  
 
   
     
     
 
Effect of exchange rate changes on cash and cash equivalents
    (107 )     (10 )     5  
 
   
     
     
 
Net increase (decrease) in cash and cash equivalents
    7,552       (916 )     (8,934 )
Cash and cash equivalents at beginning of period
    3,151       4,067       13,001  
 
   
     
     
 
Cash and cash equivalents at end of period
  $ 10,703     $ 3,151     $ 4,067  
 
   
     
     
 
Supplemental Cash Flow Information
                       
Cash paid for interest
  $ 30,547     $ 36,125     $ 15,500  
Cash paid for income taxes
  $ 6,017     $ 3,476     $ 2,112  

The accompanying notes are an integral part of these consolidated financial statements.

F-5


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

1. Organization and Significant Accounting Policies

Business Description

Select Medical Corporation and its subsidiaries (the “Company”) was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. The Company provides long-term acute care hospital services through its Select Specialty Hospital division and provides physical, occupational, and speech rehabilitation services through its outpatient divisions. Select Specialty Hospital division owns and operates long-term acute care hospitals. These hospitals, which average approximately 30 to 40 beds in size, operate generally in space leased within general acute care hospitals. These hospitals offer intensive nursing care, vent weaning, and therapy services to high acuity patients who require long lengths of hospital care before being discharged to a nursing home or home care environment. At December 31, 2001, 2000 and 1999, the Company operated 64, 54 and 44 long-term acute care hospitals, respectively. The Company’s outpatient divisions provide rehabilitation services in outpatient clinics owned or managed by the Company and under therapy contracts with nursing homes, schools, hospitals, and home care agencies. At December 31, 2001, 2000 and 1999, the Company had operations in Canada and 37, 35 and 33 states, respectively.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries, limited liability companies and limited partnerships the Company and its subsidiaries control through ownership of general and limited partnership interests. All significant intercompany balances and transactions are eliminated in consolidation. The Company does not consolidate professional corporations where it has a long-term management contract because the Company does not have a long-term controlling interest in the affiliated practices as defined in “Emerging Issues Task Force No 97-2.” Instead the Company reports management services revenue earned under the terms of the agreements.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

F-6


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost which approximates market.

Property and Equipment

Property and equipment are stated at cost net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets or the term of the lease, as appropriate. The general range of useful lives is as follows:

     
Leasehold improvements   5 years
Furniture and equipment   2 – 10 years
Buildings   40 years

Qualified internally developed software costs for internal use are capitalized subsequent to both the preliminary project stage and when management has committed to funding, in accordance with Statement of Position 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use.” Computer hardware and software are included in furniture and equipment.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash balances and trade receivables. The Company invests its excess cash with large banks. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the geographic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the Company’s only concentration of credit risk.

Assets Held for Sale

Assets held for sale, which were acquired as part of a business combination, were stated at their net realizable value less approximated costs to sell. The results of operations related to the assets held for sale were excluded from the Company’s operating results and were reflected as an adjustment to the purchase price when the assets were sold. No depreciation or amortization was recognized on the assets held for sale.

F-7


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management provides a valuation allowance for net deferred tax assets when it is more likely than not that a portion of such net deferred tax assets will not be recovered.

Intangible Assets

Identifiable assets and liabilities acquired in connection with business combinations accounted for under the purchase method are recorded at their respective fair values. Deferred taxes have been recorded to the extent of differences between the fair value and the tax basis of the assets acquired and liabilities assumed. The excess of the purchase price over the fair value of tangible net assets acquired is amortized on a straight-line basis over the estimated useful life of the intangible assets. Company management has allocated the intangible assets between identifiable intangibles and goodwill. Intangible assets other than goodwill primarily consist of the values assigned to trademarks and assembled work force. Management Service Agreements (“MSA’s”) represent consideration paid to therapists groups for entering into MSA’s with the Company. The Company’s MSA’s are for a term of 20 years with renewal options. Management believes that the estimated useful lives established at the dates of each transaction were reasonable based on the economic factors applicable to each of the businesses.

The useful life of each class of intangible asset is as follows:

     
Goodwill   40 years
Trademarks   40 years
Management services agreements   20 years
Assembled workforce   7 years

In accordance with Statement of Financial Accounting Standards No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of” (“SFAS No. 121”), the Company reviews the realizability of long-lived assets, certain intangible assets and goodwill whenever events or circumstances occur which indicate recorded costs may not be recoverable. In addition, the Company also analyzes the recovery of long-lived assets on an enterprise basis.

If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value (Note 11).

F-8


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Due to Third-Party Payors

Due to third-party payors represents the difference between amounts received under interim payment plans from third-party payors for services rendered and amounts estimated to be reimbursed by those third-party payors upon settlement of cost reports.

Insurance Risk Programs

The Company is insured for malpractice claims based on a claims made or claims incurred policy purchased in the commercial market. A liability is estimated for the premium cost for tail coverage. The Company has the unilateral right to purchase tail coverage for its claims made policy at a fixed price.

Certain insurable risks such as workers’ compensation are insured through a captive insurance company where the Company assumes direct responsibility for lower dollar claims and shares the risk of high dollar claims with the members of the captive. Accruals for claims under the captive insurance program are recorded on a claims-incurred basis.

Minority Interests

The interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by the Company are reported on the consolidated balance sheets as minority interests. Minority interests reported in the consolidated statements of operations reflect the respective interests in the income or loss of the subsidiaries, limited liability companies and limited partnerships attributable to the other parties, the effect of which is removed from the Company’s consolidated results of operations.

Treasury Stock

Treasury stock is carried at cost, determined by the first-in, first-out method.

Revenue Recognition

Net operating revenues consists of patient, contract therapy, and management services revenues and are recognized as services are rendered.

Patient service revenue is reported net of provisions for contractual allowances from third-party payors and patients. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The differences between the estimated program reimbursement rates and the standard

F-9


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

billing rates are accounted for as contractual adjustments, which are deducted from gross revenues to arrive at net operating revenues. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Accounts receivables resulting from such payment arrangements are recorded net of contractual allowances. Net operating revenues generated directly from the Medicare program represented approximately 37%, 35% and 48% of the Company’s consolidated net operating revenues for the years ended December 31, 2001, 2000 and 1999, respectively. Approximately 30% and 31% of the Company’s gross accounts receivable at December 31, 2001 and 2000, respectively, are from this payor source. Medicare payments received by the Company's specialty hospitals are paid under a cost-based reimbursement methodology and are subject to final settlement based on administrative review and audit by third parties.

Contract therapy revenues are comprised primarily of billings for services rendered to nursing homes, hospitals, schools and other third parties under the terms of contractual arrangements with these entities.

Management services revenues represent revenues earned under management service agreements with professional corporations and associations in the business of providing physical, occupational, and speech therapy. Management fee receivables resulting from such management services are included in other assets.

Significant reductions in the patient service revenues generated in a hospital may occur if the Company is unable to maintain the certification of the hospital as a long-term acute care hospital (LTACH) in accordance with Medicare regulations. Additionally, the majority of the Company’s hospitals operate in space leased from general acute care hospitals (host hospitals); consequently, these hospitals are also subject to Medicare “Hospital within Hospital” (HIH) regulations in addition to the general LTACH regulations. The HIH regulations are designed to ensure that the hospitals are organizationally and functionally independent of their host hospital. If an LTACH located in a host hospital fails to meet the HIH regulations it also loses its status as an LTACH. These determinations are made on an annual basis. Management believes its LTACH’s are in compliance with the Medicare regulations regarding HIH’s and LTACH’s and that it will be able to meet the tests to maintain the future status of its hospitals as LTACH’s under the current Medicare regulations.

Foreign Currency Translations

The Company uses the local currency as the functional currency for its Canadian operations. All assets and liabilities of foreign operations are translated into U.S. dollars at year-end exchange rates. Income statement items are translated at average exchange rates prevailing during the year. The resulting translation adjustments impacting

F-10


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

comprehensive income (loss) are recorded as a separate component of stockholders’ equity.

Basic and Diluted Net Income (Loss) Per Share

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding during each year. Diluted net income (loss) per common share is based on the weighted average number of shares of common stock outstanding during each year, adjusted for the effect of common stock equivalents arising from the assumed exercise of stock options, warrants and convertible preferred stock, if dilutive.

Financial Instruments and Hedging

Effective January 1, 2001, the Company adopted SFAS No. 133. Since the Company had no derivative financial instruments at January 1, 2001, there was no cumulative effect upon adoption. The Company enters into various instruments, including derivatives, to manage interest rate and foreign exchange risks. Derivatives are limited in use and not entered into for speculative purposes. The Company enters into interest rate swaps to manage interest rate risk on a portion of its long-term borrowings. Interest rate swaps are reflected at fair value in the consolidated balance sheet and the related gains or losses are deferred in stockholders’ equity as a component of other comprehensive income. These deferred gains or losses are then amortized as an adjustment to interest expense over the same period in which the related interest payments being hedged are recognized in income. To the extent that any derivative instrument is not designated as a hedge under SFAS No. 133, the gains and losses are recognized in income based on fair market value.

Recent Accounting Pronouncements

Statement of Financial Accounting Standards (SFAS) No. 141 “Business Combinations”

In July 2001, the Financial Accounting Standards Board (FASB) issued SFAS No. 141 which addresses financial accounting and reporting for business combinations. SFAS No. 141 supersedes Accounting Principles Board Opinion No. 16, “Business Combinations” (ABP 16) and SFAS No. 38, “Accounting for Preacquisition Contingencies of Purchased Enterprises” (SFAS 38). SFAS No. 141 requires the use of the purchase method of accounting for business combinations initiated after June 1, 2001 and prohibits the use of the pooling-of-interests method. The Company has historically not used the pooling-of-interests method and therefore this aspect of the new rules will not have an impact on the Company’s financial position or results of operations. SFAS No. 141 also changes the definition of intangible assets acquired in a business combination.

F-11


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

SFAS No. 142 “Goodwill and Other Intangible Assets”

In July 2001, the Financial Accounting Standards Board issued SFAS No. 142 which eliminates the amortization for goodwill, requires annual impairment testing of goodwill and introduces the concept of indefinite life intangible assets. The Company adopted SFAS No. 142 on January 1, 2002. SFAS No. 142 supersedes APB No. 17, “Intangible Assets”. An initial impairment test must be performed in 2002. Management believes that any impairment charge resulting from the adoption of SFAS No. 142 will not be material.

If the new standard had been in effect in 2001, pre-tax amortization expense in 2001 would have been reduced by approximately $8.7 million or approximately $.12 per diluted share.

SFAS No. 144 “Accounting for the Impairment or Disposal of Long-Lived Assets”

In October 2001, the FASB approved SFAS No. 144, which addresses financial accounting and reporting for the impairment and disposal of long-lived assets. SFAS No. 144 supercedes SFAS No. 121, “Accounting for the Impairment of Long Lived Assets to Be Disposed Of.” However, it retains the fundamental provisions of SFAS No. 121 for recognition and measurement of the impairment of long lived assets to be held, used or disposed of by sale.

Additionally, SFAS No. 144 supersedes the accounting and reporting provisions of APB Opinion No. 30 (APB 30), “Reporting the Results of Operations – Reporting the Effect of Disposal of a Segment of a Business and Extraordinary, Unusual and Infrequently Occurring Events and Transactions” for the disposal of a segment of a business. SFAS No. 144 retains the requirement of APB 30 to report discontinued operations separately from continuing operations and extends that reporting to a component of an entity (rather than a segment of a business) that either has been disposed of or is classified as held for sale. SFAS No. 144 also amends Accounting Research Bulletin No. 51, “Consolidated Financial Statements” (ARB 51), to eliminate the exception to consolidation for a temporarily controlled subsidiary.

The Company adopted SFAS No. 144 on January 1, 2002 with no material effect on net income. Prospectively, future transactions under the scope of SFAS No. 144 may result in changes in the income statement classification, from that under prior standards, for components of the Company that are disposed of or are classified as held for sale.

F-12


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

2.     Acquisitions, Disposal and Management Services Agreements

For the Year Ended December 31, 2001

Certain outpatient rehabilitation subsidiaries had minority equity owners whose purchase agreements allowed them to sell all or part of their interest to the Company in the event of an initial public offering. During 2001, the Company completed the repurchase of all or part of the minority interests of NW Rehabilitation Associates, LP, P.T. Services, Inc., Avalon Rehabilitation and Healthcare, LLC, Kentucky Orthopedic Rehabilitation, LLC and Canadian Back Institute Limited. Total consideration for these acquisitions totaled $15.9 million, including $10.9 million cash and $5.0 million of common stock.

During 2001, the Company acquired controlling interests in two outpatient therapy businesses. Outpatient therapy acquisitions consisted of Metro Therapy, Inc. on September 5, 2001 and Healthcare Innovations, Inc. on November 15, 2001.

For the Year Ended December 31, 2000

During 2000, the Company acquired controlling interests in four outpatient therapy businesses. Outpatient therapy acquisitions consisted of Delta Rehab Group, Inc. on January 20, 2000, S.T.A.R Rehab, Inc. on March 31, 2000, Crisan Physiotherapy and Sports Medicine Center, P.A. on May 31, 2000 and Rehab Health, Inc. on July 31, 2000.

For the Year Ended December 31, 1999

On January 8, 1999, the Company acquired 80% of the undivided interest in the business and certain assets of Kentucky Orthopedic Rehab Team, PSC (KORT). KORT operates rehabilitation clinics.

On November 19, 1999, the Company acquired 100% of the outstanding stock of NovaCare Physical Rehabilitation and Occupational Health Group (NovaCare) for $160,416,000 cash and $64,734,000 of liabilities assumed. The purchase was funded through the sale of 16,000,000 shares of Select Class B Convertible Preferred stock and subordinate and bank debt. The Company was indemnified against certain risks including receivables collection and certain joint venture agreements through a $36,800,000 escrow account. In November 1999, the Company recorded a $29,948,000 receivable related to the receivable collection and severance indemnification. Of this amount, $29,400,000 represents the change in estimate for allowance for doubtful accounts recorded in the NovaCare July 1, 1999 to November 19, 1999 financial statements. On July 6, 2000, the Company received proceeds of $29,948,000 from the escrow account established in connection with its acquisition of NovaCare from NovaCare’s former owner, NAHC, Inc. The Company also received $1.95 million in notes in satisfaction of certain severance and

F-13


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

other obligations NAHC, Inc. had to the Company under the purchase agreement. As a part of the acquisition, the Company accrued $5.7 million of costs related to the planned closure of approximately 60 outpatient rehab clinics, the downsizing and relocation of the NovaCare corporate headquarters and transaction-related expenses. NovaCare provides outpatient physical therapy and rehabilitation services.

The Company divested the Occupational Health segment of NovaCare with total sale proceeds of $13,000,000. The net proceeds of this sale and the cash flows of this segment until it was sold were allocated to assets held for sale in the allocation of the NovaCare purchase price. Differences between the actual and expected amount were recorded as an adjustment to goodwill during 2000.

During 1999, the Company acquired controlling interests in four outpatient therapy businesses. Outpatient therapy acquisitions consisted of Sports Rehabilitation and Physical Therapy Center, P.A. on March 1, 1999, Senior Rehab, Inc. on March 31, 1999, Central Jersey Rehabilitation Services, Inc. on May 15, 1999 and Hunsel Physical Therapy Services, Inc. on July 15, 1999.

Certain purchase agreements require additional payments to the former owners if specific financial targets are met. At December 31, 2001, aggregate contingent payments in connection with all acquisitions of approximately $1,200,000 have not been included in the initial cost of the business since the additional amount of such contingent consideration which may be paid in the future, if any, is not presently determinable.

The acquisitions were accounted for using the purchase method of accounting, and results of operations from acquired companies are included in these consolidated financial statements from the dates of acquisition.

The following unaudited results of operations have been prepared assuming all acquisitions consummated on or before December 31, 1999 had occurred as of the beginning of the periods presented. The acquisitions completed during 2000 and 2001 are not significant for pro forma disclosure. These results are not necessarily indicative of results of future operations nor of the results that would have occurred had the acquisitions been consummated as of the beginning of the periods presented.

         
    1999
   
    (unaudited)
 
       
Revenues
  $ 720,116,000  
Loss before extraordinary items
    (78,569,000 )
Net loss
    (84,383,000 )

F-14


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Information with respect to businesses acquired in purchase transactions is as follows:

                         
    For the year ended December 31,
   
    2001   2000   1999
   
 
 
Cash paid (net of cash acquired)
  $ 33,084,000     $ 5,838,000     $ 171,354,000  
Notes issued
    4,100,000       3,207,000       7,783,000  
Common stock issued
    4,973,000             --  
 
   
     
     
 
 
    42,157,000       9,045,000       179,137,000  
Liabilities assumed
    2,357,000       255,000       65,744,000  
 
   
     
     
 
 
    44,514,000       9,300,000       244,881,000  
Fair value of assets acquired, principally accounts receivable and property and equipment
    9,048,000       1,606,000       144,623,000  
Minority interest liabilities relieved
    8,268,000             --  
Trademarks
                40,000,000  
Management services agreements
                1,520,000  
Assembled workforce
                9,200,000  
 
   
     
     
 
Cost in excess of fair value of net assets acquired (goodwill)
  $ 27,198,000     $ 7,694,000     $ 49,538,000  
 
   
     
     
 

3. Property and Equipment

Property and equipment consists of the following:

                 
    December 31,
   
    2001   2000
   
 
Land
  $ 501,000     $ 501,000  
Leasehold improvements
    46,325,000       29,836,000  
Buildings
    17,000,000       17,000,000  
Furniture and equipment
    87,154,000       74,170,000  
Construction-in-progress
    1,578,000       366,000  
 
   
     
 
 
    152,558,000       121,873,000  
Less: accumulated depreciation and amortization
    60,553,000       36,897,000  
 
   
     
 
Total property and equipment
  $ 92,005,000     $ 84,976,000  
 
   
     
 

F-15


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

4. Intangible Assets

Intangible assets consist of the following:

                 
    December 31,
   
    2001   2000
   
 
Goodwill
  $ 205,667,000     $ 201,171,000  
Trademarks
    40,000,000       40,000,000  
Management services agreements
    11,250,000       10,343,000  
Assembled workforce
    17,544,000       17,544,000  
 
   
     
 
 
    274,461,000       269,058,000  
Less: accumulated amortization
    27,204,000       17,659,000  
 
   
     
 
Total intangible assets
  $ 247,257,000     $ 251,399,000  
 
   
     
 

The following summarizes the Company’s intangible asset activity:

                 
    December 31,
   
    2001   2000
   
 
Beginning balance of intangibles, net
  $ 251,399,000     $ 258,079,000  
 
   
     
 
Intangibles recorded for companies purchased in current year
    27,198,000       7,694,000  
Intangibles adjusted for companies purchased in prior year for:
               
Income tax benefits recognized
    (26,564,000 )     (8,402,000 )
Translation adjustment
    (1,113,000 )     (441,000 )
Other
    (33,000 )     635,000  
Earn-out payments
    5,660,000       3,430,000  
Amortization
    (9,290,000 )     (9,596,000 )
 
   
     
 
Net decrease in intangibles
    (4,142,000 )     (6,680,000 )
 
   
     
 
Ending balance of intangibles, net
  $ 247,257,000     $ 251,399,000  
 
   
     
 

5. Restructuring Reserves

During December 1998, the Company recorded a $7,648,000 restructuring reserve in connection with the acquisition of Intensiva Healthcare Corporation. The Company also recorded a restructuring reserve in 1999 related to the NovaCare acquisition of $5,743,000. The reserves primarily included costs associated with workforce reductions of 25 and 162 employees in 1998 and 1999, respectively, and lease buyouts in accordance with the Company’s restructuring plan. During 2000, the Company revised its estimates for the NovaCare termination costs, severance liabilities and the anticipated closure of two central billing offices related to the NovaCare acquisition. The reserves for the billing office closures primarily included costs associated with lease buyouts and workforce reductions of 67 employees. These changes in estimates have been reflected as an adjustment to the purchase price of NovaCare.

F-16


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

The following summarizes the Company’s restructuring activity:

                                 
    Lease                        
    Termination                        
    Costs   Severance   Other   Total
   
 
 
 
January 1, 1999
  $ 536,000     $ 5,914,000     $ 1,198,000     $ 7,648,000  
Amounts paid in 1999
    (109,000 )     (5,914,000 )     (1,198,000 )     (7,221,000 )
1999 restructuring liabilities assumed
    3,187,000                   3,187,000  
1999 acquisition restructuring costs
    3,600,000       700,000       1,443,000       5,743,000  
 
   
     
     
     
 
December 31, 1999
    7,214,000       700,000       1,443,000       9,357,000  
Revision of estimate
    214,000       841,000       184,000       1,239,000  
Amounts paid in 2000
    (3,743,000 )     (601,000 )     (1,551,000 )     (5,895,000 )
 
   
     
     
     
 
December 31, 2000
    3,685,000       940,000       76,000       4,701,000  
Revision of estimate
    55,000       106,000             161,000  
Amounts paid in 2001
    (2,053,000 )     (914,000 )     (76,000 )     (3,043,000 )
 
   
     
     
     
 
December 31, 2001
  $ 1,687,000     $ 132,000           $ 1,819,000  
 
   
     
     
     
 

All employees to be terminated have been severed and the Company expects to pay out the remaining restructuring reserves through 2003.

6. Long-Term Debt and Notes Payable

The components of long-term debt and notes payable are shown in the following table:

                 
    December 31,   December 31,
    2001   2000
   
 
9 1/2 % Senior Subordinated Notes
  $ 175,000,000        
Senior Credit facility
    96,782,000     $ 195,877,000  
10% Senior Subordinated Notes, net of discount of $13,228,000 in 2000
          76,772,000  
Seller notes
    14,849,000       27,888,000  
Other
    1,792,000       2,251,000  
 
   
     
 
Total debt
    288,423,000       302,788,000  
Less: current maturities
    26,774,000       18,746,000  
 
   
     
 
Total long-term debt
  $ 261,649,000     $ 284,042,000  
 
   
     
 

On June 11, 2001, the Company issued and sold $175.0 million aggregate principle amount of 9 1/2 % Senior Subordinated Notes due June 15, 2009. The net proceeds from the sale of the 9 1/2 % Senior Subordinated Notes were used to repay debt under the Company’s senior credit facility and to repay 10% Senior Subordinated Notes. Deferred financing costs and discounts of $8,676,000 related to the repayments, net of tax, were

F-17


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

reflected as an extraordinary loss in 2001. The 9 1/2 % Senior Subordinated Notes are fully and unconditionally guaranteed, jointly and severally, by certain wholly owned subsidiaries (the “Subsidiary Guarantors”). Certain of the Company’s subsidiaries have not guaranteed the notes (the “Non-Guarantor Subsidiaries”). The creditors of the Non-Guarantor Subsidiaries have priority over the rights of the Company to receive dividends or distributions from such subsidiaries.

The credit facility consists of a term portion of approximately $91.8 million and a revolving credit portion of approximately $152.4 million. The term debt began quarterly amortization in September 2001, with a final maturity date of September 2005. The revolving commitment also matures in September 2005. Borrowings under the facility bear interest at either LIBOR or Prime rate, plus applicable margins based on financial covenant ratio tests. Borrowings bore interest at approximately 7.6% and 10.2% at December 31, 2001 and 2000, respectively. Deferred financing costs of approximately $6,247,000 related to the Company’s November 19, 1999 credit facility were charged to expense as an extraordinary item during 2000. A commitment fee of .375% to .5% per annum is charged on the unused portion of the credit facility. Availability under the revolving credit facility at December 31, 2001 was approximately $143.1 million. The credit facility is collateralized by a pledge of the Company’s equity interest in its subsidiaries and includes restrictions on certain payments by the Company, including dividend payments, minimum net worth requirements and other covenants. The Company is authorized to issue up to $10,000,000 in letters of credit. Letters of credit reduce the capacity under the revolving credit facility and bear interest at applicable margins based on financial covenant ratio tests. Approximately $4.4 million and $3.6 million in letters of credit were issued at December 31, 2001 and 2000, respectively.

In 1999 and 1998, the Company issued 10% Senior Subordinated Notes to a principal stockholder of the Company and had common shares attached which were recorded at the estimated fair market value on the date of issuance. The common shares issued were recorded as a discount to the Senior Subordinated Notes and were amortized using the interest method. In connection with the repayment of the 10% Senior Subordinated Notes in full during 2001, 240,048 shares of common stock were returned to the Company.

The Company’s obligations under its previous credit agreements, which were refinanced in 1999, were collateralized by guarantees of two of the Company’s principal stockholders. In connection with the debt guarantees, the Company and certain shareholders entered into a warrant agreement. The Company issued 549,000, 460,000 and 864,000 warrants to these shareholders in 2000, 1999 and 1998, respectively, that entitle the holder of each warrant to purchase one share of common stock at an exercise price of $6.08 per share or at a price equal to the lowest selling price of common shares sold by the Company after June 30, 1998. The warrants expire on June 30, 2003. The

F-18


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

value of the warrants was accounted for as a financing cost and amortized over the term of the guarantees.

The Seller Notes relate to the acquisition of related businesses and require periodic payments of principal and interest that mature on various dates through 2007. Also, certain of the notes contain minimum net worth requirements. Interest rates are at 6% per annum.

Maturities of long-term debt for the years after 2002 are approximately as follows:

         
2003
  $ 28,655,000  
2004
    30,509,000  
2005
    27,397,000  
2006
    44,000  
2007 and beyond
    175,044,000  

7. Redeemable Preferred Stock and Stockholders’ Equity

Shareholder Rights Plan

On September 17, 2001, the Company’s Board of Directors adopted a Shareholder Rights Plan (the Plan). Under the Plan, rights were distributed as a dividend at the rate of one right for each share of common stock of the Company held by the shareholders of record as of the close of business on October 2, 2001. Until the occurrence of certain events, the rights are represented by and traded in tandem with the common stock. Each right will separate and entitle the shareholders to buy stock upon an occurrence of certain takeover or stock accumulation events. Should any person or group (Acquiring Person) acquire beneficial ownership of 15% or more of the Company’s common stock, each right not held by the Acquiring Person becomes the right to purchase, at an exercise price of $104, that number of shares of the Company's common stock that at the time of the transaction, have a market value of twice the exercise price. In addition, if after a person or group becomes an Acquiring Person the Company merges, consolidates or engages in a similar transaction in which it does not survive, each holder has a “flip-over” right to buy discounted stock in the acquiring company. Certain of our principal stockholders will not be and cannot become an Acquiring Person and will not be counted as affiliates or associates of any other person in determining whether such person is an Acquiring Person under the Plan.

Under certain circumstances, the rights are redeemable by the Company at a price of $0.001 per right. Further, if any person or group becomes an Acquiring Person, the Board of Directors has the option to exchange one share of common stock for each right held by any Person other than the Acquiring Person. The rights expire on September 17, 2011.

F-19


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Class A Preferred Stock

The Company was authorized to issue 55,000 shares of cumulative, non-voting Class A Preferred Stock. The Company sold 48,000 shares of Class A Preferred Stock during 1998. The Class A Preferred Stock had an annual cash dividend rate of 8% per share, which accrued on a daily basis.

In connection with the Company’s initial public offering in April 2001, all outstanding Class A Preferred Stock was redeemed. The accrued dividends on the Class A Preferred Stock totaling $14.1 million were subsequently paid on May 2, 2001.

Class B Preferred Stock

In connection with the NovaCare acquisition (Note 2), the Company sold 16,000,000 shares of Class B Preferred Stock at a price of $3.75 per share for net proceeds of $59,361,000. Each share of Class B preferred stock was convertible at any time, at the option of the stockholder, into .576 shares of common stock. The Class B Preferred Stock had an annual cash dividend rate of 6% per share, which accrued on a daily basis.

In connection with the Company’s initial public offering in April 2001, all 16,000,000 outstanding Class B Preferred Stock were automatically converted into 9,216,000 shares of common stock. The accrued dividends on the Class B Preferred Stock totaling $5.2 million were paid on May 2, 2001.

Common Stock

On April 10, 2001, the Company amended its Restated Certificate of Incorporation to increase the total common shares authorized to 200,000,000 from 78,000,000.

On March 28, 2001, the Company effected a 1 for .576 reverse split of its common stock. Accordingly, all common issued and outstanding share and per share information has been retroactively restated to reflect the effects of this reverse stock split.

F-20


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

In connection with the debt offering as described in Note 6, the Company repaid its 10% Senior Subordinated Notes which resulted in the return to the Company of 240,048 shares of common stock that were issued to WCAS Capital Partners III, L.P. in conjunction with the 10% Senior Subordinated Notes.

Shares of common stock sold during 2000 totaled 172,000. The shares were issued to management at $6.51 per share for proceeds totaling $1,118,000. The Company purchased 32,000 shares as treasury stock during 2000 for $210,000.

Shares of common stock sold in 1999 totaled 172,000. The shares were sold to management at prices ranging from $6.08 to $6.51 for proceeds totaling $1,041,000. The Company purchased 173,000 shares as treasury stock during 1999 for $781,000. In addition, 960,000 shares of common stock were sold in conjunction with the issuance of the 10% Senior Subordinated Notes (Note 6).

8.     Initial Public Offering

On April 10, 2001, the Company completed an initial public offering of 9,000,000 shares of its common stock at an offering price of $9.50 per share before an underwriters discount of $.665 per share. On April 20, 2001, the underwriters of the offering exercised an overallotment option and purchased an additional 1,350,000 shares at a gross price of $9.50 per share. The overallotment offering closed on April 25, 2001. The net proceeds of the initial offering and the overallotment offering of $89.2 million were used to repay senior debt under the term and revolving loan portions of the Company’s credit facility and to redeem Class A Preferred Stock. All 52,838 shares of the Class A Preferred Stock were redeemed on April 10, 2001 for $52,838,000. In addition, the Company’s Class B Preferred Stock automatically converted into 9,216,000 shares of common stock upon completion of the offering.

In January 2001, in anticipation of the initial public offering, the Company entered into an amendment to its credit agreement that became effective in April 2001. The amendment allowed for the use of the net proceeds of the offering to repay $24.0 million of our senior debt under the U.S. term loan portion of the bank credit facility and to redeem $52.8 million of Class A Preferred Stock.

In conjunction with the Company’s initial public offering, the Company purchased outstanding minority interests of certain of its subsidiaries for $10.9 million in cash and

F-21


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

$5.0 million in common stock. The acquisitions were accounted for using the purchase method of accounting.

9.     Stock Option Plan

The Company’s 1997 Stock Option Plan (the Plan) provides for the granting of options to purchase shares of Company stock to certain executives, employees and directors.

Options under the Plan carry various restrictions. Under the Plan, certain options granted to employees will be qualified incentive stock options within the meaning of Section 422A of the Internal Revenue Code and other options will be considered nonqualified stock options. Both incentive stock options and nonqualified stock options may be granted for no less than market value at the day of the grant and expire no later than ten years after the date of the grant.

Originally under the Plan, options to acquire up to 5,760,000 shares of the stock could be granted. On February 22, 2001, the Plan was amended and restated to provide for the issuance of up to 5,760,000 shares of common stock plus any additional amount necessary to make the total shares available for issuance under the Plan equal to the sum of 5,760,000 plus 14% of the total issued and outstanding common stock in excess of 34,560,000 shares, subject to adjustment for stock splits, stock dividends and similar changes in capitalization. Total options available for grant at December 31, 2001 were 7,365,000.

Transactions and other information related to the Stock Option Plan are as follows:

                           
      Price           Weighted Average
      Per Share   Shares   Exercise Price
     
 
 
Balance, December 31, 1998
  $1.74 to 6.08     1,579,000     $ 6.02  
 
Granted
  6.08 to 6.51     1,270,000       6.46  
 
Exercised
                 
 
Forfeited
  1.74 to 6.08     (88,000 )     6.08  
     
   
     
 
Balance, December 31, 1999
  $1.74 to 6.51     2,761,000     $ 6.21  
 
Granted
  6.51 to 10.42     1,876,000       7.60  
 
Exercised
    6.08       (4,000 )     6.08  
 
Forfeited
  1.74 to 6.51     (132,000 )     6.65  
     
   
     
 
Balance, December 31, 2000
  $1.74 to 10.42     4,501,000     $ 6.79  
 
Granted
  9.50 to 17.05     2,555,000       11.34  
 
Exercised
  6.08 to 10.42     (702,000 )     6.18  
 
Forfeited
  6.08 to 11.28     (96,000 )     9.30  
     
   
     
 
Balance, December 31, 2001
  $1.74 to 17.05     6,258,000     $ 8.79  
     
   
     
 

F-22


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

Additional information with respect to the outstanding options as of December 31, 2001, 2000, 1999 and 1998 is as follows:

                                 
    Range of Exercise Prices
   
      $1.74     $6.08-$6.51     $9.50-$11.75     $14.15-$17.05
   
 
 
 
Number outstanding at December 31, 1998
    18,000       1,561,000              
Options outstanding weighted average remaining contractual life
    8.86       9.91              
Number of excercisable
    3,000       1,267,000              
Number outstanding at December 31, 1999
    18,000       2,743,000                
Options outstanding weighted average remaining contractual life
    7.86       9.34              
Number of excercisable
    6,000       2,419,000              
Number outstanding at December 31, 2000
    18,000       3,973,000       510,000        
Options outstanding weighted average remaining contractual life
    6.86       8.58       9.79        
Number of excercisable
    10,000       1,404,000       1,095,000        
Number outstanding at December 31, 2001
    18,000       3,239,000       2,896,000       104,000  
Options outstanding weighted average remaining contractual life
    5.86       7.68       9.21       9.75  
Number of excercisable
    13,000       2,110,000       988,000        

As permitted by Statement of Financial Accounting Standards No. 123, “Accounting for Stock Based Compensation” (SFAS No. 123), the Company has chosen to apply APB Opinion No. 25, “Accounting for Stock Issued to Employees” (APB 25) and related interpretations in accounting for its Plan. Accordingly, no compensation cost has been recognized for options granted under the Plan. Had compensation costs for the Plan been determined based on the fair value at the grant dates for awards under the Plan consistent with the method of SFAS No. 123, approximately $4,454,000, $241,000 and $1,020,000 of additional compensation expense, net of tax, would have been recognized during the years ended December 31, 2001, 2000 and 1999, respectively.

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option pricing model assuming no dividend yield, volatility of 39% in 2001 and no volatility in 2000 and 1999 (before the initial public offering), an expected life of four years from the date of vesting and a risk free interest rate of 4.4%, 5.9% and 5.7% in 2001, 2000 and 1999, respectively.

F-23


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

For purposes of pro forma disclosures, the estimated fair value of the options is amortized to expense over the options’ vesting period. The Company’s pro forma net earnings and earnings per share were as follows:

                         
    For the year ended December 31,
   
    2001   2000   1999
   
 
 
Net income (loss) – as reported
  $ 29,681,000     $ 5,712,000     $ (13,106,000 )
Net income (loss) – pro forma
    25,227,000       5,471,000       (14,126,000 )
Weighted average grant-date fair value
    4.54       0.93       1.60  
Basic earnings (loss) per share – as reported
    0.68       (0.12 )     (0.74 )
Basic earnings (loss) per share – pro forma
    0.57       (0.13 )     (0.79 )
Diluted earnings (loss) per share – as reported
    0.62       (0.12 )     (0.74 )
Diluted earnings (loss) per share – pro forma
    0.52       (0.13 )     (0.79 )

10. Income Taxes

Significant components of the Company’s tax provision (benefit) before extraordinary items for the years ended December 31, 2001, 2000 and 1999 are as follows:

                           
      For the year ended December 31,
     

      2001   2000   1999
     
 
 
Current:
                       
 
Federal
  $ 14,630,000              
 
State and local
    2,772,000     $ 1,275,000     $ 1,497,000  
 
Foreign
    939,000       301,000        
 
   
     
     
 
Total current
    18,341,000       1,576,000       1,497,000  
Deferred
    (9,670,000 )     8,403,000       1,314,000  
 
   
     
     
 
Total income tax provision
  $ 8,671,000     $ 9,979,000     $ 2,811,000  
 
   
     
     
 

F-24


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

The difference between the expected income tax provision at the federal statutory rate of 34% and the income tax expense (benefit) recognized in the financial statements is as follows:

                         
    For the year ended December 31,
   
    2001   2000   1999
   
 
 
Expected federal tax rate
    35.0 %     35.0 %     (34.0 %)
State taxes, net of federal benefit
    3.8       3.8       22.1  
Non-deductible goodwill
    3.2       6.7       36.4  
Other permanent differences
    0.5       0.7       5.2  
Foreign taxes
    0.6       0.4       (1.1 )
Valuation allowance
    (20.6 )     (0.2 )     32.6  
Net operating loss usage
    (7.2 )           -  
Other
    3.1       (0.9 )     1.5  
 
   
     
     
 
Total
    18.4 %     45.5 %     62.7 %
 
   
     
     
 

Undistributed earnings of the Company’s foreign subsidiary are permanently reinvested. Accordingly, no deferred taxes have been provided on these earnings.

A summary of deferred tax assets and liabilities is as follows:

                 
    For the year ended December 31,
   
    2001   2000
   
 
Deferred tax assets – current
Allowance for doubtful accounts
  $ 25,232,000     $ 14,713,000  
Compensation and benefit related accruals
    3,034,000       1,853,000  
Expenses not currently deductible for tax
    679,000       339,000  
 
   
     
 
Net deferred tax asset – current
    28,945,000       16,905,000  
 
   
     
 
Deferred tax assets – non current
Expenses not currently deductible for tax
    84,000       2,983,000  
Net operating loss carry forwards
    8,759,000       14,887,000  
Depreciation and amortization
    693,000       1,238,000  
Other
          120,000  
 
   
     
 
Net deferred tax asset – non current
    9,536,000       19,228,000  
 
   
     
 
Net deferred tax asset before valuation allowance
    38,481,000       36,133,000  
Valuation allowance
    (2,862,000 )     (35,196,000 )
 
   
     
 
 
  $ 35,619,000     $ 937,000  
 
   
     
 

F-25


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

As a result of the Company's limited operating history and the cumulative losses incurred in prior years, the Company's historically provided a valuation allowance for substantially all of its deferred tax assets. Because of the cumulative profitable operations over the last three years, management has concluded that it is more likely than not that these deferred tax items will be realized. The reversal of these valuation allowances in the fourth quarter of 2001 resulted in a reduction in the tax provision of $9.7 million and a reduction in goodwill of $18.5 million. The reduction in goodwill relates to those deferred tax assets originating through acquisitions.

The decrease in the valuation allowance in 2000 is related to the utilization of net operating loss carryforwards, the benefit from which was allocated to reduce goodwill. As of December 31, 2001, the Company has approximately $9,400,000 in federal net operating loss carry forwards.

Net operating loss carry forwards expire as follows:

         
2002
  $ 461,000  
2003
    -  
2004
    -  
2005
    -  
Thereafter through 2019
    8,939,000  

As a result of the acquisition of Intensiva, American Transitional Hospitals, Inc. and NovaCare, the Company is subject to the provisions of Section 382 of the Internal Revenue Code which provide for annual limitations on the deductibility of acquired net operating losses and certain tax deductions. These limitations apply until the earlier of utilization or expiration of the net operating losses. Additionally, if certain substantial changes in the Company’s ownership should occur, there would be an annual limitation on the amount of the carryforwards that can be utilized.

11.     Special Charge

During 1999, the Company recorded a special charge for asset impairments of $5,223,000. The charge relates to the impairment of goodwill, leasehold improvements and equipment that resulted from closures and relocations of certain hospitals and clinics in December 1999. The Company also recorded an impairment writedown under FAS No. 121, on a held for use basis, related to certain outpatient rehabilitation facilities.

F-26


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

12.     Extraordinary item

As a result of the initial public offering of stock in April 2001 and the issuance of $175 million of 9 1/2% Senior Subordinated Notes in June 2001, the Company repaid $75 million of the U.S. term loan and all $90 million of the 10% Senior Subordinated Notes. The extraordinary item consists of $1.3 million of unamortized deferred financing costs related to the repayment of the U.S. term loan and $12.9 million of deferred financing costs and unamortized discount related to the repayment of our 10% Senior Subordinated Notes. These costs were offset by a tax benefit of $5.5 million.

On September 22, 2000, the Company entered into a new $230 million credit facility. This credit facility replaced the Company’s $225 million credit facility from November 19, 1999. The extraordinary item recorded during 2000 consists of the unamortized deferred financing costs of $6,247,000 related to the November 19, 1999 credit facility. There was no tax effect related to this transaction.

On November 19, 1999, the Company entered into a new $225 million credit facility in connection with the NovaCare acquisition. This credit facility replaced the Company’s $155 million credit facility from February 9, 1999. The extraordinary item recorded during 1999 consists of the unamortized deferred financing costs of $5,814,000 related to the February 9, 1999 credit facility. There was no tax effect related to this transaction.

13.     Retirement Savings Plan

Beginning March 1, 1998, the Company sponsored a defined contribution retirement savings plan for substantially all of its employees. Employees may elect to defer up to 15% of their salary. The Company matches 50% of the first 6% of compensation employees contribute to the plan. The employees vest in the employer contributions over a three-year period beginning on employee hire date. The expense incurred by the Company related to this plan was $4,617,000, $4,083,000 and $1,728,000 during the years ended December 31, 2001, 2000 and 1999, respectively.

A subsidiary sponsored a noncontributory defined contribution retirement plan for its employees during 1999. The plan was frozen during 2000 and the Company does not anticipate making future contributions to the plan. The subsidiary contributed 7.60% of employee salaries up to a maximum contribution of $13,000 per employee in 1999. Approximately $560,000 of contributions related to this plan were expensed during the year ended December 31, 1999.

F-27


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

14.     Segment Information

SFAS No. 131, “Disclosure about Segments of an Enterprise and Related Information”, establishes standards for reporting information about operating segments and related disclosures about products and services, geographic areas and major customers. The adoption of SFAS No. 131 did not affect the Company’s results of operations or financial position.

The Company’s segments consist of (i) inpatient hospitals and (ii) outpatient rehabilitation. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on EBITDA of the respective business units. EBITDA is defined as earnings before interest, minority interest, income taxes, extraordinary items, special charges, depreciation and amortization. All segment revenues are from external customers.

The following table summarizes selected financial data for the Company’s reportable segments:

                                 
    Year Ended December 31, 2001
   
    Inpatient   Outpatient                
    Hospitals   Rehabilitation   All Other   Total
   
 
 
 
Net revenue
  $ 503,021,000     $ 440,791,000     $ 15,144,000     $ 958,956,000  
EBITDA
    57,556,000       76,127,000       (21,665,000 )     112,018,000  
Total assets
    303,910,000       318,224,000       28,711,000       650,845,000  
Capital expenditures
    13,452,000       8,800,000       1,759,000       24,011,000  
                                 
    Year Ended December 31, 2000
   
    Inpatient   Outpatient                
    Hospitals   Rehabilitation   All Other   Total
   
 
 
 
Net revenue
  $ 378,910,000     $ 416,775,000     $ 10,212,000     $ 805,897,000  
EBITDA
    44,550,000       65,420,000       (18,300,000 )     91,670,000  
Total assets
    246,495,000       329,874,000       10,431,000       586,800,000  
Capital expenditures
    13,677,000       6,399,000       2,354,000       22,430,000  
                                 
    Year Ended December 31, 1999
   
    Inpatient   Outpatient                
    Hospitals   Rehabilitation   All Other   Total
   
 
 
 
Net revenue
  $ 307,464,000     $ 141,740,000     $ 6,771,000     $ 455,975,000  
EBITDA
    35,929,000       22,697,000       (16,382,000 )     42,244,000  
Total assets
    250,034,000       350,419,000       20,265,000       620,718,000  
Capital expenditures
    7,243,000       3,085,000       568,000       10,896,000  

F-28


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

A reconciliation of EBITDA to net income (loss) is as follows:

                         
    2001   2000   1999
 
 
EBITDA
  $ 112,018,000     $ 91,670,000     $ 42,244,000  
Depreciation and amortization
    (32,290,000 )     (30,401,000 )     (16,741,000 )
Special charge
                (5,223,000 )
Interest income
    507,000       939,000       362,000  
Interest expense
    (29,716,000 )     (36,126,000 )     (21,461,000 )
Minority interest
    (3,491,000 )     (4,144,000 )     (3,662,000 )
Income tax expense
    (8,671,000 )     (9,979,000 )     (2,811,000 )
Extraordinary item
    (8,676,000 )     (6,247,000 )     (5,814,000 )
 
 
Net income (loss)
  $ 29,681,000     $ 5,712,000     $ (13,106,000 )
 
 

15. Net Income (Loss) per Share

Under SFAS No. 128, “Earnings per Share” (EPS), the Company’s granting of certain stock options, warrants and convertible preferred stock resulted in potential dilution of basic EPS. The following table sets forth for the periods indicated the calculation of net income (loss) per share in the Company’s consolidated Statement of Operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute diluted EPS:

                           

F-29


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

                           
      2001   2000   1999
 
 
Numerator:
                       
Income (loss) before extraordinary item
  $ 38,357,000     $ 11,959,000     $ (7,292,000 )
Extraordinary item
    (8,676,000 )     (6,247,000 )     (5,814,000 )
 
 
 
Net income (loss)
    29,681,000       5,712,000       (13,106,000 )
 
Less: Preferred stock dividends
    2,513,000       8,780,000       5,175,000  
 
 
 
Numerator for basic earnings per share-income (loss) available to common stockholders
  $ 27,168,000     $ (3,068,000 )   $ (18,281,000 )
Effect of dilutive securities:
                       
 
Class B Preferred stock dividends
    1,067,000              
 
 
 
Numerator for diluted earnings per share - Income (loss) available to common stockholders after assumed conversions
  $ 28,235,000     $ (3,068,000 )   $ (18,281,000 )
                             
Denominator:
                       
 
Denominator for basic earnings per share-weighted average shares
    39,957,000       25,457,000       24,557,000  
 
Effect of dilutive securities:
                       
 
a) Stock options
    1,909,000       316,000        
 
b) Warrants
    1,073,000       134,000        
 
c) Convertible preferred stock
    2,525,000              
 
 
Denominator for diluted earnings per share-adjusted weighted average shares and assumed conversions
    45,464,000       25,907,000       24,557,000  
 
 
Basic earnings (loss) per common share:
                       
Income (loss) before extraordinary item
  $ 0.90     $ 0.13     $ (0.50 )
Extraordinary item
    (0.22 )     (0.25 )     (0.24 )
 
 
Income (loss) per common share
  $ 0.68     $ (0.12 )   $ (0.74 )
 
 
Diluted income (loss) per common share:
                       
Income (loss) before extraordinary item
  $ 0.81     $ 0.12     $ (0.50 )
Extraordinary item
    (0.19 )     (0.24 )     (0.24 )
 
 
Diluted income (loss) per common share
  $ 0.62     $ (0.12 )   $ (0.74 )
 
 

The following share amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

                         
    2001   2000   1999
 
 
a)   Stock options
    100,000       510,000       123,000  
b)   Warrants
                10,000  
c)   Convertible preferred stock
          9,216,000       1,136,000  

16. Fair Value of Financial Instruments

Financial instruments include cash and cash equivalents, notes payable, long-term debt and preferred stock. The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The Company is exposed to the impact of interest rate changes. The Company’s objective is to manage the impact of the interest rate changes on earnings and cash flows and on the market value of its borrowings. The Company entered into an interest rate swap in March 2001 which became effective in April 2001. The swap originally matured in March 2005. In January 2002, the swap maturity date was amended to March 2003. At December 31, 2001, approximately $69 million (notional amount) of the variable credit facility debt was converted to fixed

F-30


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

rate. At December 31, 2001, the variable interest rate of the debt was 5.3% and the fixed rate of the swap was 8.4%. The differential to be paid or received from the counterparty in the agreement is recorded as interest expense as rates reset. The net settlement resulted in a $0.8 million increase in interest expense in 2001. The swap agreement is made with a counterparty of high credit quality; therefore, management considers the risk of non-performance by the counterparty to be negligible.

The fair market value of this swap recorded as of December 31, 2001 was a liability of $1.6 million. The interest rate swap has been designated as a hedge and qualified under the provision of SFAS No. 133 as an effective hedge under the short-cut method. Accordingly, the change in the fair value for the year ended December 31, 2001 was recorded in other comprehensive income.

Borrowings under the credit facility which are not subject to the swap have variable rates that reflect currently available terms and conditions for similar debt. The carrying amount of this debt is a reasonable estimate of fair value.

The 9 1/2% Senior Subordinated Notes, which were issued and sold on June 11, 2001, are traded in public markets. The carrying value and estimated fair value of these notes was $175.0 million and $174.1 million at December 31, 2001.

The fair value of the Company’s Class A Preferred Stock, which was redeemed in 2001, and the Class B Preferred Stock, which converted into common stock in 2001, was not practicable to estimate as it was untraded; accordingly it was recorded at its redemption value.

17. Related Party Transactions

The Company has been party to various rental and other agreements with companies affiliated through common ownership. The Company made rental and other payments aggregating $1,186,000, $1,295,000, and $1,228,000 during the years ended December 31, 2001, 2000 and 1999, respectively, to the affiliated companies.

F-31


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

As of December 31, 2001, future rental commitments under outstanding agreements with the affiliated companies are approximately as follows:

         
2002
  $ 1,197,000  
2003
    1,242,000  
2004
    1,139,000  
2005
    1,086,000  
2006
    1,130,000  
Thereafter
    10,825,000  
 
   
 
 
  $ 16,619,000  
 
   
 

As further discussed in Note 6, the Company has issued warrants to certain of its principal stockholders in connection with guarantees of previous credit agreements.

In April 2000, the Company sold all of the assets of Georgia Health Group, Inc., for $5,000,000 to a company in which a principal stockholder has a majority owned interest.

In March 2000, the Company entered into three-year employment agreements with two of its principal stockholders. Under these agreements, the two stockholders will receive a combined total annual salary of $1,600,000. Additionally, one such shareholder has a life insurance policy for which the Company will pay premiums of $1,250,000 each fiscal year until 2010.

In December 1999, the Company acquired Select Air Corporation from a related party in exchange for consideration of $2,700,000, net of cash acquired.

F-32


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

18. Commitments and Contingencies

Leases

The Company leases facilities and equipment from unrelated parties under operating leases. Minimum future lease obligations on long-term non-cancelable operating leases in effect at December 31, 2001 are approximately as follows:

         
2002
  $ 53,247,000  
2003
    38,067,000  
2004
    25,853,000  
2005
    17,287,000  
2006
    12,663,000  
Thereafter
    8,375,000  
 
   
 
 
  $ 155,492,000  
 
   
 

Total rent expense for operating leases for the years ended December 31 2001, 2000 and 1999 was approximately $75,621,000, $68,731,000 and $35,929,000 respectively.

Other

In February 2002, PHICO Insurance Company (“PHICO”), at the request of the Pennsylvania Insurance Department, was placed in liquidation by an Order of the Commonwealth Court of Pennsylvania (“Liquidation Order”). The Company had placed its primary malpractice insurance coverage through PHICO from June 1998 through December 2000. In January 2001, these policies were replaced by policies issued with other issuers. Currently, the Company has approximately 20 unsettled cases in 11 states from the policy years covered by PHICO issued policies. The Liquidation Order refers these claims to various state guaranty associations. These state guaranty association statutes generally provide for coverage between $100,000-$300,000 per insured claim, depending on the state. Some states also have catastrophic loss funds to cover settlements in excess of the available state guaranty funds. Most state insurance guaranty statutes provide for net worth and residency limitations that, if applicable, may limit or prevent the Company from the recovering from these state guaranty association funds. At this time, the Company believes that it will meet the requirements for coverage under the applicable state guarantee association statutes, and that the resolution of these claims will not have a material adverse effect on the Company’s financial position, cash flow or results of operations. However, because the rules related to state guarantee funds are subject to interpretation and because these claims are still in the process of resolution, the Company’s conclusions may change as this process progresses.

F-33


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

A subsidiary of the Company has entered into a naming, promotional and sponsorship agreement for a sports complex. The naming, promotional and sponsorship agreement is in effect until 2026. The subsidiary is required to make payments in accordance with the contract terms over 25 years ranging from $1,400,000 to $1,963,000 per year and provide physical therapy and training services.

Litigation

On August 10, 1998 a complaint in the U.S. District Court for the Eastern District of Pennsylvania was filed that named as defendants NovaCare, Inc. (now known as NAHC, Inc.), other named defendants and 100 defendants who were to be named at a later time. This qui tam action sought triple damages and penalties under the False Claims Act against NAHC. The Department of Justice did not intervene in this action. The allegations involve, among other things, the distinction between individual and group billing in physical rehabilitation clinics that the Company acquired from NovaCare. On October 16, 2000 the relator plaintiff made a motion to amend the complaint to, among other things, add Select Medical Corporation and some of its subsidiaries acquired in the NovaCare acquisition as defendants in this case. This motion was granted in September of 2001. The amended complaint alleges that from about January 1, 1995 through the present, the defendants submitted false or fraudulent bills for physical therapy to various federal health programs. The United States Attorneys Office has asserted that because the complaint is being amended to add allegations against new defendants, it is entitled to a new period to determine whether to intervene in the new allegations. On January 3, 2002, NAHC entered into a settlement agreement with the relator plaintiff and the government, pursuant to which, in exchange for a payment by NAHC of $375,000, the parties settled all claims arising out of conduct that took place before Select Medical’s acquisition of the NovaCare subsidiaries that are defendants in the case. Claims against the Company and the NovaCare subsidiaries regarding conduct occurring after the NovaCare acquisition were not settled. As of February 28, 2002, the government had not advised the Company whether it intends to intervene in any remaining claims, and Select and the subsidiaries have not been served with the amended complaint. Based on a review of the amended complaint, the Company does not believe that this lawsuit is meritorious and intends to vigorously defend against this action. However, because of the uncertain nature of the litigation, the Company cannot predict the outcome of this matter.

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated, which include malpractice claims covered (subject to the above discussion regarding PHICO Insurance Company) under the Company’s insurance policy. In the opinion of management, the outcome of these actions will not have a material adverse effect on the financial position or results of operations of the Company.

F-34


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

19. Supplemental Disclosures of Cash Flow Information

Non-cash investing and financing activities are comprised of the following for the years ended December 31 2001, 2000 and 1999:

                         
Description of Transaction   2001   2000   1999

 
 
 
Acquisitions paid for in stock (Note 2)
  $ 4,973,000     $     $  
Notes issued with acquisitions (Note 2)
  $ 4,100,000     $ 3,207,000     $ 7,783,000  
Liabilities assumed with acquisitions (Note 2)
  $ 2,357,000     $ 255,000     $ 65,744,000  
Long-term debt discount (Note 6)
  $     $     $ 5,209,000  
Issuance of warrants (Note 6)
  $     $ 1,104,000     $ 2,389,000  
Related party acquisition (Note 17)
  $     $     $ 2,700,000  
Preferred stock dividends (Note 7)
  $ 2,513,000     $ 8,780,000     $ 5,175,000  
Credit facility refinancing (Note 6)
  $     $ 187,000,000     $  
Tax benefit of stock option exercises
  $ 2,513,000     $     $  

20. Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries

The Company conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for the Company, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2001 and 2000 and for the years ended December 31, 2001, 2000 and 1999. All Subsidiary Guarantors were wholly-owned as of the date of the issuance of the 9 1/2% Senior Subordinated Notes as described in Note 6.

On October 1, 2000, the Company transferred the operating assets of one of its guarantor subsidiaries into a newly organized partnership and simultaneously sold partnership units to unaffiliated investors. The operations of this business (through a 100% owned subsidiary) through October 1, 2000 have been included as a Subsidiary Guarantor. The operations commencing on October 1, 2000 through a minority owned partnership are presented as a Non-Guarantor Subsidiary.

F-35


Table of Contents

Select Medical Corporation
Notes to Consolidated Financial Statements

The equity method has been used by the Company with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

         The following table sets forth the Non-Guarantor Subsidiaries:

 
Canadian Back Institute Limited
Kentucky Orthopedic Rehabilitation, LLC
Medical Information Management Systems, LLC
Metro Therapy, Inc.
Millennium Rehab Services, LLC
Rehab Advantage Therapy Services, LLC
Select Houston Partners, L.P.
Select Management Services, LLC
Select Specialty Hospital – Biloxi, Inc.
TJ Corporation I, LLC

F-36


Table of Contents

                                           
      Select Medical Corporation
      Condensed Consolidating Balance Sheets
      December 31, 2001
     
      Select Medical                                
      Corporation                                
      (Parent Company   Subsidiary   Non-Guarantor                
      Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
     
 
 
 
 
      (dollars in thousands)
Assets
                                     
Current Assets:
                                       
 
Cash and cash equivalents
  $ 559     $ 8,086     $ 2,058     $     $ 10,703  
 
Accounts receivable, net
    (491 )     185,787       33,097             218,393  
 
Current deferred tax asset
    1,881       27,064                     28,945  
 
Other current assets
    1,964       13,766       2,714             18,444  
 
   
     
     
     
     
 
Total Current Assets
    3,913       234,703       37,869             276,485  
Property and equipment, net
    7,406       65,464       19,135             92,005  
Investment in affiliates
    320,458       72,145             (392,603 )(a)      
Intangible assets
    5,854       193,070       48,333             247,257  
Non-current deferred tax asset
    (343 )     7,017                   6,674  
Other assets
    12,494       14,095       1,835             28,424  
 
   
     
     
     
     
 
Total Assets
  $ 349,782     $ 586,494     $ 107,172     $ (392,603 )   $ 650,845  
 
   
     
     
     
     
 
Liabilities and Stockholders’ Equity
                                       
Current Liabilities:
                                       
 
Bank overdrafts
  $ 6,083     $     $     $     $ 6,083  
 
Current portion of long-term debt and notes payable
    480       26,278       16             26,774  
 
Accounts payable
    3,090       25,860       4,570             33,520  
 
Intercompany accounts
    54,253       (59,675 )     5,422              
 
Accrued payroll
    644       26,494       22             27,160  
 
Accrued vacation
    2,413       9,070       1,337             12,820  
 
Accrued restructuring
    154       1,665                   1,819  
 
Accrued other
    12,335       9,763       1,470             23,568  
 
Income taxes payable
          1,735                   1,735  
 
Due to third party payors
    (29,451 )     48,736       (3,028 )           16,257  
 
   
     
     
     
     
 
Total Current Liabilities
    50,001       89,926       9,809             149,736  
Long-term debt, net of current portion
    65,497       151,336       44,816             261,649  
 
   
     
     
     
     
 
Total Liabilities
    115,498       241,262       54,625             411,385  
Commitments and Contingencies
                                       
Minority interest in consolidated subsidiary companies
                5,176             5,176  
Stockholders’ Equity:
                                       
 
Common stock
    465                         465  
 
Capital in excess of par
    231,349                         231,349  
 
Retained earnings
    5,924       21,605       8,664       (30,269 )(b)     5,924  
 
Subsidiary investment
            323,627       38,707       (362,334 )(a)      
 
Treasury stock, at cost
    (1,560 )                       (1,560 )
 
Accumulated other comprehensive loss
    (1,894 )                       (1,894 )
 
   
     
     
     
     
 
Total Stockholders’ Equity
    234,284       345,232       47,371       (392,603 )     234,284  
 
   
     
     
     
     
 
Total Liabilities and Stockholders’ Equity
  $ 349,782     $ 586,494     $ 107,172     $ (392,603 )   $ 650,845  
 
   
     
     
     
     
 


(a)   Elimination of investments in subsidiaries.
(b)   Elimination of investments in subsidiaries’ earnings.

F-37


Table of Contents

                                           
      Select Medical Corporation
      Condensed Consolidating Statement of Operations
      For the Year Ended December 31, 2001
     
      Select Medical                                
      Corporation                                
      (Parent Company   Subsidiary   Non-Guarantor                
      Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
     
 
 
 
 
    (dollars in thousands)
Net operating revenues
  $ 14,300     $ 774,206     $ 170,450     $     $ 958,956  
 
   
     
     
     
     
 
Costs and expenses:
                                       
 
Cost of services
          637,681       138,614             776,295  
 
General and administrative
    35,630                         35,630  
 
Bad debt expense
          30,356       4,657             35,013  
 
Depreciation and amortization
    1,764       25,383       5,143             32,290  
 
   
     
     
     
     
 
Total costs and expenses
    37,394       693,420       148,414             879,228  
 
   
     
     
     
     
 
Income (loss) from operations
    (23,094 )     80,786       22,036             79,728  
Other income and expense:
                                       
Intercompany charges
    (51,183 )     41,621       9,562              
Interest income
    (401 )     (102 )     (4 )           (507 )
Interest expense
    7,223       17,478       5,015             29,716  
 
   
     
     
     
     
 
Income before minority interests and income taxes
    21,267       21,789       7,463             50,519  
Minority interest in consolidated subsidiary companies
          578       2,913             3,491  
 
   
     
     
     
     
 
Income before income taxes
    21,267       21,211       4,550             47,028  
Income tax expense (benefit)
    11,638       (3,906 )     939             8,671  
Equity in earnings of subsidiaries
    28,728       1,818             (30,546 )(a)      
 
   
     
     
     
     
 
Net income before extraordinary item
    38,357       26,935       3,611       (30,546 )     38,357  
Extraordinary item
    8,676                         8,676  
 
   
     
     
     
     
 
Net income (loss)
  $ 29,681     $ 26,935     $ 3,611     $ (30,546 )   $ 29,681  
 
   
     
     
     
     
 


(a)   Elimination of equity in net income (loss) from consolidated subsidiaries.

F-38


Table of Contents

                                             
        Select Medical Corporation
        Condensed Consolidating Statement of Cash Flows
        For the Year Ended December 31, 2001
       
        Select Medical                                
        Corporation                                
        (Parent Company   Subsidiary   Non-Guarantor                
        Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
       
 
 
 
 
      (dollars in thousands)
Operating activities
                                       
Net income (loss)
  $ 29,681     $ 26,935     $ 3,611     $ (30,546 )(a)   $ 29,681  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
                                       
 
Depreciation and amortization
    1,764       25,383       5,143             32,290  
 
Provision for bad debts
          30,356       4,657             35,013  
 
Minority interests
          578       2,913             3,491  
 
Extraordinary item
    8,676                         8,676  
 
Deferred income taxes
    2,461       (12,131 )                 (9,670 )
 
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
                                       
   
Equity (loss) in earnings of subsidiaries
    (28,728 )     (1,818 )           30,546 (a)      
   
Intercompany
    55,044       (55,973 )     929              
   
Accounts receivable
    191       (39,401 )     (10,222 )           (49,432 )
   
Other current assets
    (7,035 )     7,530       (951 )           (456 )
   
Other assets
    (1,633 )     3,296       (610 )           1,053  
   
Accounts payable
    743       3,307       665             4,715  
   
Due to third-party payors
    (13,681 )     27,046       1,381             14,746  
   
Accrued expenses
    7,170       7,218       (365 )           14,023  
   
Income taxes
    (8,190 )     19,316       514             11,640  
 
   
     
     
     
     
 
Net cash provided by operating activities
    46,463       41,642       7,665             95,770  
 
   
     
     
     
     
 
Investing activities
                                       
Purchases of property and equipment, net
    (1,682 )     (19,101 )     (3,228 )           (24,011 )
Proceeds from disposal of assets
          808                   808  
Earnout payments
          (5,660 )                 (5,660 )
Acquisition of businesses, net of cash acquired
    (33,084 )                       (33,084 )
 
   
     
     
     
     
 
Net cash used in investing activities
    (34,766 )     (23,953 )     (3,228 )           (61,947 )
 
   
     
     
     
     
 
Financing activities
                                       
Issuance of 9.5% Senior Subordinated Notes
    175,000                         175,000  
Net repayments on credit facility debt
    (98,320 )                       (98,320 )
Repayment of 10% Senior Subordinated Notes
    (90,000 )                       (90,000 )
Payment of deferred financing costs
    (4,681 )                       (4,681 )
Principal payments on seller and other debt
    (19,030 )                       (19,030 )
Proceeds from initial public offering, net of fees
    89,181                         89,181  
Redemption of Class A Preferred Stock
    (52,838 )                       (52,838 )
Payment of Class A and Class B Preferred Stock dividends
    (19,248 )                       (19,248 )
Proceeds from issuance of common stock
    4,334                         4,334  
Proceeds from (repayment of) bank overdrafts
    4,571       (9,938 )     (2,768 )           (8,135 )
Distributions to minority interests
          (680 )     (1,747 )           (2,427 )
 
   
     
     
     
     
 
Net cash used in financing activities
    (11,031 )     (10,618 )     (4,515 )           (26,164 )
 
   
     
     
     
     
 
Effect of exchange rate changes on cash and cash equivalents
    (107 )                       (107 )
 
   
     
     
     
     
 
Net increase (decrease) in cash and cash equivalents
    559       7,071       (78 )           7,552  
Cash and cash equivalents at beginning of period
          1,015       2,136             3,151  
 
   
     
     
     
     
 
Cash and cash equivalents at end of period
  $ 559     $ 8,086     $ 2,058     $     $ 10,703  
 
   
     
     
     
     
 


(a)   Elimination of equity in earnings of subsidiary.

F-39


Table of Contents

                                           
      Select Medical Corporation
      Condensed Consolidating Balance Sheets
      December 31, 2000
     
      Select Medical                                
      Corporation                                
      (Parent Company   Subsidiary   Non-Guarantor                
      Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
     
 
 
 
 
      (dollars in thousands)
Assets
                                       
Current Assets:
                                       
 
Cash and cash equivalents
  $     $ 1,015     $ 2,136     $     $ 3,151  
 
Accounts receivable, net
    (300 )     169,273       27,532             196,505  
 
Prepaid income taxes
    (6,599 )     7,417       275             1,093  
 
Other current assets
    1,528       14,116       1,763             17,407  
 
   
     
     
     
     
 
Total Current Assets
    (5,371 )     191,821     31,706           218,156  
Property and equipment, net
    4,839       60,861       19,276             84,976  
Investment in affiliates
    213,618       26,704             (240,322 )(a)      
Intangible assets
    5,953       204,735       40,711             251,399  
Other assets
    10,861       20,183       1,225             32,269  
 
   
     
     
     
     
 
Total Assets
  $ 229,900     $ 504,304     $ 92,918     $ (240,322 )   $ 586,800  
 
   
     
     
     
     
 
Liabilities and Stockholders’ Equity
                                       
Current Liabilities:
                                       
 
Bank overdrafts
  $ 1,511     $ 9,939     $ 2,768     $     $ 14,218  
 
Current portion of long-term debt and notes payable
    4,923       13,641       182             18,746  
 
Accounts payable
    2,347       22,543       3,905             28,795  
 
Intercompany accounts
    (30,624 )     30,981       (357 )            
 
Accrued payroll
    582       20,839       45             21,466  
 
Accrued vacation
    1,466       5,287       948             7,701  
 
Accrued restructuring
          4,701                   4,701  
 
Accrued other
    6,328       6,922       2,201             15,451  
 
Income taxes
    1,591       (1,352 )     (239 )            
 
Due to third party payors
    (15,770 )     21,690       (4,409 )           1,511  
 
   
     
     
     
     
 
Total Current Liabilities
    (27,646 )     135,191       5,044             112,589  
Long-term debt, net of current portion
    79,475       155,241       49,326             284,042  
 
   
     
     
     
     
 
Total Liabilities
    51,829       290,432       54,370             396,631  
Commitments and Contingencies
                                       
Minority interest in consolidated subsidiary companies
          4,516       7,582             12,098  
Preferred stock — Class A
    65,481                         65,481  
Convertible Preferred stock — Class B
    64,092                         64,092  
Stockholders’ Equity:
                                       
 
Common stock
    257                         257  
 
Capital in excess of par
    73,069                         73,069  
 
Accumulated deficit
    (23,757 )     (5,330 )     5,053       277 (b)     (23,757 )
 
Subsidiary investment
          214,686       25,913       (240,599 )(a)      
 
Treasury stock, at cost
    (1,039 )                       (1,039 )
 
Accumulated other comprehensive loss
    (32 )                       (32 )
 
   
     
     
     
     
 
Total Stockholders’ Equity
    48,498       209,356       30,966       (240,322 )     48,498  
 
   
     
     
     
     
 
Total Liabilities and Stockholders’ Equity
  $ 229,900     $ 504,304     $ 92,918     $ (240,322 )   $ 586,800  
 
   
     
     
     
     
 


(a)   Elimination of investments in subsidiaries.
(b)   Elimination of investments in subsidiaries’ earnings.

F-40


Table of Contents

                                           
      Select Medical Corporation
      Condensed Consolidating Statement of Operations
      For the Year Ended December 31, 2000
     
      Select Medical                                
      Corporation                                
      (Parent Company   Subsidiary   Non-Guarantor                
      Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
     
 
 
 
 
      (dollars in thousands)
Net operating revenues
  $ 10,157     $ 698,416     $ 97,324     $     $ 805,897  
 
   
     
     
     
     
 
Costs and expenses:
                                       
 
Cost of services
          577,406       79,055             656,461  
 
General and administrative
    28,431                         28,431  
 
Bad debt expense
          26,934       2,401             29,335  
 
Depreciation and amortization
    1,644       25,390       3,367             30,401  
 
   
     
     
     
     
 
Total costs and expenses
    30,075       629,730       84,823             744,628  
 
   
     
     
     
     
 
Income (loss) from operations
    (19,918 )     68,686       12,501             61,269  
Other income and expense:
                                       
Intercompany charges
    (42,151 )     40,606       1,545              
Interest income
    (644 )     (295 )                 (939 )
Interest expense
    9,856       21,803       4,467             36,126  
 
   
     
     
     
     
 
Income before minority interests and income taxes
    13,021       6,572       6,489             26,082  
Minority interest in consolidated subsidiary companies
          1,408       2,736             4,144  
 
   
     
     
     
     
 
Income before income taxes
    13,021       5,164       3,753             21,938  
Income tax expense
    4,415       5,263       301             9,979  
Equity in earnings of subsidiaries
    3,353       3,198             (6,551 )(a)      
 
   
     
     
     
     
 
Net income before extraordinary item
    11,959       3,099       3,452       (6,551 )     11,959  
Extraordinary item
    6,247                         6,247  
 
   
     
     
     
     
 
Net income
  $ 5,712     $ 3,099     $ 3,452     $ (6,551 )   $ 5,712  
 
   
     
     
     
     
 


(a)   Elimination of equity in net income (loss) from consolidated subsidiaries.

F-41


Table of Contents

                                               
          Select Medical Corporation
          Condensed Consolidating Statement of Cash Flows
          For the Year Ended December 31, 2000
         
          Select Medical                                
          Corporation                                
          (Parent Company   Subsidiary   Non-Guarantor                
          Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
         
 
 
 
 
        (dollars in thousands)
Operating activities
                                       
Net income (loss)
  $ 5,712     $ 3,099     $ 3,452     $ (6,551 )(a)   $ 5,712  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
                                       
 
Depreciation and amortization
    1,644       25,390       3,367             30,401  
 
Provision for bad debts
          26,934       2,401             29,335  
 
Minority interests
          1,408       2,736             4,144  
 
Extraordinary charge
    6,247                         6,247  
 
Loss on sale of assets
    111                         111  
 
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
                                       
   
Equity (loss) in earnings of subsidiaries
    (3,353 )     (3,198 )           6,551 (a)      
     
Intercompany
    12,938       (32,020 )     19,082              
     
Accounts receivable
    (1,050 )     (22,117 )     (13,797 )           (36,964 )
     
Other current assets
    (739 )     (912 )     (1,041 )           (2,692 )
     
Other assets
    13,269       (5,045 )     (13,243 )           (5,019 )
     
Accounts payable
    1,478       (2,056 )     1,958             1,380  
     
Due to third-party payors
    (6,081 )     (7,166 )     (4,426 )           (17,673 )
     
Accrued expenses
    961       (3,442 )     2,464             (17 )
     
Income taxes
    3,426       4,581       (459 )           7,548  
 
   
     
     
     
     
 
Net cash provided by (used in) operating activities
    34,563       (14,544 )     2,494             22,513  
 
   
     
     
     
     
 
Investing activities
                                       
Purchases of property and equipment, net
    (2,354 )     (16,118 )     (3,958 )           (22,430 )
Escrow receivable
          29,948                   29,948  
Disposal of assets held for sale
          13,000                   13,000  
Proceeds from disposal of assets
    2,452       495                   2,947  
Earnout payments
          (3,430 )                 (3,430 )
Acquisition of businesses, net of cash acquired
    (5,838 )                       (5,838 )
 
   
     
     
     
     
 
Net cash provided by (used in) investing activities
    (5,740 )     23,895       (3,958 )           14,197  
 
   
     
     
     
     
 
Financing activities
                                       
Net repayments on credit facility debt
    (12,000 )                       (12,000 )
Principal payments on seller and other debt
    (13,344 )     (14,233 )                 (27,577 )
Proceeds from issuance of common stock
    1,118                         1,118  
Purchase of treasury stock
    (210 )                       (210 )
Redemption of preferred stock
    (11 )                       (11 )
Proceeds from bank overdrafts
    197       4,751       2,305             7,253  
Payment of deferred financing costs
    (4,563 )                       (4,563 )
Distributions to minority interests
          (329 )     (1,297 )           (1,626 )
 
   
     
     
     
     
 
Net cash provided by (used in) financing activities
    (28,813 )     (9,811 )     1,008             (37,616 )
 
   
     
     
     
     
 
Effect of exchange rate changes on cash and cash equivalents
    (10 )                       (10 )
 
   
     
     
     
     
 
Net decrease in cash and cash equivalents
          (460 )     (456 )           (916 )
Cash and cash equivalents at beginning of period
          1,475       2,592             4,067  
 
   
     
     
     
     
 
Cash and cash equivalents at end of period
  $     $ 1,015     $ 2,136     $     $ 3,151  
 
   
     
     
     
     
 


(a)   Elimination of equity in earnings of subsidiary.

F-42


Table of Contents

                                           
      Select Medical Corporation
      Condensed Consolidating Statement of Operations
      For the Year Ended December 31, 1999
     
      Select Medical                                
      Corporation                                
      (Parent Company   Subsidiary   Non-Guarantor                
      Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
     
 
 
 
 
    (dollars in thousands)
Net operating revenues
  $ 6,771     $ 386,222     $ 62,982     $     $ 455,975  
 
   
     
     
     
     
 
Costs and expenses:
                                       
 
Cost of services
          333,023       50,430             383,453  
 
General and administrative
    21,420                         21,420  
 
Bad debt expense
          7,800       1,058             8,858  
 
Depreciation and amortization
    1,111       13,257       2,373             16,741  
 
Special charge
          5,223                   5,223  
 
   
     
     
     
     
 
Total costs and expenses
    22,531       359,303       53,861             435,695  
 
   
     
     
     
     
 
Income (loss) from operations
    (15,760 )     26,919       9,121             20,280  
Other income and expense:
                                       
Intercompany charges
    (16,079 )     15,058       1,021              
Interest income
    (238 )     (124 )                 (362 )
Interest expense
    7,509       11,169       2,783             21,461  
 
   
     
     
     
     
 
Income (loss) before minority interests and income taxes
    (6,952 )     816       5,317             (819 )
Minority interest in consolidated subsidiary companies
          1,349       2,313             3,662  
 
   
     
     
     
     
 
Income (loss) before income taxes
    (6,952 )     (533 )     3,004             (4,481 )
Income tax expense
          5,278             (2,467 )     2,811  
Equity in earnings of subsidiaries
    (340 )     2,853             (2,513 )(a)      
 
   
     
     
     
     
 
Net income (loss) before extraordinary item
    (7,292 )     (2,958 )     3,004       (46 )     (7,292 )
Extraordinary item
    5,814                         5,814  
 
   
     
     
     
     
 
Net income (loss)
  $ (13,106 )   $ (2,958 )   $ 3,004     $ (46 )   $ (13,106 )
 
   
     
     
     
     
 


(a)   Elimination of equity in net income (loss) from consolidated subsidiaries.

F-43


Table of Contents

                                                 
            Select Medical Corporation
            Condensed Consolidating Statement of Cash Flows
            For the Year Ended December 31, 1999
           
            Select Medical                                
            Corporation                                
            (Parent Company   Subsidiary   Non-Guarantor                
            Only)   Guarantors   Subsidiaries   Eliminations   Consolidated
           
 
 
 
 
          (dollars in thousands)
Operating activities
                                       
Net income (loss)
  $ (13,106 )   $ (2,958 )   $ 3,004     $ (46 )(a)   $ (13,106 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
                                       
   
Depreciation and amortization
    1,111       13,257       2,373             16,741  
   
Provision for bad debts
          7,800       1,058             8,858  
 
Special charge
          5,223                   5,223  
 
Extraordinary item
    5,814                         5,814  
 
Gain on sale of assets
          (215 )                 (215 )
   
Minority interests
          1,349       2,313             3,662  
   
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
                                       
     
Equity (loss) in earnings of subsidiaries
    340       (2,853 )           2,513 (a)      
       
Intercompany
    (35,895 )     20,866       15,029              
       
Accounts receivable
    4,335       (43,257 )     (8,368 )           (47,290 )
       
Other current assets
    (660 )     (1,095 )     27             (1,728 )
       
Other assets
    (1,506 )     909       (10,271 )           (10,868 )
       
Accounts payable
    717       (1,434 )     746             29  
       
Due to third-party payors
    (9,689 )     18,423       (19 )           8,715  
       
Accrued expenses
    1,753       (4,183 )     (258 )           (2,688 )
       
Income taxes
    8,641       (4,617 )     139       (2,467 )     1,696  
 
   
     
     
     
     
 
Net cash provided by (used in) operating activities
    (38,145 )     7,215       5,773             (25,157 )
 
   
     
     
     
     
 
Investing activities
                                       
Purchases of property and equipment, net
    (568 )     (6,761 )     (3,567 )           (10,896 )
Proceeds of disposal of assets
          988                   988  
Acquisition of businesses, net of cash acquired
    (171,354 )                       (171,354 )
 
   
     
     
     
     
 
Net cash used in investing activities
    (171,922 )     (5,773 )     (3,567 )           (181,262 )
 
   
     
     
     
     
 
Financing activities
                                       
Proceeds from issuance of debt
    68,194                         68,194  
Net repayments on credit facility debt
    86,655                         86,655  
Principal payments on seller and other debt
    (5,393 )     (4,671 )                 (10,064 )
Proceeds from issuance of common stock
    1,041                         1,041  
Proceeds from issuance of preferred stock — Class B
    59,361                         59,361  
Purchase of treasury
    (781 )                       (781 )
Redemption of preferred stock
    (214 )                       (214 )
Proceeds from bank overdrafts
    1,314       3,128       451             4,893  
Payment of deferred financing costs
    (10,883 )                       (10,883 )
Distributions to minority interests
          (295 )     (427 )           (722 )
 
   
     
     
     
     
 
Net cash provided by (used in) financing activities
    199,294       (1,838 )     24             197,480  
 
   
     
     
     
     
 
Effect of exchange rate changes on cash and cash equivalents
    5                         5  
 
   
     
     
     
     
 
Net increase (decrease) in cash and cash equivalents
    (10,768 )     (396 )     2,230             (8,934 )
Cash and cash equivalents at beginning of period
    10,768       1,871       362             13,001  
 
   
     
     
     
     
 
Cash and cash equivalents at end of period
  $     $ 1,475     $ 2,592     $     $ 4,067  
 
   
     
     
     
     
 


(a)   Elimination of equity in earnings of subsidiary.

F-44


Table of Contents

21.   Selected Quarterly Financial Data (Unaudited)

The table below sets forth selected unaudited financial data for each quarter of the last two years.

                                     
        First   Second   Third   Fourth
        Quarter   Quarter   Quarter   Quarter
       
 
 
 
        (in thousands, except per share amounts)
 
                               
Year ended December 31, 2001
                               
 
Net revenues
  $ 225,088     $ 234,199     $ 239,155     $ 260,514  
 
Income from operations
    19,216       20,789       17,794       21,929  
 
Net income before extraordinary item
    6,121       7,598       6,343       18,295  
 
Extraordinary item
          8,676              
 
Net income
    6,121       (1,078 )     6,343       18,295  
Net income (loss) per common share:
                               
 
Basic:
                               
   
Income (loss) before extraordinary item
  $ 0.15     $ 0.17     $ 0.14     $ 0.40  
   
Extraordinary item
          (0.20 )            
 
 
   
     
     
     
 
   
Income (loss) per common share
  $ 0.15     $ (0.03 )   $ 0.14     $ 0.40  
 
 
   
     
     
     
 
 
Diluted:
                               
   
Income (loss) before extraordinary item
  $ 0.13     $ 0.16     $ 0.13     $ 0.37  
   
Extraordinary item
          (0.19 )            
 
 
   
     
     
     
 
   
Income (loss) per common share
  $ 0.13     $ (0.03 )   $ 0.13     $ 0.37  
 
 
   
     
     
     
 
                                     
        First   Second   Third   Fourth
        Quarter   Quarter   Quarter   Quarter
       
 
 
 
        (in thousands, except per share amounts)
 
                               
Year ended December 31, 2000
                               
 
Net revenues
  $ 196,722     $ 200,700     $ 196,917     $ 211,558  
 
Income from operations
    15,230       18,278       13,177       14,584  
 
Net income before extraordinary item
    2,834       4,190       1,050       3,885  
 
Extraordinary item
                6,247        
 
Net income
    2,834       4,190       (5,197 )     3,885  
Net income (loss) per common share:
                               
 
Basic:
                               
   
Income (loss) before extraordinary item
  $ 0.03     $ 0.08     $ (0.04 )   $ 0.06  
   
Extraordinary item
                (0.25 )      
 
 
   
     
     
     
 
   
Income (loss) per common share
  $ 0.03     $ 0.08     $ (0.29 )   $ 0.06  
 
 
   
     
     
     
 
 
Diluted:
                               
   
Income (loss) before extraordinary item
  $ 0.03     $ 0.08     $ (0.04 )   $ 0.06  
   
Extraordinary item
                (0.25 )      
 
 
   
     
     
     
 
   
Income (loss) per common share
  $ 0.03     $ 0.08     $ (0.29 )   $ 0.06  
 
 
   
     
     
     
 

F-45


Table of Contents

Report of Independent Accountants on

Financial Statement Schedules

To the Board of Directors and Stockholders

of Select Medical Corporation:

Our audits of the consolidated financial statements referred to in our report dated February 15, 2002 appearing in this Annual Report on Form 10-K of Select Medical Corporation also included an audit of the financial statement schedule listed in Item 14(a)(2) of this Form 10-K. In our opinion, this financial statement schedule presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements.

PricewaterhouseCoopers LLP

Harrisburg, Pennsylvania
February 15, 2002

 


Table of Contents

Schedule II-Valuation and Qualifying Accounts

                                         
    Balance               Balance
    at   Charged to           at
    Beginning   Cost and           End of
Description   of Year   Expenses   Acquisitions(A)   Deductions(B)   Year

 
 
 
 
 
Year ended December 31, 2001 allowance for doubtful accounts   $ 75,517     $ 35,013     $ 1,214     $ (31,855 )   $ 79,889  
Year ended December 31, 2000 allowance for doubtful accounts   $ 69,492     $ 29,335     $     $ (23,310 )   $ 75,517  
Year ended December 31, 1999 allowance for doubtful accounts   $ 15,701     $ 8,858     $ 53,989     $ (9,056 )   $ 69,492  
Year ended December 31, 2001 income tax valuation allowance   $ 35,196     $ (9,670 )   $     $ (22,664 )   $ 2,862  
Year ended December 31, 2000 income tax valuation allowance   $ 38,941     $     $ (3,745 )   $     $ 35,196
Year ended December 31, 1999 income tax valuation allowance   $ 18,867     $     $ 20,074     $     $ 38,941  
   
(A) Represents opening balance sheet reserves resulting from purchase accounting entries.
(B) Allowance for doubtful accounts deductions represent writeoffs against the reserve. Income tax valuation allowance deductions primarily represent the reversal of valuation allowances because the Company believes certain deferred tax items will be realized.


Table of Contents

SIGNATURES

           Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

         
    SELECT MEDICAL CORPORATION
    By:   /s/ Robert A. Ortenzio
       
Robert A. Ortenzio
        Chief Executive Officer and President
        (principal executive officer)

           Pursuant to the requirements of the Securities Exchange Act of 1934, this report is signed below by the following persons on behalf of the Registrant on the dates and in the capacities indicated.

         
Signature   Title   Date

 
 
         
/s/ Rocco A. Ortenzio

Rocco A. Ortenzio
  Director and Executive Chairman   March 4, 2002
 
/s/ Robert A. Ortenzio

Robert A. Ortenzio
  Director, Chief Executive
Officer and President
(principal executive officer)
  March 4, 2002
 
/s/ Martin F. Jackson

Martin F. Jackson
  Chief Financial Officer
(principal financial officer)
  March 4, 2002
 
/s/ Scott A. Romberger

Scott A. Romberger
  Chief Accounting Officer
(principal accounting officer)
  March 4, 2002
 
/s/ Russell L. Carson

Russell L. Carson
  Director   March 4, 2002
 
/s/ David S. Chernow

David S. Chernow
  Director   March 4, 2002
 
/s/ Bryan C. Cressey

Bryan C. Cressey
  Director   March 4, 2002
 
/s/ James E. Dalton, Jr.

James E. Dalton, Jr.
  Director   March 4, 2002
 
/s/ Donald J. Edwards

Donald J. Edwards
  Director   March 4, 2002
 
/s/ Meyer Feldberg

Meyer Feldberg
  Director   March 4, 2002
 
/s/ Leopold Swergold

Leopold Swergold
  Director   March 4, 2002
 
/s/ LeRoy S. Zimmerman

LeRoy S. Zimmerman
  Director   March 4, 2002


Table of Contents

EXHIBIT INDEX

     
Exhibit    
Number   Document

 
     
2.1   Stock Purchase Agreement dated as of October 1, 1999 by and among Select Medical Corporation, NC Resources, Inc. and NovaCare, Inc., incorporated by reference to Exhibit 2.3 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
2.2   First Amendment dated as of November 19, 1999 to Stock Purchase Agreement dated as of October 1, 1999 by and among Select Medical Corporation, NC Resources, Inc. and NovaCare, Inc., incorporated by reference to Exhibit 2.4 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
3.1   Form of Restated Certificate of Incorporation, incorporated by reference to Exhibit 3.1 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
3.2   Amended and Restated Bylaws.
     
3.3   Amendment No. 1 to Amended and Restated Bylaws.
     
3.4   Amendment No. 2 to Amended and Restated Bylaws.
     
4.1   Indenture governing 9 1/2% Senior Subordinated Notes due 2009 among Select Medical Corporation, the Subsidiary Guarantors named therein and State Street Bank and Trust Company, N.A., dated June 11, 2001, incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
4.2   Form of 9 1/2% Senior Subordinated Notes due 2009 (included in Exhibit 4.1).
     
4.3   Exchange and Registration Rights Agreement, dated June 11, 2001 by and among Select Medical Corporation, the Subsidiary Guarantors named therein, J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse First Boston Corporation, CIBC World Markets Corp. and First Union Securities, Inc, incorporated by reference to Exhibit 4.3 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.1   Registration Agreement dated as of February 5, 1997 by and among Select Medical Corporation; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.1 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.2   Amendment No. 1 dated as of December 15, 1998 to Registration Agreement dated as of February 5, 1997 by and among Select Medical Corporation; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.2 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.3   Amendment No. 2 dated as of November 19, 1999 to Registration Agreement dated as of February 5, 1997 by and among Select Medical; Golder, Thoma, Cressey, Rauner Fund V, L.P.; Welsh, Carson, Anderson & Stowe VII, L.P., Rocco A. Ortenzio and Robert A. Ortenzio, incorporated by reference to Exhibit 10.3 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.4   Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.4 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.5   Employment Agreement dated as of December 16, 1998 between Select Medical Corporation and David W. Cross, incorporated by reference to Exhibit 10.8 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.6   Other Senior Management Agreement dated as of June 2, 1997 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.9 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.7   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.10 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.8   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.11 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.9   Employment Agreement dated as of December 21, 1999 between RehabClinics, Inc. and Edward R. Miersch, incorporated by reference to Exhibit 10.12 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.10   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Edward R. Miersch, incorporated by reference to Exhibit 10.13 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.11   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.14 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.12   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.15 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.13   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.16 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.14   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.17 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.15   Split Dollar Agreement dated as of October 6, 2000 between Select Medical Corporation, Michael E. Salerno and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.18 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.16   Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.19 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.17   Amendment dated as of August 8, 2000 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.20 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.18   Other Senior Management Agreement dated as of March 28, 1997 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.21 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.19   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.22 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.20   Employment Agreement dated as of May 22, 2000 between Select Medical Corporation and LeRoy S. Zimmerman, incorporated by reference to Exhibit 10.23 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.21   Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.24 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.22   First Addendum dated June 1999 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.25 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.23   Second Addendum dated as of February 1, 2000 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.26 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.24   Office Lease Agreement dated as of June 17, 1999 between Select Medical Corporation and Old Gettysburg Associates III, incorporated by reference to Exhibit 10.27 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.25   Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.28 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.26   First Amendment dated as of December 8, 1997 to Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.29 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.27   Second Amendment dated as of January 28, 2000 to Equipment Lease Agreement dated as of April 1, 1997 between Select Medical Corporation and Select Capital Corporation, incorporated by reference to Exhibit 10.30 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.28   Amended and Restated 1997 Stock Option Plan, amended and restated February 22, 2001, incorporated by reference to Exhibit 10.31 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.29   First Amendment dated as of October 15, 2000 to Employment Agreement dated as of December 16, 1998 between Select Medical Corporation and David W. Cross, incorporated by reference to Exhibit 10.33 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.30   Amended and Restated Senior Management Agreement dated as of May 7, 1997 between Select Medical Corporation, John Ortenzio, Martin Ortenzio, Select Investments II, Select Partners, L.P. and Rocco Ortenzio, incorporated by reference to Exhibit 10.34 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.31   Amendment No. 1 dated as of January 1, 2000 to Amended and Restated Senior Management Agreement dated May 7, 1997 between Select Medical Corporation and Rocco Ortenzio, incorporated by reference to Exhibit 10.35 of the Company’s Registration Statement on Form S-1 (Reg. No. 333- 48856).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.32   Naming, Promotional and Sponsorship Agreement dated as of October 1, 1997 between NovaCare, Inc. and the Philadelphia Eagles Limited Partnership, assumed by Select Medical Corporation in a Consent and Assumption Agreement dated November 19, 1999 by and among NovaCare, Inc., Select Medical Corporation and the Philadelphia Eagles Limited Partnership, incorporated by reference to Exhibit 10.36 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.33   Cost Sharing Agreement, dated December 11, 2000, among Select Transport, Inc., Select Medical Corporation and Select Air II Corporation, incorporated by reference to Exhibit 10.39 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.34   Amended and Restated Deferred Compensation Agreement dated January 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.40 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.35   Settlement Agreement dated as of July 6, 2000 by and among Select Medical Corporation, NC Resources, Inc, NAHC Inc., and NovaCare Holdings, Inc, incorporated by reference to Exhibit 10.44 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.36   First Amendment dated December 28, 2000 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.45 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.37   Second Amendment dated January 18, 2001 to the Amended Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC, Inc., incorporated by reference to Exhibit 10.46 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.38   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.47 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.39   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.48 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.40   Amendment No. 2 dated as of February 23, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.49 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.41   Amendment No. 1 dated as of February 23, 2001 to Employment Agreement dated as of May 22, 2000 between Select Medical Corporation and LeRoy S. Zimmerman, incorporated by reference to Exhibit 10.50 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.42   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Edward R. Miersch, incorporated by reference to Exhibit 10.51 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.43   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.44   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and S. Frank Fritsch, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.45   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.54 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-48856).
     
10.46   Third Amendment dated May 31, 2001 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, The Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC Inc., incorporated by reference to Exhibit 10.49 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.47   Amendment No. 3 dated as of April 24, 2001 to Employment Agreement dated as of March 1, 2000 between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.50 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.48   First Amendment to Cost Sharing Agreement dated as of April 1, 2001 by and among Select Medical Corporation, Select Transport, Inc. and Select Air II Corporation, incorporated by reference to Exhibit 10.51 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.49   Third Addendum dated as of May 17, 2001 to Office Lease Agreement dated as of May 18, 1999 between Select Medical Corporation and Old Gettysburg Associates I, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.50   Office Lease Agreement dated as of May 15, 2001 by and between Select Medical Corporation and Old Gettysburg Associates II, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).

 


Table of Contents

     
Exhibit    
Number   Document

 
     
10.51   Purchase Agreement, dated June 11, 2001 by and among Select Medical Corporation, the Subsidiary Guarantors named therein, J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse First Boston Corporation, CIBC World Markets Corp. and First Union Securities, Inc, incorporated by reference to Exhibit 10.54 of the Company’s Registration Statement on Form S-4 (Reg. No. 333-63828).
     
10.52   Amendment No. 4 to Employment Agreement dated as of September 17, 2001 between Select Medical Corporation and Rocco A. Ortenzio.
     
10.53   Amendment No. 3 to Employment Agreement dated as of September 17, 2001 between Select Medical Corporation and Robert A. Ortenzio.
     
10.54   Fourth Addendum to Lease Agreement dated as of September 1, 2001 by and between Old Gettysburg Associates and Select Medical Corporation.
     
10.55   Rights Agreement dated as of September 17, 2001, between Select Medical Corporation and Mellon Investor Services LLC, as Rights Agent, incorporated by reference to Exhibit 1.1 of the Company’s Registration Statement on Form 8-A filed October 1, 2001 (SEC File No. 000-32499).
     
10.56   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Scott A. Romberger.
     
10.57   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and Scott A. Romberger.
     
10.58   Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and James J. Talalai.
     
10.59   Amendment dated as of February 23, 2001 to Change of Control Agreement dated as of March 1, 2000 between Select Medical Corporation and James J. Talalai.
     
10.60   Fourth Amendment dated October 5, 2001 to the Credit Agreement dated as of September 22, 2000 among Select Medical Corporation, Canadian Back Institute Limited, The Chase Manhattan Bank, the Chase Manhattan Bank of Canada, Banc of America Securities, LLC and CIBC Inc.
     
10.61   Change of Control Agreement dated as of November 21, 2001 between Select Medical Corporation and David W. Cross.
     
12.1   Computation of Ratio of Earnings to Fixed Charges.
21.1   Subsidiaries of Select Medical Corporation.
     
23.1   Consent of PricewaterhouseCoopers LLP.

 

 

Exhibit 3.2

SELECT MEDICAL CORPORATION

AMENDED AND RESTATED BYLAWS

As adopted on March 23, 2001

 


 

TABLE OF CONTENTS

         
ARTICLE I STOCKHOLDERS
    1  
 
       
Section 1.1 Annual Meetings
    1  
Section 1.2 Special Meetings
    1  
Section 1.3 Notice of Meetings; Waiver
    1  
Section 1.4 Quorum
    2  
Section 1.5 Voting
    2  
Section 1.6 Voting by Ballot
    2  
Section 1.7 Adjournment
    2  
Section 1.8 Proxies
    3  
Section 1.9 Notice of Stockholder Business and Nominations
    3  
Section 1.10 Organization; Procedure
    5  
Section 1.11 Inspectors of Elections
    5  
Section 1.12 Opening and Closing of Polls
    6  
Section 1.13 No Stockholder Action by Written Consent or Telephone Conference
    6  
 
       
ARTICLE II BOARD OF DIRECTORS
    7  
 
       
Section 2.1 General Powers
    7  
Section 2.2 Number and Term of Office
    7  
Section 2.3 Election of Directors
    7  
Section 2.4 Annual and Regular Meetings
    7  
Section 2.5 Special Meetings; Notice
    8  
Section 2.6 Quorum; Voting
    8  
Section 2.7 Adjournment
    8  
Section 2.8 Action Without a Meeting
    8  
Section 2.9 Regulations; Manner of Acting
    9  
Section 2.10 Resignations
    9  
Section 2.11 Removal of Directors
    9  
Section 2.12 Vacancies and Newly Created Directorships
    9  
Section 2.13 Reliance on Accounts and Reports, etc.
    10  
 
       
ARTICLE III COMMITTEES OF DIRECTORS AND ADVISORY BOARD
    10  
 
       
Section 3.1 Committees of Directors
    10  
Section 3.2 Proceedings
    10  
Section 3.3 Quorum and Manner of Acting
    10  
Section 3.4 Action by Telephonic Communications
    11  
Section 3.5 Absent or Disqualified Members
    11  
Section 3.6 Resignations
    11  
Section 3.7 Removal
    11  
Section 3.8 Vacancies
    11  

 


 

         
ARTICLE IV OFFICERS
    11  
 
       
Section 4.1 Number
    11  
Section 4.2 Election
    12  
Section 4.3 Compensation
    12  
Section 4.4 Removal and Resignation; Vacancies
    12  
Section 4.5 Authority and Duties of Officers
    12  
Section 4.6 Chairman of the Board
    12  
Section 4.7 Vice Chairman of the Board
    13  
Section 4.8 Chief Executive Officer
    13  
Section 4.9 President
    13  
Section 4.10 Vice Presidents
    13  
Section 4.11 Secretary
    13  
Section 4.12 Assistant Secretary
    14  
Section 4.13 Treasurer
    14  
Section 4.14 Additional Officers
    14  
Section 4.15 Security
    14  
 
       
ARTICLE V CAPITAL STOCK
    15  
 
       
Section 5.1 Certificates of Stock, Uncertificated Shares
    15  
Section 5.2 Signatures; Facsimile
    15  
Section 5.3 Lost, Stolen or Destroyed Certificates
    15  
Section 5.4 Transfer of Stock
    15  
Section 5.5 Record Date
    16  
Section 5.6 Registered Stockholders
    16  
Section 5.7 Transfer Agent and Registrar
    16  
 
       
ARTICLE VI INDEMNIFICATION
    16  
 
       
Section 6.1 Nature of Indemnity
    16  
Section 6.2 Successful Defense
    17  
Section 6.3 Determination that Indemnification is Proper
    18  
Section 6.4 Advance Payment of Expenses
    18  
Section 6.5 Procedure for Indemnification of Directors and Officers
    18  
Section 6.6 Survival; Preservation of Other Rights
    19  
Section 6.7 Insurance
    19  
Section 6.8 Severability
    19  
Section 6.9 Limitation on Liability
    20  
Section 6.10 Appearance as a Witness
    20  
Section 6.11 Indemnification of Employees and Agents
    20  
 
       
ARTICLE VII OFFICES
    20  
 
       
Section 7.1 Registered Office and Agent
    20  
Section 7.2 Other Offices
    20  

ii


 

         
ARTICLE VIII GENERAL PROVISIONS
    21  
 
       
Section 8.1 Dividends
    21  
Section 8.2 Reserves
    21  
Section 8.3 Execution of Instruments
    21  
Section 8.4 Deposits
    21  
Section 8.5 Checks
    21  
Section 8.6 Sale, Transfer, etc.
    21  
Section 8.7 Voting as Stockholder
    21  
Section 8.8 Fiscal Year
    22  
Section 8.9 Seal
    22  
Section 8.10 Books and Records; Inspection
    22  
 
       
ARTICLE IX AMENDMENT OF BYLAWS
    22  
 
       
Section 9.1 Amendment
    22  
 
       
ARTICLE X CONSTRUCTION
    22  
 
       
Section 10.1 Construction
    22  

iii


 

SELECT MEDICAL CORPORATION

BYLAWS

AMENDED AND RESTATED AS OF

March 23, 2001

ARTICLE I

STOCKHOLDERS

         Section 1.1  Annual Meetings. The annual meeting of the stockholders of the Corporation for the election of Directors and for the transaction of such other business as properly may come before such meeting, including, without limitation, for the purpose of the delivery of an annual report of the Board of Directors, shall be held at such place, within or without the State of Delaware, such date, and such time as designated by the Board of Directors and set forth in the notice or waiver of notice of the meeting.

         Section 1.2  Special Meetings. Special meetings of the stockholders for any proper purpose or purposes may be called at any time by the Chief Executive Officer, or pursuant to a resolution approved by a majority of the entire Board of Directors. Such special meetings of the stockholders shall be held at such places, within or without the State of Delaware, as shall be specified in the respective notices or waivers of notice thereof. Only business within the purpose or purposes described in the notice or waiver thereof required by these Bylaws may be conducted at a special meeting of the stockholders. No stockholder shall have the power to require that a meeting of the stockholders be held or that any matter be voted on by the stockholders at any special meeting, except as required by law.

         Section 1.3  Notice of Meetings; Waiver.

                  (a) Written or printed notice of the place, date and hour of the meeting of the stockholders, and, in the case of a special meeting, the purpose or purposes for which such meeting is called, shall be delivered not less than ten nor more than sixty days prior to the meeting, either personally or by mail, by or at the direction of the Board of Directors or person calling the meeting, to each stockholder of record entitled to vote at such meeting. If such notice is mailed, it shall be deemed to have been delivered to a stockholder on the third day after it is deposited in the United States mail, postage prepaid, addressed to the stockholder at his or her address as it appears on the record of stockholders of the Corporation, or, if he or she shall have filed with the Secretary of the Corporation a written request that notices to him or her be mailed

 


 

to some other address, then directed to him or her at such other address. Such further notice shall be given as may be required by law or otherwise by these Bylaws.

                  (b) No notice of any meeting of stockholders need be given to any stockholder who submits a signed waiver of notice, whether before or after the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in a written waiver of notice. The attendance of any stockholder at a meeting of stockholders shall constitute a waiver of notice of such meeting, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business on the ground that the meeting is not lawfully called or convened.

         Section 1.4  Quorum. Except as otherwise required by law or by the Certificate of Incorporation, a quorum shall be present at a meeting of stockholders if the holders of record of more than 50% of the then outstanding shares entitled to vote at a meeting of the stockholders are represented at the meeting in person or by proxy.

         Section 1.5  Voting. If, pursuant to Section 5.5 of these Bylaws, a record date has been fixed, every holder of record of shares entitled to vote at a meeting of stockholders shall be entitled to one vote, or such other number of votes as may be prescribed in a Preferred Stock Certificate of Designation (as such term is defined in the Certificate of Incorporation), for each share outstanding in his or her name on the books of the Corporation at the close of business on such record date. If no record date has been fixed, then every holder of record of shares entitled to vote at a meeting of stockholders shall be entitled to one vote, or such other number of votes as may be prescribed in a Preferred Stock Certificate of Designation, for each share of stock standing in his or her name on the books of the Corporation at the close of business on the business day next preceding the day on which notice of the meeting is given, or, if notice is waived, at the close of business on the business day next preceding the day on which the meeting is held. Except as otherwise required by law or by the Certificate of Incorporation or by these Bylaws, the vote of a majority of the shares represented in person or by proxy at any meeting at which a quorum is present shall be sufficient for the transaction of any business at such meeting.

         Section 1.6  Voting by Ballot. No vote of the stockholders need be taken by written ballot unless otherwise required by law. Any vote which need not be taken by ballot may be conducted in any manner approved by the chairman of the meeting.

         Section 1.7  Adjournment. The chairman of the meeting or the holders of record of more than 50% of the then outstanding shares entitled to vote at a meeting of the stockholders shall have the power to adjourn such meeting from time to time, without any notice other than announcement at the meeting of the time and place of the holding of the adjourned meeting, provided that if the adjournment is for more than thirty days, or if after the adjournment a new record date for the adjourned meeting is fixed pursuant to Section 5.5 of these Bylaws, a notice of the adjourned meeting, conforming to the requirements of Section 1.3 of these Bylaws, shall be given to each stockholder of record entitled to vote at such meeting. If such meeting is adjourned by the stockholders, the resumption of such meeting shall occur at such time and place

2


 

as shall be determined by a vote of the holders of record of more than 50% of the then outstanding shares entitled to vote at such meeting of the stockholders. Upon the resumption of such adjourned meeting, any business may be transacted that might have been transacted at the meeting as originally called.

         Section 1.8  Proxies. Any stockholder entitled to vote at any meeting of the stockholders or to express consent to or dissent from corporate action in writing without a meeting may vote in person or may authorize another person or persons to vote at any such meeting and express such consent or dissent for him or her by proxy executed in writing by the stockholder. A stockholder may authorize a valid proxy by executing a written instrument signed by such stockholder, or by causing his or her signature to be affixed to such writing by any reasonable means, including, but not limited to, by facsimile signature or photographic, photostatic, or similar reproduction or by transmitting or authorizing the transmission of a telegram or any other means of electronic communication that results in a writing to the person designated as the holder of the proxy, a proxy solicitation firm or a like authorized agent. No such proxy shall be voted or acted upon after the expiration of three years from the date of such proxy unless such proxy provides for a longer period. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or by filing another duly executed proxy bearing a later date with the Secretary. Proxies by telegram or other electronic communication must either set forth or be submitted with information from which it can be determined that the telegram or other electronic communication was authorized by the stockholder. Any copy, facsimile telecommunication or other reliable reproduction of a writing or transmission created pursuant to this section may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.

         Section 1.9  Notice of Stockholder Business and Nominations.

                  (a)  Annual Meetings of Stockholders.

                           (1)  Nominations of persons for election to the Board of Directors of the Corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i) by or at the direction of the Board of Directors or the Chairman of the Board, or (ii) by any stockholder of the Corporation who is entitled to vote at the meeting, who complies with the notice procedures set forth in clauses (2) and (3) of this paragraph and who was a stockholder of record at the time such notice is delivered to the Secretary or any Assistant Secretary of the Corporation.

                           (2)  For nominations or other business to be properly brought before an annual meeting by a stockholder, pursuant to clause (ii) of paragraph (A)(1) of this Bylaw, the stockholder must have given timely notice thereof in writing to the Secretary or any Assistant Secretary of the Corporation. To be timely, a stockholder’s notice shall be delivered to the Secretary or any Assistant Secretary at the principal executive offices of the Corporation not

3


 

less than ninety days nor more than one hundred and twenty days prior to the first anniversary of the preceding year’s annual meeting; provided, that if the date of the annual meeting is advanced by more than twenty days or delayed by more than seventy days from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than one hundred and twenty days prior to such annual meeting and not later than the close of business on the later of the ninetieth day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first made. In no event shall the adjournment of an annual meeting commence a new time period for the giving of a stockholder’s notice as described above. Such stockholder’s notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a Director all information relating to such person that is required to be disclosed in solicitations of proxies for election of Directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the Exchange Act), and Rule 14a-11 thereunder, in each case including any successor Rule or Regulation thereto, including such person’s written consent to being named in the proxy statement as a nominee and to serving as a Director if elected; (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and of any beneficial owner on whose behalf the proposal is made; and (c) as to the stockholder giving the notice and any beneficial owner on whose behalf the nomination or proposal is made (i) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner and (ii) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner.

                           (3)  Notwithstanding anything in the second sentence of paragraph (A)(2) of this Bylaw to the contrary, in the event that the number of Directors to be elected to the Board of Directors of the Corporation is increased and there is no public announcement naming all of the nominees for Director or specifying the size of the increased Board of Directors made by the Corporation at least one hundred days prior to the first anniversary of the preceding year’s annual meeting, a stockholder’s notice under this paragraph shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth day following the day on which such public announcement is first made by the Corporation.

                  (b)  Special Meetings of Stockholders. Only such business as shall have been brought before the special meeting of the stockholders pursuant to the Corporation’s notice of meeting pursuant to Section 1.3 of these Bylaws shall be conducted at such meeting. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which Directors are to be elected pursuant to the Corporation’s notice of meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who is entitled to vote at the meeting, who complies with the notice procedures set forth in this Bylaw and who is a stockholder of record at the time such notice is delivered to the Secretary of the Corporation. Nominations by stockholders of persons for election to the Board

4


 

of Directors may be made at such special meeting of stockholders if the stockholder’s notice as required by paragraph (A)(2) of this Bylaw shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the one hundred and twentieth day prior to such special meeting and not later than the close of business on the later of the ninetieth day prior to such special meeting or the tenth day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the adjournment of a special meeting commence a new time period for the giving of a stockholder’s notice as described above.

                  (c)  General.

                           (1)  Only persons who are nominated in accordance with the procedures set forth in this Bylaw shall be eligible to serve as Directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Bylaw. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the procedures set forth in this Bylaw and, if any proposed nomination or business is not in compliance with this Bylaw, to declare that such defective proposal or nomination shall be disregarded.

                           (2)  For purposes of this Bylaw, public announcement shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act.

                           (3)  Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Bylaw. Nothing in this Bylaw shall be deemed to affect any right of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.

         Section 1.10  Organization; Procedure. At every meeting of stockholders the presiding officer shall be the chairman of the meeting, who shall be a Director (or representative thereof) designated by a majority of the Board of Directors. The order of business and all other matters of procedure at every meeting of stockholders, including the regulation of the manner of voting and the conduct of discussion as seem to him or her in order, shall be determined by such presiding officer. All meetings of the stockholders shall be held at the principal place of business of the Corporation or at such other place within or without the State of Delaware as shall be specified or fixed in the notices or waivers of notice thereof.

         Section 1.11  Inspectors of Elections. Preceding any meeting of the stockholders, the Board of Directors shall appoint one or more persons to act as inspectors of elections, and may designate one or more alternate inspectors. In the event no inspector or alternate is able to act, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

5


 

Each inspector, before entering upon the discharge of the duties of an inspector, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector shall:

                  (a)  ascertain the number of shares outstanding and the voting power of each,

                  (b)  determine the shares represented at a meeting and the validity of proxies and ballots, count all votes and ballots,

                  (c)  determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and

                  (d)  certify his or her determination of the number of shares represented at the meeting, and his or her count of all votes and ballots.

                  The inspector may appoint or retain other persons or entities to assist in the performance of the duties of inspector.

                  When determining the shares represented and the validity of proxies and ballots, the inspector shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in accordance with Section 1.8 of these Bylaws, ballots and the regular books and records of the Corporation. The inspector may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers or their nominees or a similar person which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspector considers other reliable information as outlined in this section, the inspector, at the time of his or her certification pursuant to (d) of this section, shall specify the precise information considered, the person or persons from whom the information was obtained, when this information was obtained, the means by which the information was obtained, and the basis for the inspector’s belief that such information is accurate and reliable.

         Section 1.12  Opening and Closing of Polls. The date and time for the opening and the closing of the polls for each matter to be voted upon at a stockholder meeting shall be announced at the meeting. The inspector of the election shall be prohibited from accepting any ballots, proxies or votes or any revocations thereof or changes thereto after the closing of the polls, unless the Court of Chancery upon application by a stockholder shall determine otherwise.

         Section 1.13  No Stockholder Action by Written Consent or Telephone Conference.

                  Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders of the Corporation, and the ability of the stockholders to consent in writing or by telephone to the taking of any action is specifically denied.

6


 

ARTICLE II

BOARD OF DIRECTORS

         Section 2.1  General Powers. Except as may otherwise be provided by law, by the Certificate of Incorporation or by these Bylaws, the property, affairs and business of the Corporation shall be managed by or under the direction of the Board of Directors and the Board of Directors may exercise all the powers of the Corporation and may make all decisions and take all actions for the Corporation. The powers of the Corporation which may be exercised by the Directors without the approval of the stockholders shall include, without limitation, the power to purchase, hold and sell investments; to borrow and loan funds and provide guarantees of the obligations of others; and to acquire other companies in the ordinary course of business.

         Section 2.2  Number and Term of Office. The number of Directors shall be fixed from time to time exclusively pursuant to a resolution adopted by a majority of the entire Board of Directors, but shall consist of not less than five (5) Directors nor more than nine (9) Directors. The Directors, other than those who may be elected by the holders of any series of Preferred Stock, if any, shall be divided into three classes, designated Classes I, II and III, which shall be as nearly equal in number as possible. Directors of Class I shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 2002, Directors of Class II shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 2003 and Directors of Class III shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 2004. At each succeeding annual meeting of stockholders following such initial classification and election, the respective successors of each class shall be elected for three year terms. Each Director (whenever elected) shall hold office until his or her successor has been duly elected and qualified, or until his or her earlier death, insanity, retirement, resignation or removal. Directors need not be residents of the State of Delaware.

         Section 2.3  Election of Directors. Except as otherwise provided in Sections 2.11 and 2.12 of these Bylaws, the Directors shall be elected at each annual meeting of the stockholders. If the annual meeting for the election of Directors is not held on the date designated therefor, the Directors shall cause the meeting to be held as soon thereafter as convenient. At each meeting of the stockholders for the election of Directors, provided a quorum is present, the Directors shall be elected by a plurality of the votes validly cast in such election.

         Section 2.4  Annual and Regular Meetings. The annual meeting of the Board of Directors for the purpose of electing officers and for the transaction of such other business as may come before the meeting shall be held as soon as possible following adjournment of the annual meeting of the stockholders at the place of such annual meeting of the stockholders. Notice of such annual meeting of the Board of Directors need not be given. The Board of Directors from time to time may by resolution provide for the holding of regular meetings and fix the place (which may be within or without the State of Delaware) and the date and hour of such meetings, provided that such meetings shall be held no less frequently than quarterly. Notice of regular meetings need not be given, provided, however, that if the Board of Directors

7


 

shall fix or change the time or place of any regular meeting, notice of such action shall be mailed promptly, or sent by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, telegraph, facsimile, electronic mail or other electronic means to each Director who shall not have been present at the meeting at which such action was taken, addressed to him or her at his or her usual place of business, or shall be delivered to him or her personally.

         Section 2.5  Special Meetings; Notice. Special meetings of the Board of Directors shall be held whenever called by the Chairman or the Chief Executive Officer, or by a majority of the Directors, date and hour as may be specified in the respective notices or waivers of notice of such meetings. Special meetings of the Board of Directors may be called on at least seventy-two hours’ notice to each other Director, if notice is given to each Director personally or by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, telegraph, facsimile, electronic mail or other electronic means, or on five days’ notice from the official date of deposit in the mail if notice is mailed to each Director, addressed to him or her at his or her usual place of business. Such notice need not state the purpose or purposes of, nor the business to be transacted at, such meeting, except as may otherwise be required by law or provided for by the Certificate of Incorporation.

         Section 2.6  Quorum; Voting. Unless otherwise required by law or provided in the Certificate of Incorporation, at all meetings of the Board of Directors, the presence of a majority of the total number of Directors then in office shall constitute a quorum for the transaction of business of the Directors. Except as otherwise required by law, or except as provided herein or in the Certificate of Incorporation, the act or vote of a majority of directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. A Director who is present at a meeting of the Directors at which action on any matter of the Corporation is taken shall be presumed to have assented to the action unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent to such action with the person acting as secretary of the meeting before the adjournment thereof or shall deliver such dissent to the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favor of such action.

         Section 2.7  Adjournment. A majority of the Directors present, whether or not a quorum is present, may adjourn any meeting of the Board of Directors to another time or place. No notice need be given of any adjourned meeting unless the time and place of the adjourned meeting are not announced at the time of adjournment, in which case notice conforming to the requirements of Section 2.5 of these Bylaws shall be given to each Director.

         Section 2.8  Action Without a Meeting. Any action permitted or required by law, the Certificate of Incorporation, or these Bylaws to be taken at a meeting of the Directors or of any committee designated by the Directors may be taken without a meeting if a consent in writing, setting forth the action to be taken, is signed by all the Directors or members of such committee, as the case may be, provided that the writing or writings are filed with the minutes of proceedings of the Board of Directors or committee. Such consent shall have the same force and

8


 

effect as a unanimous vote at a meeting and may be stated as such in any document or instrument filed with the Secretary of State of Delaware, and the execution of such consent shall constitute attendance or presence in person at a meeting of the Board of Directors or any such committee, as the case may be. Subject to the requirements of law, the Certificate of Incorporation, or these Bylaws for notice of meetings, Directors, or members of any committee designated by the Board of Directors, may participate in and hold a meeting of the Board of Directors or any committee of Directors, as the case may be, by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in such meeting shall constitute attendance and presence in person at such meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened.

         Section 2.9  Regulations; Manner of Acting. Meetings of the Board of Directors may be held at such place or places as shall be determined from time to time by resolution of the Directors. At all meetings of the Board of Directors, business shall be transacted in such order as shall from time to time be determined by resolution of the Directors to the extent consistent with applicable law, the Certificate of Incorporation and these Bylaws. The Board of Directors may adopt such other rules and regulations for the conduct of meetings of the Board of Directors and for the management of the property, affairs and business of the Corporation as the Board of Directors may deem appropriate. Attendance of a Director at a meeting shall constitute a waiver of notice of such meeting, except where a Director attends a meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened. The Directors shall act only as a Board, and the individual Directors shall have no power as such.

         Section 2.10  Resignations. Any Director may resign at any time. Such resignation shall be made in writing, signed by such Director, to the Corporation and shall take effect at the time specified therein, or if no time be specified, at the time of its receipt by the Chairman or the Secretary. The acceptance of a resignation shall not be necessary to make it effective, unless expressly so provided in the resignation.

         Section 2.11  Removal of Directors. Any Director may be removed at any time, but only for cause upon the affirmative vote of the holders of a majority of the combined voting power of the then outstanding stock of the Corporation entitled to vote generally in the election of Directors at any meeting of such stockholders, including meetings called expressly for that purpose, and at which a quorum of stockholders is present. Subject to the rights of the holders of any series of preferred stock of the Corporation, any vacancy in the Board of Directors caused by any such removal shall be filled at such meeting by the stockholders entitled to vote for the election of the Director so removed.

         Section 2.12  Vacancies and Newly Created Directorships. Subject to the rights of the holders of any series of preferred stock of the Company and except as provided in Section 2.11, if any vacancies occur in the Board of Directors, by reason of death, resignation, removal or otherwise, or if the authorized number of Directors shall be increased, the Directors then in

9


 

office shall continue to act and such vacancies and newly created Directorships may be filled by a majority of the Directors then in office, although less than a quorum. A Director elected to fill a vacancy or a newly created Directorship shall hold office until the next election of the class of Directors for which such Director has been chosen and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal.

         Section 2.13  Reliance on Accounts and Reports, etc. A Director, or a member of any committee designated by the Board of Directors shall, in the performance of his or her duties, be fully protected in relying in good faith upon the records of the Corporation and upon information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees designated by the Board of Directors, or by any other person as to the matters the Director or member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

ARTICLE III

COMMITTEES OF DIRECTORS AND ADVISORY BOARD

         Section 3.1  Committees of Directors. The Board of Directors may designate one or more committees, each such committee to consist of one or more Directors, as fixed from time to time by the Board of Directors. The Board of Directors may designate one or more Directors as alternate members of any such committee, who may replace any absent or disqualified member or members at any meeting of such committee. Thereafter, members (and alternate members, if any) of each such committee may be designated at the annual meeting of the Board of Directors. Any such committee may be dissolved or re-designated from time to time by the Board of Directors. Each member (and each alternate member) of any such committee (whether designated at an annual meeting of the Board of Directors or to fill a vacancy or otherwise) shall hold office until his or her successor shall have been designated or until he or she shall cease to be a Director, or until his or her earlier death, resignation or removal.

         Section 3.2  Proceedings. Any such committee may fix its own rules of procedure and may meet at such place (within or without the State of Delaware), at such time and upon such notice, if any, as it shall determine from time to time. Any such committee shall keep regular minutes of its meetings and report the same to the Board of Directors at the next meeting of the Board following such committee meeting, except that when the Board meeting is held within two days after the committee meeting, such report shall, if not made at the first meeting, be made to the Board of Directors at its second meeting following such committee meeting.

         Section 3.3  Quorum and Manner of Acting. Except as may be otherwise provided in the resolution creating such committee, at all meetings of any committee the presence of members (or alternate members) constituting a majority of the total authorized membership of such committee shall constitute a quorum for the transaction of business. The act of the majority of the members present at any meeting at which a quorum is present shall be the act of such committee. Any action required or permitted to be taken at any meeting of any such committee

10


 

may be taken without a meeting if all members of such committee shall consent to such action in writing and such writing or writings are filed with the minutes of the proceedings of the committee. The members of any such committee shall act only as a committee, and the individual members of such committee shall have no power as such.

         Section 3.4  Action by Telephonic Communications. Members of any committee designated by the Board of Directors may participate in a meeting of such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this provision shall constitute presence in person at such meeting.

         Section 3.5  Absent or Disqualified Members. In the absence or disqualification of a member of any committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.

         Section 3.6  Resignations. Any member (and any alternate member) of any committee may resign at any time by delivering a written notice of resignation, signed by such member, to the Chairman, the Chief Executive Officer or the President. Unless otherwise specified therein, such resignation shall take effect upon delivery.

         Section 3.7  Removal. Any member (and any alternate member) of any committee may be removed from his or her position as a member (or alternate member, as the case may be) of such committee at any time, either for or without cause, by resolution adopted by a majority of the whole Board of Directors.

         Section 3.8  Vacancies. If any vacancy shall occur in any committee, by reason of disqualification, death, resignation, removal or otherwise, the remaining members (and any alternate members) shall continue to act, and any such vacancy may be filled by the Board of Directors.

ARTICLE IV

OFFICERS

         Section 4.1  Number. The officers of the Corporation shall be designated by the Board of Directors and shall include such officers as the Directors may from time to time determine, which officers may (but need not) include a Chairman of the Board, a Vice Chairman of the Board, a Chief Executive Officer, a President, one or more Vice Presidents (and in the case of each such Vice President, with such descriptive title, if any, as the Directors shall deem appropriate), a Secretary, an Assistant Secretary, and a Treasurer. The Board of Directors also may elect one or more other officers as the Board of Directors may determine. Any number of offices may be held by the same person. No officer need be a Director of the Corporation.

11


 

         Section 4.2  Election. Officers shall be chosen in such manner and shall hold their offices for such terms as determined by the Board of Directors. Each officer shall hold office until his or her successor has been elected and qualified in his stead, or until his or her earlier death, resignation, retirement, disqualification, or removal from office.

         Section 4.3  Compensation. The Corporation shall have the authority to pay and provide compensation and other benefits to its officers and employees. The compensation and benefits of all officers of the Corporation shall be fixed from time to time by the Board of Directors, unless otherwise delegated by the Board of Directors to a particular committee or officer.

         Section 4.4  Removal and Resignation; Vacancies. Any officer may be removed for or without cause at any time by the Board of Directors, the Chief Executive Officer or the President, if such powers of removal have been expressly conferred by the Board of Directors, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Designation of an officer shall not itself create contract rights. Any officer may resign at any time by delivering a written notice of resignation, signed by such officer, to the Board of Directors, the Chief Executive Officer or the President. Unless otherwise specified therein, such resignation shall take effect upon delivery. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise, shall be filled by the Board of Directors. The Board of Directors may abolish any office at any time unless prohibited by law or statute.

         Section 4.5  Authority and Duties of Officers. In addition to any specifically enumerated duties, services, and powers, the officers of the Corporation shall have such authority and shall exercise such powers and perform such duties as may be specified by law or statute, by the Certificate of Incorporation, and by these Bylaws, or as the Board of Directors may from time to time determine or as may be assigned to such officers by any competent superior officer. The Board of Directors may also at any time limit or circumvent the enumerated duties, services and powers of any officer. In addition to the designation of officers and the enumeration of their respective duties, services and powers, the Board of Directors may grant powers of attorneys to individuals to act as agent for or on behalf of the Corporation, to do any act which would be binding on the Corporation, to incur any expenditures on behalf of or for the Corporation, or to execute, deliver and perform any agreements, acts, transactions or other matters on behalf of the Corporation. Such powers of attorney may be revoked or modified as deemed necessary by the Board of Directors.

         Section 4.6  Chairman of the Board. The Chairman of the Board shall, if one is designated by the Board of Directors and if present, preside at all meetings of the stockholders and of the Board of Directors and exercise and perform such other powers and duties as may be from time to time assigned by the Board of Directors. He shall assist the Directors in the formulation of the policies of the Corporation, and shall be available to other officers for consultation and advice.

12


 

         Section 4.7  Vice Chairman of the Board. The Vice Chairman of the Board, if one is designated by the Board of Directors, shall, in the absence of the Chairman of the Board, preside at all meetings of the stockholders and of the Board of Directors and exercise and perform such other powers and duties as may be from time to time assigned by the Board of Directors.

         Section 4.8  Chief Executive Officer. The Chief Executive Officer shall have day-to-day supervision of the affairs of the Corporation, such powers and duties subject at all times to the authority of the Board of Directors. In the absence or disability of the Chairman of the Board and the Vice Chairman of the Board, the Chief Executive Officer shall exercise the powers and perform the duties of the Chairman of the Board.

         Section 4.9  President. The President, if one is designated by the Board of Directors, shall generally assist the Chief Executive Officer and shall have such powers and perform such duties and services as shall from time to time be prescribed or delegated to him by the Chief Executive Officer or the Board of Directors. In the absence or disability of the Chief Executive Officer, the President shall exercise the powers and perform the duties of the Chief Executive Officer.

         Section 4.10  Vice Presidents. Each Vice President that is designated by the Board of Directors shall generally assist the President and shall have such powers and perform such duties and services as shall from time to time be prescribed or delegated to him by the President or the Board of Directors.

         Section 4.11  Secretary. The Secretary, if one is designated by the Board of Directors, shall have the following powers and duties:

                  (a)  He or she shall keep or cause to be kept a record of all the proceedings of the meetings of the stockholders and of the Board of Directors in books provided for that purpose.

                  (b)  He or she shall cause all notices to be duly given in accordance with the provisions of these Bylaws and as required by law.

                  (c)  Whenever any committee shall be appointed pursuant to a resolution of the Board of Directors, he or she shall furnish a copy of such resolution to the members of such committee.

                  (d)  He or she shall be the custodian of the records and of the seal of the Corporation and cause such seal (or a facsimile thereof) to be affixed to all certificates representing shares of the Corporation prior to the issuance thereof and to all instruments the execution of which on behalf of the Corporation under its seal shall have been duly authorized in accordance with these Bylaws, and when so affixed he or she may attest the same.

13


 

                  (e)  He or she shall properly maintain and file all books, reports, statements, certificates and all other documents and records required by law, the Certificate of Incorporation or these Bylaws.

                  (f)  He or she shall have charge of the stock books and ledgers of the Corporation and shall cause the stock and transfer books to be kept in such manner as to show at any time the number of shares of stock of the Corporation of each class issued and outstanding, the names (alphabetically arranged) and the addresses of the holders of record of such shares, the number of shares held by each holder and the date as of which each became such holder of record.

                  (g)  He or she shall sign (unless the Treasurer, an Assistant Treasurer or an Assistant Secretary shall have signed) certificates representing shares of the Corporation the issuance of which shall have been authorized by the Board of Directors.

                  (h)  He or she shall perform, in general, all duties incident to the office of Secretary and such other duties as may be specified in these Bylaws or as may be assigned to him or her from time to time by the Board of Directors, the Chief Executive Officer or the President.

         Section 4.12  Assistant Secretary. The Assistant Secretary, if one is designated by the Board of Directors, shall generally assist the Secretary.

         Section 4.13  Treasurer. The Treasurer, if one is designated by the Board of Directors, or such other officer as may be designated by the Board of Directors, shall be the chief accounting and financial officer of the Corporation and have custody of all the funds, securities and other valuables of the Corporation which may have or shall come into his or her hands. The Treasurer shall have active control of and shall be responsible for all matters pertaining to the accounts and finances of the Corporation and shall have such powers and perform such duties as may be prescribed by the Chief Executive Officer, the President, the Board of Directors or elsewhere in these Bylaws.

         Section 4.14  Additional Officers. The Board of Directors may appoint such other officers and agents as it may deem appropriate, and such other officers and agents shall hold their offices for such terms and shall exercise such powers and perform such duties as may be determined from time to time by the Board of Directors. The Board of Directors from time to time may delegate to the Chief Executive Officer or President the power to appoint subordinate officers or agents and to prescribe their respective rights, terms of office, authorities and duties. Any such officer or agent may remove any such subordinate officer or agent appointed by him or her, for or without cause.

         Section 4.15  Security. The Board of Directors may require any officer, agent or employee of the Corporation to provide security for the faithful performance of his or her duties, in such amount and of such character as may be determined from time to time by the Board of Directors.

14


 

ARTICLE V

CAPITAL STOCK

         Section 5.1  Certificates of Stock, Uncertificated Shares. The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of the stock of the Corporation shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until each certificate is surrendered to the Corporation. Notwithstanding the adoption of such a resolution by the Board of Directors, every holder of stock in the Corporation represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the Corporation, by the Chief Executive Officer, the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, representing the number of shares registered in certificate form. Such certificate shall be in such form as the Board of Directors may determine, to the extent consistent with applicable law, the Certificate of Incorporation and these Bylaws.

         Section 5.2  Signatures; Facsimile. All of such signatures on the certificate referred to in Section 5.1 of these Bylaws may be a facsimile, engraved or printed, to the extent permitted by law. In case any officer, transfer agent or registrar who has signed, or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue.

         Section 5.3  Lost, Stolen or Destroyed Certificates. The Corporation may direct that a new certificate be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon delivery to the Corporation of an affidavit of the owner or owners of such certificate, setting forth such allegation. The Corporation may require the owner of such lost, stolen or destroyed certificate, or his or her legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of any such new certificate.

         Section 5.4  Transfer of Stock. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares, duly endorsed or accompanied by appropriate evidence of succession, assignment or authority to transfer, the Corporation shall issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books. Within a reasonable time after the transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to Sections 151, 156, 202(a) or 218(a) of the Delaware General Corporation Law. Subject to the provisions of the Certificate of Incorporation and these Bylaws, the Board of Directors may prescribe such additional rules and regulations as

15


 

it may deem appropriate relating to the issue, transfer and registration of shares of the Corporation.

         Section 5.5  Record Date. In order to determine the stockholders entitled to notice of, or entitled to vote at, any meeting of stockholders or any adjournment thereof, the Board of Directors may fix in advance a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted by the Board of Directors, and which shall not be more than sixty nor less than ten days before the date of such meeting. A determination of stockholders of record entitled to notice of or entitled to vote at a meeting of stockholders shall apply to any adjournment of the meeting, provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

                  In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights of the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

         Section 5.6  Registered Stockholders. Prior to due surrender of a certificate for registration of transfer, the Corporation may treat the registered owner as the person exclusively entitled to receive dividends and other distributions, to vote, to receive notice and otherwise to exercise all the rights and powers of the owner of the shares represented by such certificate, and the Corporation shall not be bound to recognize any equitable or legal claim to or interest in such shares on the part of any other person, whether or not the Corporation shall have notice of such claim or interests. Whenever any transfer of shares shall be made for collateral security, and not absolutely, it shall be so expressed in the entry of the transfer if, when the certificates are presented to the Corporation for transfer or uncertificated shares are requested to be transferred, both the transferor and transferee request the Corporation to do so.

         Section 5.7  Transfer Agent and Registrar. The Board of Directors may appoint one or more transfer agents and one or more registrars, and may require all certificates representing shares to bear the signature of any such transfer agents or registrars.

ARTICLE VI

INDEMNIFICATION

         Section 6.1  Nature of Indemnity. The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (a Proceeding), whether civil, criminal, administrative, arbitrative, or investigative, or any appeal in such a Proceeding or any inquiry or investigation that could lead to such a Proceeding, by reason of the fact that he or she, or a person of whom he or she is the

16


 

legal representative, is or was or has agreed to become a Director or officer of the Corporation, or is or was serving or has agreed to serve at the request of the Corporation as a director, officer, partner, venturer, proprietor, trustee, employee, agent, or similar functionary of another foreign or domestic corporation, limited liability company, partnership, joint venture, sole proprietorship, trust, employee benefit plan, or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her or on his or her behalf in connection with such action, suit or proceeding and any appeal therefrom, provided that he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding had no reasonable cause to believe his or her conduct was unlawful. The indemnification provided in this Article VI could involve indemnification for negligence or under theories of strict liability. In the case of an action or suit by or in the right of the Corporation to procure a judgment in its favor (1) the indemnification of a Director or officer shall be limited to expenses (including attorneys’ fees) actually and reasonably incurred by such person in the defense or settlement of such action or suit, and (2) no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. Notwithstanding the foregoing, but subject to Section 6.5 of these Bylaws, the Corporation shall not be obligated to indemnify a Director or officer of the Corporation in respect of a Proceeding (or part thereof) instituted by such Director or officer, unless such Proceeding (or part thereof) has been authorized by the Board of Directors.

                  The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.

                  The rights granted pursuant to this Article VI shall be deemed contract rights. No amendment, modification or repeal of this Article VI shall have the effect of limiting or denying any such rights with respect to actions taken or Proceedings arising prior to any such amendment, modification or repeal.

         Section 6.2  Successful Defense. To the extent that a present or former Director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 6.1 of these Bylaws or in defense of any claim, issue or matter therein, he or she shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by him or her in connection therewith.

17


 

         Section 6.3  Determination that Indemnification is Proper. Any indemnification of a present or former Director or officer of the Corporation under Section 6.1 of these Bylaws (unless ordered by a court) shall be made by the Corporation unless a determination is made that indemnification of the Director or officer is not proper in the circumstances because he or she has not met the applicable standard of conduct set forth in Section 6.1 of these Bylaws. Any such determination shall be made (1) by a majority vote of the Directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are no such Directors, or if such Directors so direct, by independent legal counsel in a written opinion, or (4) by the stockholders.

         Section 6.4  Advance Payment of Expenses. The right to indemnification conferred in this Article VI shall include the right to be paid or reimbursed by the Corporation the reasonable expenses incurred by a person of the type entitled to be indemnified under Sections 6.1, 6.2, and 6.3 who was, is, or is threatened to be made a named defendant or respondent in a Proceeding in advance of the final disposition of the Proceeding and without any determination as to the person’s ultimate entitlement to indemnification; provided, however, that the payment of such expenses incurred by any such person in advance of the final disposition of a Proceeding shall be made only upon delivery to the Corporation of a written affirmation by such person of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification under this Article VI and a written undertaking, by or on behalf of such person, to repay all amounts so advanced if it shall ultimately be determined that such person is not entitled to be indemnified under this Article VI or otherwise. The Board of Directors may authorize the Corporation’s counsel to represent such present or former Director or officer in any action, suit or proceeding, whether or not the Corporation is a party to such action, suit or proceeding.

         Section 6.5  Procedure for Indemnification of Directors and Officers. Any indemnification of a Director or officer of the Corporation under Sections 6.1, 6.2, and 6.3 of these Bylaws, or advance of costs, charges and expenses to a Director or officer under Section 6.4 of these Bylaws, shall be made promptly, and in any event within thirty days, upon the written request of such person. If a determination by the Corporation that the Director or officer is entitled to indemnification pursuant to this Article is required, and the Corporation fails to respond within sixty days to a written request for indemnity, the Corporation shall be deemed to have approved such request. If the Corporation denies a written request for indemnity or advancement of expenses, in whole or in part, or if payment in full pursuant to such request is not made within thirty days, the right to indemnification or advances as granted by this Article shall be enforceable by the Director or officer in any court of competent jurisdiction. Such person’s costs and expenses incurred in connection with successfully establishing his or her right to indemnification, in whole or in part, in any such action shall also be indemnified by the Corporation. It shall be a defense to any such action (other than an action brought to enforce a claim for the advance of costs, charges and expenses under Section 6.4 of these Bylaws where the required undertaking, if any, has been received by or tendered to the Corporation) that the claimant has not met the standard of conduct set forth in Section 6.1 of these Bylaws, but the burden of proving such defense shall be on the Corporation. Neither the failure of the

18


 

Corporation (including its Board of Directors, its independent legal counsel, and its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in Section 6.1 of these Bylaws, nor the fact that there has been an actual determination by the Corporation (including its Board of Directors, its independent legal counsel, and its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to such action or create a presumption that the claimant has not met the applicable standard of conduct.

         Section 6.6  Survival; Preservation of Other Rights. The foregoing indemnification provisions shall be deemed to be a contract between the Corporation and each Director or officer who serves in any such capacity at any time while these provisions are in effect and any repeal or modification thereof shall not affect any right or obligation then existing with respect to any state of facts then or previously existing or any action, suit or proceeding previously or thereafter brought or threatened based in whole or in part upon any such state of facts. Such a contract right may not be modified retroactively without the consent of such Director or officer.

                  The indemnification and the advancement and payment of expenses provided by this Article VI shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any Bylaw, common or statutory law, provision of the Certificate of Incorporation, agreement, vote of stockholders or disinterested Directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a Director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person.

         Section 6.7  Insurance. The Corporation shall purchase and maintain insurance, at its expense, to protect the Corporation and any person who is or was or has agreed to become a Director or officer, or is or was serving at the request of the Corporation as a Director, officer, partner, venturer, proprietor, trustee, employee, agent, or similar functionary of another foreign or domestic corporation, limited liability company, partnership, joint venture, sole proprietorship, trust, employee benefit plan, or other enterprise against any expense, liability, or loss asserted against him or her or incurred by him or her or on his or her behalf in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under the provisions of this Article, provided that such insurance is available on acceptable terms, which determination shall be made by a vote of a majority of the entire Board of Directors.

         Section 6.8  Severability. If this Article VI or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify and hold harmless each Director or officer or any other person indemnified pursuant to this Article VI as to costs, charges and expenses (including reasonable attorneys’ fees), judgments, fines and amounts paid in settlement with respect to any action, suit or proceeding, whether civil, criminal, administrative or investigative to the full extent permitted by any

19


 

applicable portion of this Article VI that shall not have been invalidated and to the fullest extent permitted by applicable law.

         Section 6.9  Limitation on Liability. No Director or officer shall be personally liable, as such, for any action taken or omitted from being taken unless: (i) such Director or officer breached or failed to perform the duties of his office; and (ii) the breach or failure to perform constituted recklessness, self-dealing or willful misconduct. The foregoing shall not apply to any responsibility or liability under a criminal statute or liability for the payment of taxes under Federal, state, or local law.

         Section 6.10  Appearance as a Witness. Notwithstanding any other provision of this Article VI, the Corporation shall pay or reimburse expenses incurred by a Director or officer in connection with his appearance as a witness or other participation in a Proceeding at a time when he is not a named defendant or respondent in the Proceeding.

         Section 6.11  Indemnification of Employees and Agents. The Corporation, by adoption of a resolution of the Board of Directors, may indemnify and advance expenses to an employee or agent of the Corporation to the same extent and subject to the same conditions under which it may indemnify and advance expenses to Directors and officers under this Article VI; and, the Corporation may indemnify and advance expenses to persons who are not or were not Directors, officers, employees or agents of the Corporation but who are or were serving at the request of the Corporation as director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or domestic corporation, limited liability company, partnership, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise against any liability asserted against him or her and incurred by him or her in such a capacity or arising out of his or her status as such a person to the same extent that it may indemnify and advance expenses to Directors and officers of the Corporation under this Article VI.

ARTICLE VII

OFFICES

         Section 7.1  Registered Office and Agent. The registered agent and office of the Corporation in the State of Delaware shall be the Corporation Trust Company, located at 1209 Orange Street in the City of Wilmington, County of New Castle (19801) or such other agent and office (which need not be a place of business of the company) as the Board of Directors may designate from time to time in the manner provided by law.

         Section 7.2  Other Offices. The Corporation may maintain offices or places of business at such other locations within or without the State of Delaware as the Board of Directors may from time to time determine or as the business of the Corporation may require.

20


 

ARTICLE VIII

GENERAL PROVISIONS

         Section 8.1  Dividends. Subject to any applicable provisions of law and the Certificate of Incorporation, dividends upon the shares of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors and any such dividend may be paid in cash, property, or shares of the Corporation’s capital stock.

         Section 8.2  Reserves. There may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, thinks proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation or for such other purpose as the Board of Directors shall think conducive to the interest of the Corporation, and the Board of Directors may similarly modify or abolish any such reserve.

         Section 8.3  Execution of Instruments. The Chief Executive Officer, the President, any Vice President, the Secretary or the Treasurer may enter into any contract or execute and deliver any instrument in the name and on behalf of the Corporation. The Board of Directors, the Chief Executive Officer or the President may authorize any other officer or agent to enter into any contract or execute and deliver any instrument in the name and on behalf of the Corporation. Any such authorization may be general or limited to specific contracts or instruments.

         Section 8.4  Deposits. Any funds of the Corporation may be deposited from time to time in such banks, trust companies or other depositories as may be determined by the Board of Directors, the Chief Executive Officer or the President, or by such officers or agents as may be authorized by the Board of Directors, the Chief Executive Officer or the President to make such determination.

         Section 8.5  Checks. All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such agent or agents of the Corporation, and in such manner, as the Board of Directors or the Chief Executive Officer or President from time to time may determine.

         Section 8.6  Sale, Transfer, etc. of Securities. To the extent authorized by the Board of Directors or by the Chief Executive Officer, the President, any Vice President, the Secretary or the Treasurer or any other officers designated by the Board of Directors, the Chief Executive Officer or the President may sell, transfer, endorse, and assign any shares of stock, bonds or other securities owned by or held in the name of the Corporation, and may make, execute and deliver in the name of the Corporation, under its corporate seal, any instruments that may be appropriate to effect any such sale, transfer, endorsement or assignment.

         Section 8.7  Voting as Stockholder. Unless otherwise determined by resolution of the Board of Directors, the Chief Executive Officer or the President or any Vice President shall have full power and authority on behalf of the Corporation to attend any meeting of stockholders of

21


 

any corporation in which the Corporation may hold stock and to act, vote (or execute proxies to vote) and exercise in person or by proxy all other rights, powers and privileges incident to the ownership of such stock. Such officers acting on behalf of the Corporation shall have full power and authority to execute any instrument expressing consent to or dissent from any action of any such corporation without a meeting. The Board of Directors may by resolution from time to time confer such power and authority upon any other person or persons.

         Section 8.8  Fiscal Year. The fiscal year of the Corporation shall commence on the first day of January of each year (except for the Corporation’s first fiscal year which shall commence on the date of incorporation) and shall terminate in each case on December 31.

         Section 8.9  Seal. The seal of the Corporation shall be circular in form, and shall contain the name of the Corporation, the year of its incorporation and the words Corporate Seal and Delaware. The form of such seal shall be subject to alteration by the Board of Directors. The seal may be used by causing it or a facsimile thereof to be impressed, affixed or reproduced, or may be used in any other lawful manner.

         Section 8.10  Books and Records; Inspection. Except to the extent otherwise required by law, the books and records of the Corporation shall be kept at such place or places within or without the State of Delaware as may be determined from time to time by the Board of Directors.

ARTICLE IX

AMENDMENT OF BYLAWS

         Section 9.1  Amendment. Subject to any express provision in the Certificate of Incorporation to the contrary, these Bylaws may be amended, altered or repealed:

                  (a)  by resolution adopted by a majority of the Board of Directors at any special or regular meeting of the Board of Directors without the assent or vote of the stockholders of the Corporation if, in the case of such special meeting only, notice of such amendment, alteration or repeal is contained in the notice or waiver of notice of such meeting; or

                  (b)  at any regular or special meeting of the stockholders upon the affirmative vote of not less than two-thirds (66-2/3% of the holders of the combined voting power of the outstanding shares of the Corporation entitled to vote generally in the election of Directors if, in the case of such special meeting only, notice of such amendment, alteration or repeal is contained in the notice or waiver of notice of such meeting.

ARTICLE X

CONSTRUCTION

         Section 10.1  Construction. In the event of any conflict between the provisions of these Bylaws as in effect from time to time and the provisions of the Certificate of Incorporation of the

22


 

Corporation as in effect from time to time, the provisions of such Certificate of Incorporation shall be controlling.

23

 

Exhibit 3.3

AMENDMENT No. 1 TO THE

AMENDED AND RESTATED BYLAWS OF

SELECT MEDICAL CORPORATION

         This is an Amendment, dated September 17, 2001 (the “Amendment”) to the Amended and Restated Bylaws of SELECT MEDICAL CORPORATION, a Delaware corporation (the “Company”), which were adopted on March 23, 2001 (the “Bylaws”).

Background

         The Board of Directors of the Company wishes to designate the Chairman of the Board of Directors as the Executive Chairman of the Company, and wishes to amend the Bylaws to allow for such designation.

Amendment

1.  Section 4.1 of the Bylaws is hereby amended by inserting in the third line thereof the parenthetical “(who may be designated as an Executive Chairman) immediately prior to the phrase”, a Vice Chairman of the Board.”

2.  Section 4.6 of the Bylaws is hereby amended and restated in its entirety as follows:

         “Section 4.6.  Chairman of the Board. The Chairman of the Board shall, if one is designated by the Board of Directors and if present, preside at all meetings of the stockholders and of the Board of Directors and exercise and perform such other powers and duties as may be from time to time assigned by the Board of Directors. In addition, if designated by the Board as Executive Chairman, the Chairman shall also assist the Directors and the senior officers of the Corporation in the formulation of the strategy and policies of the Corporation, shall be available to other officers for consultation and advice, and may execute documents on behalf of the Corporation, subject at all times to the authority of the Board of Directors.”

3.  Except as amended hereby, the Bylaws shall continue in effect in accordance with their terms.

 

 

Exhibit 3.4

AMENDMENT No. 2 TO THE

AMENDED AND RESTATED BYLAWS OF

SELECT MEDICAL CORPORATION

         This is an Amendment, dated December 31, 2001 (the “Amendment”) to the Amended and Restated Bylaws of SELECT MEDICAL CORPORATION, a Delaware corporation (the “Company”), which were adopted on March 23, 2001 and were amended on September 17, 2001 (the “Bylaws”).

Background

         The Board of Directors of the Company wishes to increase the authorized number of members of the Board of Directors, and wishes to amend the Bylaws to allow for such an increase.

Amendment

1.     Section 2.2 of the Bylaws is hereby amended by replacing the phrase “nine (9)” in its entirety in the third line thereof with the phrase “ten (10).”

2.     Except as amended hereby, the Bylaws shall continue in effect in accordance with their terms.

 

Exhibit 10.52

AMENDMENT NO. 4 TO
EMPLOYMENT AGREEMENT

This is an Amendment, dated September 17, 2001 (the Amendment) to the Employment Agreement made as of the 1st day of March, 2000 by and between SELECT MEDICAL CORPORATION, a Delaware corporation (the Employer), and ROCCO A. ORTENZIO, an individual (the Employee).

Background

A.     The Employer and the Employee executed and delivered that certain Employment Agreement dated as of March 1, 2000, that certain Amendment No. 1 to Employment Agreement dated as of August 8, 2000, that certain Amendment No. 2 to Employment Agreement dated as of February 23, 2001, and that certain Amendment No. 3 to Employment Agreement dated as of April 24, 2001 (as amended, the Employment Agreement). The Employer and the Employee now desire to further amend the Employment Agreement as hereinafter provided.

B.     Accordingly, and intended to be legally bound hereby, the Employer and the Employee agree as follows:

Agreement

1.     Section 1.02 of the Employment Agreement is hereby amended and restated as follows:

1.02 Capacity. The Employee shall serve as Chairman of the Board of Directors of the Employer. The Employee shall also serve as Chief Executive Officer of the Employer until September 17, 2001. From and after September 17, 2001, the Employee shall serve as Executive Chairman of the Employer.

2.     Except as amended hereby, the Employment Agreement shall continue in effect in accordance with its terms.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

     
    SELECT MEDICAL CORPORATION
     
    By: /s/ Michael E. Tarvin
   
    Michael E. Tarvin,
    Senior Vice President
     
    /s/ Rocco A. Ortenzio
   
    Rocco A. Ortenzio

 

 

Exhibit 10.53

AMENDMENT NO. 3 TO
EMPLOYMENT AGREEMENT

This is an Amendment dated September 17, 2001 (the Amendment) to the Employment Agreement (as hereinafter defined) by and between SELECT MEDICAL CORPORATION, a Delaware corporation (the Employer), and ROBERT A. ORTENZIO, an individual (the Employee).

Background

A.     The Employer and the Employee executed and delivered that certain Employment Agreement dated as of March 1, 2000, that certain Amendment No. 1 to Employment Agreement dated as of August 8, 2000, and that certain Amendment No. 2 to Employment Agreement dated as of February 23, 2001 (as amended, the Employment Agreement). The Employer and the Employee now desire to further amend the Employment Agreement as hereinafter provided.

B.     Accordingly, and intended to be legally bound hereby, the Employer and the Employee agree as follows:

Agreement

1.     Section 1.02 of the Employment Agreement is hereby amended and restated as follows:

1.02 Capacity. The Employee shall serve as President and Chief Operating Officer of the Employer until September 17, 2001. From and after September 17, 2001, the Employee shall serve as the Chief Executive Officer, President and Chief Operating Officer of the Employer.

2.     Effective as of the first of the Company’s payroll periods beginning after September 17, 2001, the Employee’s base salary under Section 3.01 of the Employment Agreement shall be increased to $800,000.

3.     Except as amended hereby, the Employment Agreement shall continue in effect in accordance with its terms.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

         
    SELECT MEDICAL CORPORATION
         
    By:   /s/ Michael E. Tarvin
       
        Michael E. Tarvin,
        Senior Vice President
       
      /s/ Robert A. Ortenzio
       
      Robert A. Ortenzio

 

 

Exhibit 10.54

Old Gettysburg Associates
4718 Old Gettysburg Road
Mechanicsburg, PA 17055

Fourth Addendum to Lease Agreement

THIS FOURTH AMENDMENT (this Fourth Amendment) is made as of the 1st day of September, 2001, by and between OLD GETTYSBURG ASSOCIATES, a Pennsylvania general partnership (Landlord), and SELECT MEDICAL CORPORATION, a Delaware corporation (Tenant).

BACKGROUND:

A.     Landlord and Tenant are parties to that certain Office Lease Agreement dated June 15, 1999 (as amended by the First, Second and Third Addenda thereto, the Lease), pursuant to which Landlord leased to Tenant, and Tenant hired from Landlord, approximately 12,400 rentable square feet of space in the building located at 4718 Old Gettysburg Road, Mechanicsburg, Pennsylvania. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Lease.

B.     On August 31, 2001, Tenant desires to surrender possession of 175 square feet of space which is located on the 4th floor of the Premises, and Landlord desires to accept possession of such space. Therefore, Tenant and Landlord now desire to amend the Lease to reflect a reduction in the size of the Premises by 175 square feet.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and intending to be legally bound hereby, Landlord and Tenant agree as follows:

1.     From and after September 1, 2001, the Premises will consist of 12,225 square feet of space rather than 12,400 square feet of space. Monthly rent will be $19,184.62 payable on September 1, 2001 and October 1, 2001. Monthly rent will be $18,372.37 (i.e., to provide a credit of $541.50 for over-payments during September and October 2001) payable on November 1, 2001. Monthly rent will be $18,913.87 payable on December 1, 2001 and thereafter until it is increased as provided in the Lease.

2.     All other terms and conditions contained in the Lease not amended hereby remain in full force and effect.

IN WITNESS WHEREOF, Landlord and Tenant have caused this Fourth Amendment to be duly executed as of the day and year first above written.

Landlord:

OLD GETTYSBURG ASSOCIATES
a Pennsylvania general partnership

     
    By: /s/ Michael E. Salerno
   
            Michael E. Salerno
            Agent for Owner


 

Tenant:

SELECT MEDICAL CORPORATION,
a Delaware corporation

     
    By: /s/ Michael E. Tarvin
   
            Michael E. Tarvin,
            Senior Vice President
 

Exhibit 10.56

SELECT MEDICAL CORPORATION

4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055

March 1, 2000

Mr. Scott A. Romberger
Select Medical Corporation
4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, PA 17055

         Re: Agreement in the Event of a Change of Control of SMC

Dear Mr. Romberger:

         The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.

         In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this Letter Agreement), the Company and you hereby agree, intending to be legally bound hereby, as follows:

         1.     Covered Termination. A Covered Termination shall be deemed to occur if your employment with the Company terminates under any one of the following circumstances: (i) within the two-year period immediately following a Change of Control (as defined below), your employment with the Company (a) is terminated by the Company without Cause (as defined below), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.

         2.     Payments Upon a Covered Termination. If a Covered Termination occurs, then (i) the Company agrees that such termination is not a voluntary termination or a termination for cause as contemplated by any of the Company’s stock option or other incentive plans and any stock option or other award agreements entered into between you and the Company (including agreements that may be entered into in the future in connection with additional awards granted pursuant to any Company plan, the Award Agreements) and the Company agrees that all unvested, unexercised stock options held by you which were granted to you by the Company shall become fully vested and exercisable as of the date of the Covered Termination and you will have the right to exercise, at any time prior to the earlier of three months after the date of termination or the expiration date of such option, all such options to purchase the Company’s stock notwithstanding any contrary vesting

 


 

schedule that may be contained in the applicable plan or Award Agreement, and

(ii)  the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).

           3. Definitions.
 
           (a) Change of Control.

                                 (i) Prior to a Public Offering(as defined below), a Change of Control shall be deemed to have occurred, subject to Section 3(a)(iii) below, upon (i) any sale, lease, exchange or other transfer of all or substantially all of the property and assets of the Company (on a consolidated basis) to an entity, other than an entity at least 75% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale or other transfer, (ii) any merger or consolidation to which the Company is a party and as a result of which the holders of the voting securities of the Company immediately prior thereto own less than a majority of the outstanding voting securities of the surviving entity immediately following such transaction, or (iii) any person’s (excluding WCAS, GTCR and Thoma Cressey Partners, the financial sponsors of the Company as of the date hereof), including a group’s, becoming the beneficial owner of securities representing more than 50% of the voting securities of the Company then outstanding.

                                 (ii) Following a Public Offering, a Change of Control shall be deemed to have occurred if, subject to Section 3(a)(iii) below, (i) any person including a group, but excluding any stockholder of the Company who immediately prior to the Public Offering beneficially owned 12% or more of the Company’s outstanding shares, becomes the beneficial owner of shares of the Company having more than 50% of the total number of votes that may be cast for the election of directors of the Company, (ii) any person including a group, other than you or any group of which you are a party, increases its beneficial ownership of shares of the Company beyond such person’s ownership immediately after the Public Offering by a number of shares equal to or greater than 33% of the total number of votes that may be cast for the election of directors; (iii) the individuals who serve on the Board of Directors of the Company as of the effective date hereof (the Incumbent Directors) cease for any reason to constitute at least a majority of the Board of Directors of the Company; provided, however, any person who becomes a director subsequent to the effective date hereof, whose election or nomination for election was approved by a vote of at least a majority of the directors then constituting the Incumbent Directors, shall for purposes of this clause (iii) be considered an Incumbent Director; (iv) the consummation of a merger or consolidation of the Company in which the stockholders of the Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing in the aggregate more than 50% of the combined voting power of the

-2-


 

voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.

                                 (iii) Notwithstanding the foregoing, in no event shall a Change of Control be deemed to occur for purposes of this Letter Agreement, whether prior to or following a Public Offering, unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $3.75 per share of common stock of the Company (the Minimum Value); provided that such Minimum Value shall be adjusted to reflect changes to such common stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.

                                 (iv) For purposes of this Section 3(a), (A) the terms person, group, beneficial owner, and beneficially own have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term Public Offering shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term voting securities shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).

         (b)  Cause. For purposes of this Letter Agreement, Cause shall mean

(i)  your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered willful or reckless only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Company’s intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.

         (c)  Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, (x) you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control, (y) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (z) you are required to be based anywhere other than the Company’s principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Company’s business to an extent substantially consistent with your business travel obligations prior to the Change of Control).

-3-


 

         4.     Additional Payments.

         (a)  If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the Payments) would constitute an excess parachute payment within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the Code) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the Excise Tax) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a Gross-Up Payment) in cash, in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the Parachute Gross-up) shall be computed and made in writing by the Employer’s then independent public accountants (the Accountants), whose determination shall be, subject to the Employee’s reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.

         (b) As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an Underpayment), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an Overpayment). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.

-4-


 

         5.     Miscellaneous.

         (a)  The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, Company shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.

         (b)  This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.

         (c)  The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.

         (d)  Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.

         (e)  All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.

         (f)  Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:

          If to Employee:

         Scott A. Romberger
         440 Boyer Street
         Halifax, PA 17032

          If to the Company:

         Select Medical Corporation
         4716 Old Gettysburg Road
         Mechanicsburg, PA 17055
         Attention: General Counsel

-5-


 

         6.     Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.

         Please indicate your acceptance of the above agreement by signing below in the space indicated.

         
    Very truly yours,     
   
    SELECT MEDICAL CORPORATION, a Delaware
corporation
   
   
    By: /s/ Robert A. Ortenzio,    
   
   
         Robert A. Ortenzio,    
         President    
 
Agreed to and accepted:
/s/ Scott A. Romberger

Scott A. Romberger

-6-

 

Exhibit 10.57

SELECT MEDICAL CORPORATION

P.O. Box 2034, 4716 Old Gettysburg Road
Mechanicsburg, Pennsylvania 17055

February 23, 2001

Mr. Scott A. Romberger
Select Medical Corporation
P.O. Box 2034
4716 Old Gettysburg Road
Mechanicsburg, PA 17055

         Re: Amendment to Agreement in the Event of a Change of Control of SMC

Dear Mr. Romberger:

         The following will confirm our desire to amend the Letter Agreement dated as of March 1, 2000 (the Letter Agreement) of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.

         In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this Amendment to the Letter Agreement (the Amendment), the Company and you hereby agree, intending to be legally bound hereby, as follows:

         1.     The portion of Section 1 of the Letter Agreement which appears before clause (ii) is hereby amended and restated as follows:

  A Covered Termination shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Company’s principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Company’s business to an extent substantially consistent with your business travel obligations prior to the Change of Control),
 
  2. Section 3(c) of the Letter Agreement is hereby amended and restated as follows:

  (c) Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control.
 
  3. The Letter Agreement is hereby amended by the addition of the following

         Section 7 in its entirety, to be inserted immediately after Section 6 in its entirety:

         7.     Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the Claimant), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimant’s claim. The Company shall also furnish the Claimant at that time with a written notice containing:

           (A) A specific reference to pertinent provisions of this Letter Agreement;
 
           (B) A description of any additional material or information necessary for the Claimant to perfect the claim if possible, and an explanation of why such material or information is needed; and
 
           (C) An explanation of the claim review procedure set forth in this Section 7.

         Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Company’s decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (Prior Board Member). So long as the Claimant’s request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committee’s decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter

-2-


 

         Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Company’s decision reconsidered by the Appeal Committee.

         4.     Except as amended hereby, the Letter Agreement shall continue in effect in accordance with its terms.

         Please indicate your acceptance of the above Amendment by signing below in the space indicated.

     
    Very truly yours,
   
    SELECT MEDICAL CORPORATION, a Delaware
Corporation
  By: /s/ Robert A. Ortenzio,
   
    Robert A. Ortenzio,
    President
 
Agreed to and accepted:
/s/ Scott A. Romberger

Scott A. Romberger

-3-

 

Exhibit 10.58

SELECT MEDICAL CORPORATION

4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055

March 1, 2000

Mr. James J. Talalai
Select Medical Corporation
4716 Old Gettysburg Road
P.O. Box 2034
Mechanicsburg, PA 17055

         Re: Agreement in the Event of a Change of Control of SMC

Dear Mr. Talalai:

         The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.

         In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this Letter Agreement), the Company and you hereby agree, intending to be legally bound hereby, as follows:

         1.     Covered Termination. A Covered Termination shall be deemed to occur if your employment with the Company terminates under any one of the following circumstances: (i) within the two-year period immediately following a Change of Control (as defined below), your employment with the Company (a) is terminated by the Company without Cause (as defined below), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.

         2.     Payments Upon a Covered Termination. If a Covered Termination occurs, then (i) the Company agrees that such termination is not a voluntary termination or a termination for cause as contemplated by any of the Company’s stock option or other incentive plans and any stock option or other award agreements entered into between you and the Company (including agreements that may be entered into in the future in connection with additional awards granted pursuant to any Company plan, the Award Agreements) and the Company agrees that all unvested, unexercised stock options held by you which were granted to you by the Company shall become fully vested and exercisable as of the date of the Covered Termination and you will have the right to exercise, at any time prior to the earlier of three months after the date of termination or the expiration date of such option, all such options to purchase the Company’s stock notwithstanding any contrary vesting

 


 

schedule that may be contained in the applicable plan or Award Agreement, and (ii) the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).

         3.     Definitions.

         (a)  Change of Control.

         (i)  Prior to a Public Offering(as defined below), a Change of Control shall be deemed to have occurred, subject to Section 3(a)(iii) below, upon (i) any sale, lease, exchange or other transfer of all or substantially all of the property and assets of the Company (on a consolidated basis) to an entity, other than an entity at least 75% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale or other transfer, (ii) any merger or consolidation to which the Company is a party and as a result of which the holders of the voting securities of the Company immediately prior thereto own less than a majority of the outstanding voting securities of the surviving entity immediately following such transaction, or (iii) any person’s (excluding WCAS, GTCR and Thoma Cressey Partners, the financial sponsors of the Company as of the date hereof), including a group’s, becoming the beneficial owner of securities representing more than 50% of the voting securities of the Company then outstanding.

         (ii)  Following a Public Offering, a Change of Control shall be deemed to have occurred if, subject to Section 3(a)(iii) below, (i) any person including a group, but excluding any stockholder of the Company who immediately prior to the Public Offering beneficially owned 12% or more of the Company’s outstanding shares, becomes the beneficial owner of shares of the Company having more than 50% of the total number of votes that may be cast for the election of directors of the Company, (ii) any person including a group, other than you or any group of which you are a party, increases its beneficial ownership of shares of the Company beyond such person’s ownership immediately after the Public Offering by a number of shares equal to or greater than 33% of the total number of votes that may be cast for the election of directors; (iii) the individuals who serve on the Board of Directors of the Company as of the effective date hereof (the Incumbent Directors) cease for any reason to constitute at least a majority of the Board of Directors of the Company; provided, however, any person who becomes a director subsequent to the effective date hereof, whose election or nomination for election was approved by a vote of at least a majority of the directors then constituting the Incumbent Directors, shall for purposes of this clause (iii) be considered an Incumbent Director; (iv) the consummation of a merger or consolidation of the Company in which the stockholders of the Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing in the aggregate more than 50% of the combined voting power of the

-2-


 

voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.

         (iii)  Notwithstanding the foregoing, in no event shall a Change of Control be deemed to occur for purposes of this Letter Agreement, whether prior to or following a Public Offering, unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $3.75 per share of common stock of the Company (the Minimum Value); provided that such Minimum Value shall be adjusted to reflect changes to such common stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.

         (iv)  For purposes of this Section 3(a), (A) the terms person, group, beneficial owner, and beneficially own have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term Public Offering shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term voting securities shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).

         (b)  Cause. For purposes of this Letter Agreement, Cause shall mean (i) your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered willful or reckless only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Company’s intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.

         (c)  Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, (x) you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control, (y) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (z) you are required to be based anywhere other than the Company’s principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Company’s business to an extent substantially consistent with your business travel obligations prior to the Change of Control).

-3-


 

         4.     Additional Payments.

         (a)  If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the Payments) would constitute an excess parachute payment within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the Code) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the Excise Tax) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a Gross-Up Payment) in cash, in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the Parachute Gross-up) shall be computed and made in writing by the Employer’s then independent public accountants (the Accountants), whose determination shall be, subject to the Employee’s reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.

         (b)  As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an Underpayment), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an Overpayment). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.

-4-


 

         5.     Miscellaneous.

         (a)  The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, Company shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.

         (b)  This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.

         (c)  The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.

         (d)  Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.

         (e)  All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.

         (f)  Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:

If to Employee:

James J. Talalai
5224 Meadowbrook Drive
Mechanicsburg, PA 17055

If to the Company:

Select Medical Corporation
4716 Old Gettysburg Road
Mechanicsburg, PA 17055
Attention: General Counsel

-5-


 

         6.     Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.

Please indicate your acceptance of the above agreement by signing below in the space indicated.

     
    Very truly yours,
         
    SELECT MEDICAL CORPORATION, a Delaware
corporation
         
    By:   /s/ Robert A. Ortenzio,
Robert A. Ortenzio,
President

Agreed to and accepted:

 

/s/ James J. Talalai

     James J. Talalai  

-6-

 

Exhibit 10.59

SELECT MEDICAL CORPORATION

P.O. Box 2034, 4716 Old Gettysburg Road
Mechanicsburg, Pennsylvania 17055

February 23, 2001

Mr. James J. Talalai
Select Medical Corporation
P.O. Box 2034
4716 Old Gettysburg Road
Mechanicsburg, PA 17055

         Re: Amendment to Agreement in the Event of a Change of Control of SMC

Dear Mr. Talalai:

         The following will confirm our desire to amend the Letter Agreement dated as of March 1, 2000 (the Letter Agreement) of Select Medical Corporation, a Delaware corporation (the Company), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.

         In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this Amendment to the Letter Agreement (the Amendment), the Company and you hereby agree, intending to be legally bound hereby, as follows:

         1.     The portion of Section 1 of the Letter Agreement which appears before clause (ii) is hereby amended and restated as follows:

    A Covered Termination shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Company’s principal executive offices in (or within 25 miles of) Mechanicsburg, Pennsylvania (except for required travel on the Company’s business to an extent substantially consistent with your business travel obligations prior to the Change of Control),

         2.     Section 3(c) of the Letter Agreement is hereby amended and restated as follows:

 


 

         (c)  Good Reason. For purposes of this Letter Agreement, you shall have Good Reason to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control.

         3.     The Letter Agreement is hereby amended by the addition of the following Section 7 in its entirety, to be inserted immediately after Section 6 in its entirety:

         7.     Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the Claimant), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimant’s claim. The Company shall also furnish the Claimant at that time with a written notice containing:

         (A)  A specific reference to pertinent provisions of this Letter Agreement;

         (B)  A description of any additional material or information necessary for the Claimant to perfect the claim if possible, and an explanation of why such material or information is needed; and

         (C)  An explanation of the claim review procedure set forth in this Section 7.

Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Company’s decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (Prior Board Member). So long as the Claimant’s request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committee’s decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter

-2-


 

Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Company’s decision reconsidered by the Appeal Committee.

         4.     Except as amended hereby, the Letter Agreement shall continue in effect in accordance with its terms.

         Please indicate your acceptance of the above Amendment by signing below in the space indicated.

     
    Very truly yours,
         
    SELECT MEDICAL CORPORATION, a Delaware
Corporation
         
    By:   /s/ Robert A. Ortenzio,
Robert A. Ortenzio, President

Agreed to and accepted:

         

/s/ James J. Talalai

     James J. Talalai  

 

 

Exhibit 10.60

CONFORMED COPY

           FOURTH AMENDMENT dated as of October 5, 2001 (this “Amendment”) to the Credit Agreement dated as of September 22, 2000 (the “Credit Agreement”) as heretofore amended, among Select Medical Corporation, a Delaware corporation (the “Company”), Canadian Back Institute Limited, an Ontario corporation and a wholly owned subsidiary of the Company (“CBIL” and, together with the Company, the “Borrowers”), the Lenders party thereto, The Chase Manhattan Bank, as US Agent and US Collateral Agent, The Chase Manhattan Bank of Canada, as Canadian Agent and Canadian Collateral Agent, Banc of America Securities, LLC, as Syndication Agent, and CIBC, Inc., as Documentation Agent.

         WHEREAS, the Borrowers have requested that the Lenders (such term and each other capitalized term used but not otherwise defined herein having the meaning assigned to it in the Credit Agreement) approve amendments to certain provisions of the Credit Agreement;

         WHEREAS, the undersigned Lenders are willing, on the terms and subject to the conditions set forth herein, to approve such amendments to the Credit Agreement;

         NOW, THEREFORE, in consideration of these premises, the Borrowers and the undersigned Lenders hereby agree as follows:

         SECTION 1. Amendments. Effective as of the Amendment Effective Date (as defined in Section 4 hereof):

         (a)  Paragraph (g) of Section 6.04 of the Credit Agreement is hereby amended by inserting at the end thereof, immediately prior to the semicolon, the words “and Investments in connection with the repurchase of common stock of the Company permitted under subsection 6.11(g)”.

         (b)  Section 6.11 of the Credit Agreement is hereby amended by deleting the word “and” at the end of paragraph (e), replacing the period at the end of paragraph (f) with “; and” and adding a new paragraph (g) as follows:

           "(g) so long as no Default shall have occurred and be continuing or would result therefrom, purchase, redeem or otherwise acquire shares of its common stock in an aggregate amount not to exceed US$10,000,000 for all such purchases, redemptions or other acquisitions.”

 


 

2

         SECTION 2. Representations and Warranties. Each of the Borrowers represents and warrants to each of the Lenders that, after giving effect to the amendments contemplated hereby, (a) the representations and warranties of such Borrower set forth in the Credit Agreement are true and correct in all material respects on and as of the date of this Amendment, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties shall be true and correct in all material respects as of the earlier date) and (b) no Default has occurred and is continuing.

         SECTION 3. Effectiveness. This Amendment shall become effective as of the date (the “Amendment Effective Date”) when the Administrative Agent (or its counsel) shall have received copies hereof that, when taken together, bear the signatures of the Borrowers and the Required Lenders.

         SECTION 4. Applicable Law. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

         SECTION 5. No Other Amendments. Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of any party under, the Credit Agreement, nor alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. This Amendment shall apply and be effective only with respect to the provisions of the Credit Agreement specifically referred to herein. This Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents.

         SECTION 6. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall constitute an original, but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart of a signature page of this Amendment by facsimile transmission shall be as effective as delivery of a manually executed counterpart of this Amendment.

         SECTION 7. Headings. Section headings used herein are for convenience of reference only, are not part of this Amendment and are not to affect the construction of, or to be taken into consideration in interpreting, this Amendment.

 


 

3

         IN WITNESS WHEREOF, the Borrower and the undersigned Lenders have caused this Amendment to be duly executed by their duly authorized officers, all as of the date first above written.

             
      SELECT MEDICAL CORPORATION,
             
        by:
  /s/ Michael E. Tarvin

Name: Michael E. Tarvin
Title: Senior Vice
President
             
      CANADIAN BACK INSTITUTE
LIMITED,
             
        by:
  /S/ Michael E. Tarvin

Name: Michael E. Tarvin
Title: Vice President
             
      THE CHASE MANHATTAN BANK,
individually and as US Agent
and US Collateral Agent,
             
        by:
  /s/ Dawn Lee Lum

Name: Dawn Lee Lum
Title: Vice President
             
      THE CHASE MANHATTAN BANK OF
CANADA, individually and as
Canadian Agent and Canadian
Collateral Agent,
             
        by:
  /s/ Christine Chan

Name: Christine Chan
Title: Vice President
             
        by:
  /s/ Drew McDonald

Name: Drew McDonald
Title: Vice President

 


 

4

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
         
    Name of Institution:
         
    CIBC Inc.

     
    by   /s/ Terence Moore

Name: Terence Moore
Title: Executive Director

 


 

5

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
         
    Name of Institution:
         
    First Union National Bank

         
    by   /s/ Jeanette A. Griffin

Name: Jeanette A. Griffin
Title: Vice President

 


 

6

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
 
    Name of Institution:
    KZH Cypress Tree-1 LLC

         
    by   /s/ Susan Lee

Name: Susan Lee
Title: Authorized Agent

 


 

7

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
     
Name of Institution:
         
    KZH Sterling LLC

         
    by   /s/ Susan Lee

Name: Susan Lee
Title: Authorized Agent

 


 

8

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
 
    Name of Institution:
         
    Merrill Lynch Capital Corp.

         
    by   /s/ Carol J.E. Feeley

Name: Carol J.E. Feeley
Title: Vice President

 


 

9

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
 
    Name of Institution:
         
    PNC Bank, National Association

         
    by   /s/ Marie T. Boyer

Name: Marie T. Boyer
Title: Vice President

 


 

10

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
 
    Name of Institution:
         
    Morgan Guaranty Trust Co.

         
    by   /s/ Dawn Lee Lum

Name: Dawn Lee Lum
Title: Vice President

 


 

11

         
    To approve the Fourth Amendment
dated as of October 5, 2001 (the
“Amendment”) to the Select Medical
Corporation Credit Agreement dated
as of September 22, 2000:
 
    Name of Institution:
         
    Societe Generale

         
    by   /s/ Richard Bernal

Name: Richard Bernal
Title: Director
Corporate Banking
 

Exhibit 10.61

SELECT MEDICAL CORPORATION

4716 Old Gettysburg Road P.O. Box 2034
Mechanicsburg, Pennsylvania 17055

November 21, 2001

Mr. David W. Cross
Select Medical Corporation
7733 Forsyth Boulevard
Suite 800
St. Louis, MO 63105

         Re: Agreement in the Event of a Change of Control of SMC

Dear Mr. Cross:

                  The following will confirm the agreement of Select Medical Corporation, a Delaware corporation (the “Company”), with you concerning the consequences upon certain terminations of your employment in connection with a change in control of the Company.

                  In consideration of your past and continued service to the Company and in consideration of the mutual covenants and agreements contained in this letter (this “Letter Agreement”), the Company and you hereby agree, intending to be legally bound hereby, as follows:

                  1.         Covered Termination. A “Covered Termination” shall be deemed to occur if (i) within the five-year period immediately following a Change of Control (as defined below), (a) your employment with the Company is terminated by the Company without Cause (as defined below), (b) there is a reduction by the Company in your compensation from that in effect prior to such Change of Control, or (c) you are required to be based anywhere other than the Company’s executive offices in (or within 25 miles of) St. Louis, Missouri (except for required travel on the Company’s business to an extent substantially consistent with your business travel obligations prior to the Change of Control), (ii) within the six-month period immediately following a Change of Control, you terminate your employment with the Company for Good Reason (as defined below), or (iii) within the six-month period preceding a Change of Control, your employment is terminated by the Company other than for Cause, and you reasonably demonstrate that such termination of employment was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control.

                  2.          Payments Upon a Covered Termination. If a Covered Termination occurs, then (i) the Company agrees that such termination is not a voluntary termination or a termination “for cause” as contemplated by any of the Company’s stock option or other incentive plans and any stock option or other award agreements entered into between you and the Company (including agreements that may be entered into in the future in connection with additional awards granted pursuant to any

 


 

Company plan, the “Award Agreements”) and the Company agrees that all unvested, unexercised stock options held by you which were granted to you by the Company shall become fully vested and exercisable as of the date of the Covered Termination and you will have the right to exercise, at any time prior to the earlier of three months after the date of termination or the expiration date of such option, all such options to purchase the Company’s stock notwithstanding any contrary vesting schedule that may be contained in the applicable plan or Award Agreement, and (ii) the Company will, on or before your last day as an employee of the Company, pay to you, in lieu of any other rights to cash compensation other than the payment of your salary for services performed before the date of termination and as a severance benefit, a lump sum cash payment equal to your total base salary plus bonus compensation from the Company for the preceding three years (or, if you shall have been employed for less than three years, an amount equal to three times your average total annual cash compensation for base salary and bonus for your years of service to the Company).

                  3.          Definitions.

                  (a)         Change of Control.

                           (i)         A “Change of Control” shall be deemed to have occurred if, subject to Section 3(a)(ii) below, (i) any person including a group, but excluding any stockholder of the Company who immediately prior to the Public Offering (as defined below) beneficially owned 12% or more of the Company’s outstanding shares, becomes the beneficial owner of shares of the Company having more than 50% of the total number of votes that may be cast for the election of directors of the Company, (ii) any person including a group, other than you or any group of which you are a party, increases its beneficial ownership of shares of the Company beyond such person’s ownership immediately after the Public Offering by a number of shares equal to or greater than 33% of the total number of votes that may be cast for the election of directors; (iii) the individuals who serve on the Board of Directors of the Company as of the effective date hereof (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board of Directors of the Company; provided, however, any person who becomes a director subsequent to the effective date hereof, whose election or nomination for election was approved by a vote of at least a majority of the directors then constituting the Incumbent Directors, shall for purposes of this clause (iii) be considered an Incumbent Director; (iv) the consummation of a merger or consolidation of the Company in which the stockholders of the Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own, directly or indirectly, shares representing in the aggregate more than 50% of the combined voting power of the voting securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (v) there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (on a consolidated basis), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to such sale.

                           (ii)         Notwithstanding the foregoing, in no event shall a “Change of Control” be deemed to occur for purposes of this Letter Agreement unless the total consideration for the transaction or transactions which would, absent this clause (iii), constitute a Change of Control, has a value that is equal to or greater than $6.51 per share of common stock of the Company (the “Minimum Value”); provided that such Minimum Value shall be adjusted to reflect changes to such common

-2-


 

stock in the event of a stock dividend, stock split, reverse stock split, stock combination, reclassification, recapitalization, or other similar change in the structure or capitalization of the Company, or any other event which in the discretion of the Board of Directors of the Company necessitates such an adjustment.

                           (iii)         For purposes of this Section 3(a), (A) the terms “person,” “group,” “beneficial owner,” and “beneficially own” have the same meanings as such terms under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, (B) the term “Public Offering” shall mean the consummation of the first public offering of shares of common stock of the Company in a firm commitment underwritten offering registered under the Securities Act of 1933, as amended, on Form S-1 or its successor forms, and (C) the term “voting securities” shall mean securities, the holders of which are ordinarily, in the absence of contingencies, entitled to elect the corporate directors (or persons performing similar functions).

                  (b)         Cause. For purposes of this Letter Agreement, “Cause” shall mean (i) your willful and continued failure to substantially perform your duties hereunder (other than any such failure resulting from incapacity due to physical or mental illness); (ii) your engaging in willful or reckless misconduct which is demonstrably and materially injurious to the Company, monetarily or otherwise; or (iii) your conviction of a felony involving moral turpitude; provided that an act, or failure to act, on your part shall be considered “willful” or “reckless” only if done, or omitted to be done, by you not in good faith and without a reasonable belief that his action or omission was in the best interest of the Company. Your employment shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to you (i) reasonable notice setting forth the reasons for the Company’s intention to terminate your employment for Cause; (ii) an opportunity to cure any such breach during the 30-day period after your receipt of such notice; (iii) a reasonable opportunity, at any time during the 30-day period after your receipt of such notice, together with your counsel, to be heard before the Board of Directors; and (iv) a notice of termination stating that, in the good faith opinion of not less than a majority of the entire membership of the Board of Directors of the Company, you are guilty of the conduct set forth in any of clauses (i), (ii) or (iii) of the definition of Cause above.

                  (c)         Good Reason. For purposes of this Letter Agreement, you shall have “Good Reason” to terminate your employment after a Change of Control if you make good faith determination that, as a result of such Change of Control, you are unable to perform your services effectively or there is any significant adverse change in your authority or responsibilities, as performed immediately prior to such Change of Control.

                  4.         Additional Payments.

                  (a)         If all, or any portion, of the payments or other benefits provided under any section of this Agreement, either alone or together with other payments and benefits that you receive or are entitled to receive from the Company or its affiliates, (whether or not under an existing plan, arrangement or other agreement) (collectively the “Payments”) would constitute an excess “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and would result in the imposition on you of an excise tax under Section 4999 of the Code, (such excise tax, together with any interest and penalties related thereto, are hereinafter collectively referred to as the “Excise Tax”) then, in addition to any other benefits to which you are entitled under this Agreement, you will be entitled to receive an additional payment (a “Gross-Up Payment”) in cash,

-3-


 

in an amount such that after you pay all taxes including, without limitation, (i) any income taxes (and any interest and penalties imposed with respect thereto) and (ii) any Excise Tax, imposed upon the Gross-Up Payment, you will retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Unless you and the Company otherwise agree in writing, any determination required under this Section 4, including without limitation, the amount of payments under this Article 6 (the “Parachute Gross-up”) shall be computed and made in writing by the Employer’s then independent public accountants (the “Accountants”), whose determination shall be, subject to the Employee’s reasonable approval of the calculations required under this Article 6, conclusive and binding upon the Employee and the Employer for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4.

                  (b)         As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that (i) Gross-Up Payments which will not have been made by the Company should have been made (an “Underpayment”), consistent with the calculations required to be made hereunder or that (ii) Gross-Up Payments that have been made will be determined to have been in excess of the Gross-Up Payments actually required (an “Overpayment”). In the event that you are required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for your benefit. In the event that it is finally determined that an Overpayment has occurred, you will promptly, and in any event within 30 days of such determination, refund the amount of the Overpayment, plus any interest actually paid to you with respect to the Overpayment, to the Company. The Company shall have the right with respect to the determination of either an Underpayment or an Overpayment to you to appeal the assertion of any Underpayment or to claim, and sue for, a refund of any Excise Tax paid by you upon any Payment or Gross-Up Payment, provided that the Company shall promptly reimburse you for all expenses, including counsel and accounting fees, incurred in connection with any such proceeding. Alternatively, the Company may undertake any such proceeding, and you shall cooperate with the Company in any such proceeding.

                  5.          Miscellaneous.

                  (a)         The Company will require any purchaser of all or substantially all of the assets of the Company, by agreement in form and substance reasonably satisfactory to you, to expressly assume and agree to perform this Letter Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Letter Agreement and shall entitle you to compensation from the Company in the same amount and on the same terms as you would be entitled hereunder if a Covered Termination had occurred. As used in this Letter Agreement, “Company” shall mean the Company as hereinbefore defined and any purchaser of its assets as aforesaid which executed and delivers the agreement provided for herein.

-4-


 

                  (b)         This Letter Agreement shall remain in effect for so long as you are employed by the Company. This Letter Agreement may not be modified or waived except in writing and agreed to by the Company and you. This Letter Agreement shall be governed by the laws of the Commonwealth of Pennsylvania and shall inure to the benefit of your heirs.

                  (c)         The Company represents that this Letter Agreement has been duly authorized and is binding on and enforceable against the Company. The invalidity or unenforceability of any provision of this Letter Agreement shall not affect the validity or enforceability of any other provision, which shall remain in full force and effect.

                  (d)         Upon payment of the amount required under paragraph 1 hereof, you shall deliver to the Company a general release of liability of the Company and its officers and directors in a form reasonably satisfactory to the Company.

                  (e)         All payments made pursuant to this Letter Agreement shall be subject to withholding of applicable deductions and income and employment taxes.

                  (f)         Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally or sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mails to the following addresses:

                  If to Employee:

                  David W. Cross
                  10 Lindworth Drive
                  St. Louis, MO 63124

                  If to the Company:

                  Select Medical Corporation
                  4716 Old Gettysburg Road
                  Mechanicsburg, PA 17055
                  Attention: General Counsel

                  6.          Claims Procedure. Any claim for benefits under this Letter Agreement by you shall be made in writing and sent to the Company at its principal offices in Mechanicsburg, Pennsylvania, or such other place as the Company shall hereafter designate in writing. If you, or any beneficiary following your death (collectively, the “Claimant”), believes he or she has been denied any benefits or payments under this Letter Agreement, either in total or in an amount less than the full benefit or payment to which the Claimant would normally be entitled, the Company shall advise the Claimant in writing of the amount of the benefit, or payment, if any, and the specific reasons for the denial within thirty (30) days of the receipt of the Claimant’s claim. The Company shall also furnish the Claimant at that time with a written notice containing:

-5-


 

                  (a)         A specific reference to pertinent provisions of this Letter Agreement;

                  (b)         A description of any additional material or information necessary for the Claimant to perfect the claim if possible, and
                  an explanation of why such material or information is needed; and

                  (c)         An explanation of the claim review procedure set forth in this Section 6.

Within sixty (60) days of receipt of the information described above, the Claimant shall, if further review is desired, file a written request of reconsideration of the Company’s decision with the Appeal Committee. The Appeal Committee shall consist of those individuals who were serving as the Compensation Committee of the Board of Directors of the Company immediately prior to the Change of Control. The Appeal Committee shall select from its membership a chairperson and a secretary and may adopt such rules and procedures as it deems necessary to carry out its functions. In the event any individual is unable to serve on the Appeal Committee, then the chairperson of the Appeal Committee shall appoint a successor provided such successor must have been a member of the Board of Directors of the Company prior to the Change of Control (“Prior Board Member”). So long as the Claimant’s request for review is pending with the Appeal Committee (including such 60-day period), the Claimant, or his duly authorized representative, may review pertinent documents and may submit issues and comments in writing to the Appeal Committee. A final and binding decision shall be made by the Appeal Committee within thirty (30) days of the filing by the Claimant of the request for reconsideration. The Appeal Committee’s decision shall be conveyed to the Claimant in writing and shall include specific reasons for the decision and specific references to the pertinent provisions of this Letter Agreement on which the decision is based. The Appeal Committee shall discharge its duties under this claims procedure in accordance with the fiduciary standards of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and in doing so, to the extent permitted by law, shall be indemnified and held harmless by the Company (to the extent not indemnified or saved harmless under any liability insurance or other indemnification arrangement with the Company) for or against all liability to which the Appeal Committee may be subjected by reason of any act done in good faith with respect to the adjudication of any claim under this Letter Agreement, including reasonable expenses. Notwithstanding anything to the contrary herein contained, the Claimant shall be entitled to submit his or her claim for determination to any court having competent jurisdiction regardless of whether he or she has first exercised his or her right to have the Company’s decision reconsidered by the Appeal Committee.

                  7.          Entire Agreement. This writing represents the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may not be altered or amended except by an agreement in writing.

-6-


 

                  Please indicate your acceptance of the above agreement by signing below in the space indicated.

         
    Very truly yours,
         
    SELECT MEDICAL CORPORATION , a Delaware
corporation
         
    By:
  /s/ Robert A. Ortenzio
     
 
      Robert A. Ortenzio,
      President
         
Agreed to and accepted:        
/s/ David W. Cross        

       
David W. Cross        

-7-

 

Exhibit 12.1

Ratio of Earnings to Fixed Charges

                                           
Year Ended December 31,

2001 2000 1999 1998 1997





(dollars in thousands)
Pre-tax income (loss) from continuing operations before adjustment for minority interests in consolidated subsidiaries or income or loss from equity investees (A)
  $ 50,519     $ 26,082   $ (819 )   $ (16,482 )   $ 3,255  
     
     
     
     
     
 
Fixed charges:
                                       
 
Interest expense and amortization of debt discount and premium on all indebtedness
    29,716       36,126       21,461       5,382       183  
Rentals:
                                       
 
Buildings — 33%
    19,810       18,394       8,899       2,865       450  
 
Office and other equipment — 33%
    5,397       4,516       3,428       1,094       74  
Preferred stock dividend requirements of consolidated subsidiaries (A)
    4,120       16,110       13,874       2,515       445  
     
     
     
     
     
 
Total fixed charges
  $ 59,043     $ 75,146     $ 47,662     $ 11,856     $ 1,152  
     
     
     
     
     
 
Pre-tax income (loss) from continuing operations before adjustment for minority interests in consolidated subsidiaries or income or loss from equity investees plus fixed charges, less preferred stock dividend requirements of consolidated subsidiaries
  $ 105,442     $ 85,118   $ 32,969     $ (7,141 )   $ 3,962  
     
     
     
     
     
 
Ratio of earnings to fixed charges
    1.79       1.13     (B)(C )     (B)(C     3.44  
     
     
     
     
     
 


(A)   The preferred stock dividend requirements of consolidated subsidiaries is included in fixed charges (i.e., the denominator of the ratio calculation) but excluded from the numerator of the ratio calculation because such amount was not deducted in arriving at the pre-tax income (loss) from continuing operations, as defined.
(B)   Due to the Company's losses in 1998 and 1999, the ratio coverage was less than 1:1. The Company would have had to generate additional earnings of approximately $19.0 million and $14.7 million in 1998 and 1999, respectively, to achieve a coverage ratio of 1:1.
(C)   Included in earnings for 1998 and 1999 were special charges of $10.2 million and $5.2 million, respectively, relating to asset impairments and litigation settlement costs. If such charges were not taken the Company would have needed to generate additional earnings of $8.8 million and $9.5 million in 1998 and 1999, respectively, to achieve a coverage ratio of 1:1.
 

Exhibit 21.1

Subsidiaries

     
U.S. Subsidiaries   State of Incorporation
Abel Center for Rehabilitation Therapies, Inc.   Oregon
Affiliated Physical Therapists, Ltd.   Arizona
Allegany Hearing and Speech, Inc.   Maryland
American Transitional Hospitals, Inc.   Delaware
Athens Sport Medicine Clinic, Inc.   Georgia
Ather Sports Injury Clinic, Inc.   California
Atlantic Health Group, Inc.   Delaware
Atlantic Rehabilitation Services, Inc.   New Jersey
Boca Rehab Agency, Inc.   Delaware
Buendel Physical Therapy, Inc.   Florida
C.E.R. — West, Inc.   Michigan
CCISUB, Inc.   North Carolina
CMC Center Corporation   California
Cenla Physical Therapy & Rehabilitation Agency, Inc.   Louisiana
Center for Evaluation & Rehabilitation, Inc.   Michigan
Center for Physical Therapy and Sports Rehabilitation, Inc.   New Mexico
CenterTherapy, Inc.   Minnesota
Champion Physical Therapy, Inc.   Pennsylvania
C.O.A.S.T. Institute Physical Therapy, Inc.   California
Connecticut NovaCare Ventures, Inc.   Connecticut
Coplin Physical Therapy Associates, Inc.   Minnesota
Crowley Physical Therapy Clinic, Inc.   Louisiana
Douglas Avery & Associates, Ltd.   Virginia
Elk County Physical Therapy, Inc.   Pennsylvania
Fine, Bryant & Wah, Inc.   Maryland
Francis Naselli, Jr. & Stewart Rich Physical Therapists, Inc.   Pennsylvania
Gallery Physical Therapy Center, Inc.   Minnesota
Georgia NovaCare Ventures, Inc.   Georgia
Georgia Physical Therapy of West Georgia, Inc.   Georgia
Georgia Physical Therapy, Inc.   Georgia
Greater Sacramento Physical Therapy Associates, Inc.   California
Grove City Physical Therapy and Sports Medicine, Inc.   Pennsylvania
Gulf Breeze Physical Therapy, Inc.   Florida
Gulf Coast Hand Specialists, Inc.   Florida
Hand Therapy and Rehabilitation Associates, Inc.   California
Hand Therapy Associates, Inc.   Arizona
Hangtown Physical Therapy, Inc.   California

-1-


 

     
U.S. Subsidiaries   State of Incorporation
Hawley Physical Therapy, Inc.   California
Hudson Physical Therapy Services, Inc.   New Jersey
Human Performance and Fitness, Inc.   California
Indianapolis Physical Therapy and Sports Medicine, Inc.   Indiana
Intensiva Healthcare Corporation   Delaware
Intensiva Hospital of Greater St. Louis, Inc.   Missouri
Joyner Sports Science Institute, Inc.   Pennsylvania
Joyner Sportsmedicine Institute, Inc.   Pennsylvania
Kentucky Rehabilitation Services, Inc.   Kentucky
Lynn M. Carlson, Inc.   Arizona
Mark Butler Physical Therapy Center, Inc.   New Jersey
Metro Rehabilitation Services, Inc.   Michigan
Metro Therapy, Inc.   New York
Michigan Therapy Centre, Inc.   Michigan
MidAtlantic Health Group, Inc.   Delaware
Monmouth Rehabilitation, Inc.   New Jersey
New England Health Group, Inc.   Massachusetts
New Mexico Physical Therapists, Inc.   New Mexico
Northside Physical Therapy, Inc.   Ohio
NovaCare Occupational Health Services, Inc.   Delaware
NovaCare Outpatient Rehabilitation East, Inc.   Delaware
NovaCare Outpatient Rehabilitation of California   California
NovaCare Outpatient Rehabilitation, Inc.   Kansas
NovaCare Outpatient Rehabilitation West, Inc.   Delaware
NovaCare Rehabilitation, Inc.   Minnesota
Ortho Rehab Associates, Inc.   Florida
P.T. Services Company   Ohio
P.T. Services, Inc.   Ohio
P.T. Services Rehabilitation, Inc.   Ohio
Peter Trailov R.P.T. Physical Therapy Clinic, Orthopedic Rehabilitation & Sports Medicine, Ltd.   Illinois
Physical Rehabilitation Partners, Inc.   Louisiana
Physical Therapy Enterprises, Inc.   Arizona
Physical Therapy Institute, Inc.   Louisiana
Physical Therapy Services of the Jersey Cape, Inc.   New Jersey
Physio-Associates, Inc.   Pennsylvania
Pro Active Therapy of Ahoskie, Inc.   North Carolina
Pro Active Therapy of Gaffney, Inc.   South Carolina

-2-


 

     
U.S. Subsidiaries   State of Incorporation
Pro Active Therapy of Greenville, Inc.   North Carolina
Pro Active Therapy of North Carolina, Inc.   North Carolina
Pro Active Therapy of Rocky Mount, Inc.   North Carolina
Pro Active Therapy of South Carolina, Inc.   South Carolina
Pro Active Therapy of Virginia, Inc.   Virginia
Pro Active Therapy, Inc.   North Carolina
Professional Therapeutic Services, Inc.   Ohio
Quad City Management, Inc.   Iowa
RCI (Colorado), Inc.   Delaware
RCI (Exertec), Inc.   Delaware
RCI (Michigan), Inc.   Delaware
RCI (S.P.O.R.T.), Inc.   Delaware
RCI (WRS), Inc.   Delaware
RCI Nevada, Inc.   Delaware
Rebound Oklahoma, Inc.   Oklahoma
Redwood Pacific Therapies, Inc.   California
Rehab Advantage, Inc.   Delaware
Rehab Managed Care of Arizona, Inc.   Delaware
Rehab Provider Network — California, Inc.   California
Rehab Provider Network — East I, Inc.   Delaware
Rehab Provider Network — East II, Inc.   Maryland
Rehab Provider Network — Georgia, Inc.   Georgia
Rehab Provider Network — Indiana, Inc.   Indiana
Rehab Provider Network — Michigan, Inc.   Michigan
Rehab Provider Network — New Jersey, Inc.   New Jersey
Rehab Provider Network — Ohio, Inc.   Ohio
Rehab Provider Network — Oklahoma, Inc.   Oklahoma
Rehab Provider Network — Pennsylvania, Inc.   Pennsylvania
Rehab Provider Network — Virginia, Inc.   Virginia
Rehab Provider Network — Washington, D.C., Inc.   District of Columbia
Rehab Provider Network of Colorado, Inc.   Colorado
Rehab Provider Network of Florida, Inc.   Florida
Rehab Provider Network of Nevada, Inc.   Nevada
Rehab Provider Network of New Mexico, Inc.   New Mexico
Rehab Provider Network of North Carolina, Inc.   North Carolina
Rehab Provider Network of Texas, Inc.   Texas
Rehab Provider Network of Wisconsin, Inc.   Wisconsin
Rehab World, Inc.   Delaware
Rehab/Work Hardening Management Associates, Ltd.   Pennsylvania
RehabClinics (GALAXY), Inc.   Illinois
RehabClinics (New Jersey), Inc.   Delaware
RehabClinics (PTA), Inc.   Delaware
RehabClinics (SPT), Inc.   Delaware

-3-


 

     
U.S. Subsidiaries   State of Incorporation
RehabClinics Abilene, Inc.   Delaware
RehabClinics Dallas, Inc.   Delaware
RehabClinics Pennsylvania, Inc.   Pennsylvania
RehabClinics, Inc.   Delaware
S.T.A.R.T., Inc.   Massachusetts
Select Air Corporation   Delaware
Select Employment Services, Inc.   Delaware
Select Hospital Investors, Inc.   Delaware
SelectMark, Inc.   Delaware
Select Medical of Kentucky, Inc.   Delaware
Select Medical of Maryland, Inc.   Delaware
Select Medical of New Jersey, Inc.   Delaware
Select Medical of New York, Inc.   Delaware
Select Medical of Ohio, Inc.   Delaware
Select Medical of Pennsylvania, Inc.   Delaware
Select Rehabilitation Management Services, Inc.   Delaware
Select Specialty Hospital — Akron, Inc.   Missouri
Select Specialty Hospital — Akron II, Inc.   Delaware
Select Specialty Hospital — Ann Arbor, Inc.   Missouri
Select Specialty Hospital — Battle Creek, Inc.   Missouri
Select Specialty Hospital — Beech Grove, Inc.   Missouri
Select Specialty Hospital — Biloxi, Inc.   Mississippi
Select Specialty Hospital — Bloomington, Inc.   Delaware
Select Specialty Hospital — Central Detroit, Inc.   Delaware
Select Specialty Hospital — Charleston, Inc.   Delaware
Select Specialty Hospital — Cincinnati, Inc.   Missouri
Select Specialty Hospital — Columbus, Inc.   Delaware
Select Specialty Hospital — Columbus/University, Inc.   Missouri
Select Specialty Hospital — Dallas, Inc.   Delaware
Select Specialty Hospital — Denver, Inc.   Delaware
Select Specialty Hospital — Durham, Inc.   Delaware
Select Specialty Hospital — Erie, Inc.   Delaware
Select Specialty Hospital — Evansville, Inc.   Missouri
Select Specialty Hospital — Flint, Inc.   Missouri
Select Specialty Hospital — Fort Smith, Inc.   Missouri
Select Specialty Hospital — Fort Wayne, Inc.   Missouri
Select Specialty Hospital — Greensburg, Inc.   Delaware
Select Specialty Hospital — Houston, Inc.   Delaware
Select Specialty Hospital — Indianapolis, Inc.   Delaware
Select Specialty Hospital — Jackson, Inc.   Delaware
Select Specialty Hospital — Johnstown, Inc.   Missouri
Select Specialty Hospital — Kansas City, Inc.   Missouri
Select Specialty Hospital — Knoxville, Inc.   Delaware
Select Specialty Hospital — Little Rock, Inc.   Delaware
Select Specialty Hospital — Louisville, Inc.   Delaware

-4-


 

     
U.S. Subsidiaries   State of Incorporation
Select Specialty Hospital — Macomb County, Inc.   Missouri
Select Specialty Hospital — Memphis, Inc.   Delaware
Select Specialty Hospital — Mesa, Inc.   Delaware
Select Specialty Hospital — Milwaukee, Inc.   Delaware
Select Specialty Hospital — Morgantown, Inc.   Delaware
Select Specialty Hospital — Nashville, Inc.   Delaware
Select Specialty Hospital — New Orleans, Inc.   Delaware
Select Specialty Hospital — North Knoxville, Inc.   Missouri
Select Specialty Hospital — Northwest Detroit, Inc.   Delaware
Select Specialty Hospital — Northwest Indiana, Inc.   Missouri
Select Specialty Hospital — Oklahoma City/East Campus, Inc.   Missouri
Select Specialty Hospital — Oklahoma City, Inc.   Delaware
Select Specialty Hospital — Omaha, Inc.   Missouri
Select Specialty Hospital — Philadelphia/AEMC, Inc.   Missouri
Select Specialty Hospital — Phoenix, Inc.   Delaware
Select Specialty Hospital — Pittsburgh, Inc.   Missouri
Select Specialty Hospital — Pontiac, Inc.   Missouri
Select Specialty Hospital — Reno, Inc.   Missouri
Select Specialty Hospital — Saginaw, Inc.   Delaware
Select Specialty Hospital — San Antonio, Inc.   Delaware
Select Specialty Hospital — Sarasota, Inc.   Delaware
Select Specialty Hospital — Sioux Falls, Inc.   Missouri
Select Specialty Hospital — South Dallas, Inc.   Delaware
Select Specialty Hospital — Topeka, Inc.   Missouri
Select Specialty Hospital — TriCities, Inc.   Delaware
Select Specialty Hospital — Tulsa, Inc.   Delaware
Select Specialty Hospital — West Columbus, Inc.   Delaware
Select Specialty Hospital — Western Michigan, Inc.   Missouri
Select Specialty Hospital — Wichita, Inc.   Missouri
Select Specialty Hospital — Wilmington, Inc.   Missouri
Select Specialty Hospital — Wyandotte, Inc.   Delaware
Select Specialty Hospital — Youngstown, Inc.   Missouri
Select Specialty Hospitals, Inc.   Delaware
Select Synergos, Inc.   Delaware
Select Unit Management, Inc.   Delaware
SLMC Finance Corporation   Delaware
SMC of Florida, Inc.   Delaware
South Jersey Physical Therapy Associates, Inc.   New Jersey
South Jersey Rehabilitation and Sports Medicine Center, Inc.   New Jersey
South Philadelphia Occupational Health, Inc.   Pennsylvania
Southpointe Fitness Center, Inc.   Pennsylvania
Southwest Emergency Associates, Inc.   Arizona
Southwest Physical Therapy, Inc.   New Mexico
Southwest Therapists, Inc.   New Mexico
Sports & Orthopedic Rehabilitation Services, Inc.   Florida
Sports Therapy and Arthritis Rehabilitation, Inc.   Delaware

-5-


 

     
U.S. Subsidiaries   State of Incorporation
Star Physical Therapy, Inc.   Florida
Stephenson-Holtz, Inc.   California
The Center for Physical Therapy and Rehabilitation, Inc.   New Mexico
The Orthopedic Sports and Industrial Rehabilitation Network, Inc.   Pennsylvania
Treister, Inc.   Ohio
Valley Group Physical Therapists, Inc.   Pennsylvania
Vanguard Rehabilitation, Inc.   Arizona
Victoria Healthcare, Inc.   Florida
Wayzata Physical Therapy Center, Inc.   Minnesota
West Penn Rehabilitation Services, Inc.   Pennsylvania
West Side Physical Therapy, Inc.   Ohio
West Suburban Health Partners, Inc.   Minnesota
Yuma Rehabilitation Center, Inc.   Arizona

-6-


 

     
Canadian Subsidiaries   Province of Incorporation
Canadian Back Institute Limited   Ontario
1263568 Ontario Limited   Ontario
Dynamic Rehabilitation, Inc.   Ontario
Eastern Rehabilitation, Inc.   Ontario
Rehab Health, Inc.   Ontario
S.T.A.R. Rehab, Inc.   Saskatchewan
S.T.A.R. Rehab (North Battleford), Inc.   Saskatchewan
     
U.S. Partnerships and Limited Liability Companies   State of Formation
Avalon Rehabilitation & Healthcare, LLC   Delaware
G.P. Therapy L.L.C.   Georgia
Kentucky Orthopedic Rehabilitation, LLC   Delaware
Medical Information Management Systems, LLC   Delaware
Millennium Rehab Services, L.L.C.   Delaware
NovaCare Health Group, LLC   Delaware
NW Rehabilitation Associates, L.P.   Delaware
Rehab Advantage Therapy Services, LLC   Delaware
Select Management Services, LLC   Delaware
Select — Houston Partners, L.P.   Delaware
Select Software Ventures, LLC   Delaware
Select Specialty Hospital — Camp Hill, L.P.   Delaware
TJ Corporation I, L.L.C.   Delaware
TJ Partnership I   Florida
     
Canadian Limited Partnerships   Province of Declaration of Partnership
CBI Barrie Limited Partnership   Ontario
CBI Burnaby Limited Partnership   Ontario
CBI Cambridge Limited Partnership   Ontario
CBI Edmonton Limited Partnership   Ontario
CBI Gatineau Limited Partnership   Ontario
CBI Kitchener Limited Partnership   Ontario
CBI Lethbridge Limited Partnership   Ontario
CBI London East Limited Partnership   Ontario
CBI London Limited Partnership   Ontario
CBI Mississauga Limited Partnership   Ontario
CBI Montreal Limited Partnership   Ontario
CBI Niagara Limited Partnership   Ontario
CBI Ottawa Limited Partnership   Ontario
CBI Ottawa West Limited Partnership   Ontario
CBI Port Coquitlam Limited Partnership   Ontario
CBI Regina Limited Partnership   Ontario
CBI Richmond Limited Partnership   Ontario

-7-


 

     
CBI Sarnia Limited Partnership   Ontario
CBI St. Clair West Limited Partnership   Ontario
CBI Sudbury Limited Partnership   Ontario
Surrey Limited Partnership   Ontario
CBI Windsor Limited Partnership   Ontario

-8-

 

Exhibit 23.1

CONSENT OF INDEPENDENT ACCOUNTANTS

      We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-58424) of Select Medical Corporation of our report dated February 15, 2002 relating to the financial statements, which appears in this Annual Report on Form 10-K. We also consent to the incorporation by reference of our report dated February 15, 2002 relating to the financial statement schedule, which appears in this Form 10-K.

PricewaterhouseCoopers LLP

Harrisburg, Pennsylvania

March 4, 2002